Mass General Brigham Incorporated and Affiliates

Report on Federal Awards in Accordance with the OMB Uniform Guidance
September 30, 2025
EIN 04-3230035

Mass General Brigham Incorporated and Affiliates
Index
September 30, 2025

Page(s)

Part I – Financial Statements

Report of Independent Auditors 1–3

Mass General Brigham Consolidated Financial Statements
and Notes to Financial Statements 4–49

Schedule of Expenditures of Federal Awards
and Notes to Schedule of Expenditures of Federal Awards 50–98

Part II – Reports on Compliance and Internal Controls

Report on Independent Auditors on Internal Control Over Financial Reporting
and on Compliance and Other Matters Based on an Audit of Financial Statements
Performed in Accordance with Government Auditing Standards 99–101

Report of Independent Auditors on Compliance with Requirements That Could Have
Have a Direct and Material Effect on Each Major Program and on Internal Control
Over Compliance in Accordance with the OMB Uniform Guidance 102–104

Part III – Federal Award Findings and Questioned Costs

Schedule of Findings and Questioned Costs 105-106

Summary of Status of Prior Years Findings 107

pwc

Report of Independent Auditors

To the Board of Directors of Mass General Brigham Incorporated

Opinion

We have audited the accompanying consolidated financial statements of Mass General Brigham Incorporated (the “Company”) and its affiliates, which comprise the consolidated balance sheets as of September 30, 2025 and 2024, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company and its affiliates as of September 30, 2025 and 2024, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards,* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates’ ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of

assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended September 30, 2025 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and are not required parts of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 19, 2025 on our consideration of the Company and its affiliates' internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended September 30, 2025. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company and its affiliates' internal control over financial reporting and compliance.



Boston, Massachusetts
December 19, 2025

Mass General Brigham Incorporated and Affiliates
Consolidated Balance Sheets
September 30, 2025 and 2024

(in thousands of dollars)	2025	2024
Assets		
Current assets		
Cash and equivalents	$ 529,648	$ 105,924
Investments	4,660,478	4,479,974
Current portion of investments limited as to use	3,364,140	3,651,727
Patient accounts receivable, net	1,774,269	1,731,496
Research grants receivable, net	429,227	248,415
Other current assets	1,390,446	1,205,371
Total current assets	12,148,208	11,422,907
Investments limited as to use, less current portion	7,404,116	6,443,033
Long-term investments	3,941,173	3,138,592
Property and equipment, net	7,829,880	7,471,740
Right-of-use operating lease assets	801,815	920,702
Other assets	3,703,237	2,360,443
Total assets	$ 35,828,429	$ 31,757,417
Liabilities and Net Assets		
Current liabilities		
Current portion of long-term obligations	$ 448,435	$ 353,249
Accounts payable and accrued expenses	1,276,076	1,426,104
Accrued medical claims and related expenses	215,581	258,520
Accrued employee compensation and benefits	1,414,617	1,281,714
Current portion of operating lease obligations	155,897	203,879
Unexpended funds on research grants	469,114	369,851
Total current liabilities	3,979,720	3,893,317
Accrued professional liability	594,421	573,796
Accrued employee benefits	990,808	891,868
Interest rate swaps liability	85,312	139,170
Accrued other	421,081	463,907
Operating lease obligations, less current portion	545,738	598,065
Long-term obligations, less current portion	5,599,780	5,837,579
Total liabilities	12,216,860	12,397,702
Commitments and contingencies		
Net assets		
Net assets without donor restrictions	18,874,645	15,306,802
Noncontrolling ownership interests in subsidiaries	93,653	106,788
Total net assets without donor restrictions	18,968,298	15,413,590
With donor restrictions	4,643,271	3,946,125
Total net assets	23,611,569	19,359,715
Total liabilities and net assets	$ 35,828,429	$ 31,757,417

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Operations
Years Ended September 30, 2025 and 2024

(in thousands of dollars)	2025	2024
Operating revenues		
Net patient service revenue	$ 14,480,064	$ 13,439,956
Premium revenue	2,537,401	2,169,968
Direct research and nonresearch sundry revenue	2,324,147	2,240,832
Indirect research and nonresearch sundry revenue	716,296	659,918
Other revenue	2,749,861	2,039,604
Total operating revenues	22,807,769	20,550,278
Operating expenses		
Employee compensation and benefit expenses	11,122,914	10,264,778
Supplies and other expenses	6,524,901	5,540,276
Medical claims and related expenses	1,819,473	1,505,038
Direct research and nonresearch sundry expenses	2,324,147	2,240,832
Depreciation and amortization expenses	791,752	778,337
Interest expense	165,406	175,279
Total operating expenses	22,748,593	20,504,540
Income from operations	59,176	45,738
Nonoperating gains (loss)		
Income from investments	1,751,132	1,950,070
Change in fair value of interest rate swaps	84,167	(84,228)
Other nonoperating expenses	(3,512)	(38,624)
Research and nonresearch sundry gifts net of spending	257,903	(48,187)
Nonservice related pension income	236,776	222,910
Total nonoperating gains, net	2,326,466	2,001,941
Excess of revenues over expenses	2,385,642	2,047,679
Other changes in net assets		
Funds utilized for property and equipment	36,549	434,073
Change in funded status of defined benefit plans	1,135,994	(445,729)
Other changes in net assets	(3,477)	15,122
Increase in net assets without donor restrictions	$ 3,554,708	$ 2,051,145

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Changes in Net Assets
Years Ended September 30, 2025 and 2024

(in thousands of dollars)	Without Donor Restrictions	With Donor Restrictions	Total
Net assets at September 30, 2023	$ 13,362,445	$ 3,739,156	$ 17,101,601
Increases (decreases)			
Income from operations	45,738	-	45,738
Income from investments	1,950,070	356,508	2,306,578
Change in fair value of interest rate swaps	(84,228)	-	(84,228)
Other nonoperating (expenses) income	(38,624)	240,919	202,295
Research and nonresearch sundry gifts net of spending	(48,187)	-	(48,187)
Nonservice related pension income	222,910	-	222,910
Funds utilized for property and equipment	434,073	(393,305)	40,768
Change in funded status of defined benefit plans	(445,729)	-	(445,729)
Other changes in net assets	15,122	2,847	17,969
Change in net assets	2,051,145	206,969	2,258,114
Net assets at September 30, 2024	15,413,590	3,946,125	19,359,715
Increases (decreases)			
Income from operations	59,176	-	59,176
Income from investments	1,751,132	284,594	2,035,726
Change in fair value of interest rate swaps	84,167	-	84,167
Other nonoperating (expenses) income	(3,512)	435,519	432,007
Research and nonresearch sundry gifts net of spending	257,903	-	257,903
Nonservice related pension income	236,776	-	236,776
Funds utilized for property and equipment	36,549	(25,516)	11,033
Change in funded status of defined benefit plans	1,135,994	-	1,135,994
Other changes in net assets	(3,477)	2,549	(928)
Change in net assets	3,554,708	697,146	4,251,854
Net assets at September 30, 2025	$ 18,968,298	$ 4,643,271	$ 23,611,569

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Cash Flows
Years Ended September 30, 2025 and 2024

(in thousands of dollars)	2025	2024
Cash flows from operating activities		
Change in net assets	$ 4,251,854	$ 2,258,114
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Change in funded status of defined benefit plans	(1,135,994)	445,729
Gain on refunding of debt	-	(7,010)
Change in fair value of interest rate swaps	(84,167)	84,228
Depreciation and amortization	791,752	778,337
Amortization of bond discount, premium and issuance costs	(17,862)	(11,164)
(Gain) loss on disposal of property	(3,636)	324
Change in right-of-use operating lease assets	178,045	120,409
Net realized and unrealized change in investments	(2,407,738)	(2,570,863)
Donor restricted contributions and investment income	(428,885)	(292,309)
Cash premium received upon issuance of bonds	-	34,049
Increases (decreases) in cash resulting from a change in		
Patient accounts receivable	(42,773)	(93,190)
Other assets	(498,881)	(371,302)
Accounts payable and other accrued expenses	166,265	378,627
Accrued medical claims and related expenses	(42,939)	66,085
Operating lease obligations	(159,467)	(119,242)
Settlements with third-party payers	(52,882)	185,245
Net cash provided by operating activities	512,692	886,067
Cash flows from investing activities		
Purchases of property and equipment	(1,174,376)	(1,492,907)
Proceeds from sale of property	4,329	1,392
Purchase of investments	(1,387,071)	(1,734,338)
Proceeds from sales of investments	2,138,228	1,649,745
Net cash used for investing activities	(418,890)	(1,576,108)
Cash flows from financing activities		
Borrowings under taxable commercial paper	171,842	-
Repayments of borrowings under taxable commercial paper	(109,907)	(119,870)
Borrowings under lines of credit	625,000	270,000
Repayments of borrowings under lines of credit	(625,000)	(270,000)
Payments on long-term obligations	(124,751)	(110,891)
Proceeds from long-term obligations	-	524,802
Deposits into refunding trusts	(61,935)	(69,844)
Net gain on interest rate swap terminations	25,788	-
Donor restricted contributions and investment income	428,885	292,309
Net cash provided by financing activities	329,922	516,506
Net increase (decrease) in cash and equivalents	423,724	(173,535)
Cash and equivalents		
Beginning of year	105,924	279,459
End of year	$ 529,648	$ 105,924
Noncash purchases of property and equipment in accounts payable and accrued expenses	$ 86,288	$ 110,631

The accompanying notes are an integral part of these consolidated financial statements.

(in thousands of dollars)

1. Organization and Community Benefit Commitments

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in these consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Insurance Company) (collectively referred to as the Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), Medicare Advantage program, ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations.

Community Health

The Mass General Brigham *Health Equity & Community Health* program aims to make measurable, impactful and sustainable improvements in clinical equity for our patients, along with better health outcomes for the communities we serve.

We are focused on health conditions that are the greatest contributor to premature mortality and reduced life expectancy in these communities: cardiometabolic disease (including hypertension and diabetes), substance use disorder, cancer and maternal-child health.

We are committed to addressing the root causes of health disparities by building and strengthening our community-based partnerships to make the greatest impact on issues such as food insecurity, housing instability, limited economic mobility and educational opportunities, and barriers to accessing care.

Charity Care

We provide charity care to all emergent patients regardless of their ability to pay. The cost of and reimbursement for providing that care, as reflected in the consolidated statements of operations, is summarized below.

State Programs

Massachusetts

Acute care hospitals in The Commonwealth of Massachusetts (the Commonwealth or Massachusetts) are partially reimbursed for charity care services through the statewide Health Safety Net Trust Fund (HSN). A portion of the funding for the HSN is paid by an assessment on acute care hospitals' charges for private sector payers. The statewide assessment was $163,784 and $165,231 in 2025 and 2024, respectively, and the assessment expense on our acute care hospitals was $57,819 in both 2025 and 2024.

(in thousands of dollars)

Acute care hospitals are reimbursed for charity care based on claims for eligible patients and services that are submitted to and adjudicated by the HSN. Payments are based on Medicare rates and payment policies. The Commonwealth reported that HSN was under-funded by approximately $284,292 and $133,027 as of September 30, 2025 and 2024, respectively. This shortfall is allocated to acute care hospitals based on their share of total statewide patient care costs. We have estimated our share being approximately $105,445 and $67,980 as of September 30, 2025 and 2024, respectively. The Commonwealth passed a hospital relief package in 2025 that included $77,000 for statewide HSN shortfall relief of which $4,104 was paid to and recognized by us. In 2025, there was no net HSN reimbursement recognized due to the HSN shortfall, resulting in no cost of charity care coverage. In 2024, our acute care hospitals received charity care funding covering 14% of the estimated cost of charity care provided.

The Commonwealth levies an additional assessment on Massachusetts acute care hospitals that is redistributed back to hospitals based on provisions within the MassHealth Section 1115 Demonstration. A new five-year waiver period began effective October 1, 2022. The total assessment was $1,290,493 and $709,685 in 2025 and 2024, respectively, and our assessment expense was $294,968 and $197,473 in 2025 and 2024, respectively. The total amount redistributed to hospitals across Massachusetts was $2,338,288 and $1,613,052 in 2025 and 2024, respectively, of which we recognized $285,829 and $179,114 in 2025 and 2024, respectively.

There is an assessment for our post-acute hospitals which totaled $14,072 and $5,756 in 2025 and 2024, respectively.

New Hampshire
The State of New Hampshire (New Hampshire) imposes a Medicaid Enhancement Tax (MET) on hospital net patient service revenue. For both of New Hampshire's fiscal years ended June 30, 2025 and 2024, the MET imposed was 5.4%. We incurred $32,578 and $30,343 of MET in 2025 and 2024, respectively.

In 2025, New Hampshire acute care hospitals received direct inpatient and outpatient payments, inpatient service rate increases and disproportionate share payments based on a settlement agreement reached between New Hampshire and the New Hampshire state hospitals. We received $11,139 in 2025. In 2024, New Hampshire acute care hospitals received disproportionate share payments based on a portion of their charity care relative to other acute care hospitals. We received $17,582 in 2024.

Medicaid
Medicaid is a health insurance program jointly funded by the states and the federal government. Each state administers its own program and sets rules for eligibility, benefits and provider payments within broad federal guidelines and in some cases, including the Commonwealth and New Hampshire, within a Waiver Agreement between each state and the federal government. The program provides health care coverage to low-income adults and children. Eligibility is determined by a variety of factors which include income relative to the federal poverty line, age, immigrant status and assets.

Medicaid payments to our providers do not cover the full cost of services provided to Medicaid patients. In aggregate, our reimbursement from Medicaid covered approximately 62% and 64% of the estimated cost of services that we provided in 2025 and 2024, respectively.

(in thousands of dollars)

Mass General Brigham Health Plan, Inc. has an Accountable Care Organization (ACO) contract with the Executive Office of Health and Human Services of the Commonwealth (EOHHS) covering MassHealth members whose providers participate in the Mass General Brigham ACO.

Federal Program

Medicare

Medicare is a federally sponsored health insurance program for people age 65 or older, under age 65 with certain disabilities and any age with End-Stage Renal Disease. Medicare's payments historically have not kept pace with increases in the cost of care provided at many hospitals. Compounding this shortfall in payments is the continued shift of care from higher paying inpatient services to lower paying outpatient services.

Consequently, Medicare payments to our providers do not cover the full cost of services provided. In aggregate, our reimbursement from Medicare covered approximately 70% and 71% of the estimated cost of services that we provided in 2025 and 2024, respectively.

Mass General Brigham Health Plan, Inc. is authorized by the Centers for Medicare & Medicaid Services (CMS) to offer Medicare Advantage products to its eligible members.

Summary

For charity care, Medicaid and Medicare, the estimated cost of services provided is either obtained directly from a costing system or based on an entity specific ratio of cost to gross charges. In the latter case, cost is derived by applying this ratio to gross charges associated with providing care to charity care, Medicaid and Medicare patients. The following summarizes, by program, the cost of services provided, net reimbursement and cost of services in excess of reimbursement for each year:

	Years Ended September 30,	
	2025	**2024**
Cost of services provided		
Charity care	$ 169,148	$ 171,217
Medicaid	2,196,782	2,002,532
Medicare	6,427,357	5,780,976
	$ 8,793,287	$ 7,954,725
Net reimbursement		
Charity care reimbursement (shortfall absorption)	$ (8,184)	$ 20,259
Medicaid	1,365,114	1,285,520
Medicare	4,518,303	4,110,328
	$ 5,875,233	$ 5,416,107
Cost of services in excess of reimbursement		
Charity care	$ 177,332	$ 150,958
Medicaid	831,668	717,012
Medicare	1,909,054	1,670,648
	$ 2,918,054	$ 2,538,618

(in thousands of dollars)

In addition, there are significant losses related to self-pay patients who fail to make payment for services rendered or insured patients who fail to remit co-payments and deductibles as required under the applicable health insurance arrangement. The estimated cost of providing these services was approximately $114,760 and $105,896 for 2025 and 2024, respectively.

2. Summary of Significant Accounting Policies

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting and include the accounts of the Company and its affiliates. Interaffiliate accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are made in the areas of patient accounts receivable, research grants receivable, investments, receivables and accrual for settlements with third-party payers, accrued medical claims and related expenses, accrued employee compensation and benefits, accrued professional liability, interest rate swaps liability and accrued other.

Income Taxes

The Company and substantially all of its affiliates are tax-exempt organizations under Sections 501(c)(3) or 501(c)(4) of the Internal Revenue Code (IRC) or are disregarded entities for tax purposes and therefore are exempt from federal and state income tax except on unrelated business taxable income. No provision for income taxes related to these tax-exempt entities has been made as the effect of any unrelated business income tax is not material to the accompanying consolidated financial statements.

Fair Value of Financial Instruments

The fair value of financial instruments approximates the carrying amount reported in the consolidated balance sheets for cash and equivalents, investments and investments limited as to use, patient accounts receivable, research grants receivable, accounts payable and accrued expenses and interest rate swaps liability.

Cash and Equivalents

Cash and equivalents represent cash, registered money market funds and highly liquid debt instruments with a maturity at the date of purchase of three months or less. Our cash and equivalents are maintained with several national banks, and cash deposits typically exceed federal insurance limits. Our policy is to monitor these banks' financial strength on an ongoing basis, and no losses have been experienced to date.

(in thousands of dollars)

Investments
Investments in equity securities with readily determinable fair values, debt securities and alternative investments are measured at fair value. Alternative investments, consisting of various hedge funds, private equity funds, private debt funds, other private partnerships and restricted securities of public companies that are not traded on a national securities exchange, are valued based on amounts reported by the fund manager and evaluated by management. Investments in securities sold short or traded on a national securities exchange are valued based on quoted market prices.

Income from investments (including realized gains and losses, unrealized change in value of investments, interest, dividends and endowment income distributions) is included in excess of revenues over expenses unless the income or loss is restricted by donor or law. Income from investments is reported net of investment-related expenses.

Each year as part of our endowment spending policy, we establish a fixed distribution rate for spending. Distributions will come from either income and/or net accumulated appreciation. Our endowment spending policy is based on the Tobin Distribution Rule. The Tobin Distribution Rule sets the annual distribution through a quantitative formula that has a stability term (a percentage of the prior year's spending, adjusted for inflation) and a market term (a percentage of the long-term sustainable rate of distribution times the market value of the endowment).

Investments Limited as to Use
Investments limited as to use primarily include assets whose use is contractually limited by external parties as well as assets set aside by the boards (or management) for identified purposes and over which the boards (or management) retain control such that the boards (or management) may, at their discretion, subsequently use such assets for other purposes. Certain investments corresponding to deferred compensation are accounted for such that all income and appreciation (depreciation) is recorded as a direct addition (reduction) to the asset and corresponding liability.

Investment Companies
Certain investment companies are required to be consolidated for financial reporting purposes. Where such entities are not wholly owned by the Company, the portion of the consolidated entity's net assets that is not owned by the Company is disclosed as a non-controlling interest (Note 18). The fair value of consolidated investment company assets and liabilities included in the Company's consolidated financial statements are as follows:

	September 30,	
	2025	**2024**
Consolidated investment company assets	$ 128,812	$ 132,605
Consolidated investment company liabilities	3,000	1,315

Derivative Instruments
Derivatives are recognized on the balance sheets at fair value with changes in the fair value recorded in excess of revenues over expenses.

Patient Accounts Receivable
The payments received for health care services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care payers, commercial insurance companies and patients are subject to explicit and implicit discounts. These discounts are based on

(in thousands of dollars)

contractual agreements, discount policies and management's assessment of historical experiences and are reflected in the period of service.

Research Grants Receivable
Mass General Brigham receives direct and pass-through research funding from the National Institutes for Health and other federal agencies, industry, corporate, foundation, nonprofits and other sponsors. Research grants receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor, or in limited circumstances, represent accelerated spending in anticipation of future funding. Research grants receivable are recognized at net realizable value.

As of September 30, 2025 and 2024, we have approximately $4,280,855 and $4,598,252, respectively, of conditional research grants for future research to be performed. The timing and amounts of funds received under such grants are subject to continued government funding and may change over time.

Other Current Assets
Other current assets include prepaid expenses, inventory, nonpatient receivables, current portion of receivable for settlements with third-party payers, current portion of pledges receivable and premiums receivable. Inventory (primarily supplies and pharmaceuticals) is accounted for on a first-in, first-out method basis and is recorded at the lower of average weighted cost or net realizable value.

Property and Equipment
Property and equipment is reported on the basis of cost less accumulated depreciation. Donated items are recorded at fair value at the date of contribution. All research grants received for capital are recorded in the year of expenditure as a change in net assets without donor restrictions. Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Depreciation of property and equipment is calculated by use of the straight-line method at rates intended to depreciate the cost of assets over their estimated useful lives, which generally range from three to fifty years. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized, net of any interest earned, as a component of the cost of acquiring those assets.

Asset Retirement Obligations
Asset retirement obligations, reported in accrued other, are legal obligations associated with the retirement of long-lived assets. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Any changes to the liability due either to the passage of time, better information or the settlement of an obligation are reflected in the current period.

Other Assets
Other assets consist of long-term receivables, intangible assets, malpractice insurance receivables, receivable for settlements with third-party payers, investments in health care related limited partnerships, long-term pledges and contributions receivable and defined benefit pension plan and postretirement health care benefit plan assets in excess of plan benefit obligations. The carrying value of other assets is evaluated for impairment if the facts and circumstances suggest that the carrying value may not be recoverable.

(in thousands of dollars)

Compensated Absences
In accordance with formal policies concerning vacation and other compensated absences, accruals of $478,271 and $443,417 were recorded as of September 30, 2025 and 2024, respectively.

Unexpended Funds on Research Grants
Research grants received in advance of corresponding grant expenditures are accounted for as a direct addition to investments limited as to use and unexpended funds on research grants.

Self-Insurance Reserves
We are generally self-insured for employee health care, disability, workers' compensation and certain other employee benefits. These costs are accounted for on an accrual basis to include estimates of future payments for claims incurred prior to year-end and are included in accrued employee compensation and benefits and long-term accrued employee benefits.

Net Assets
Net assets with donor restrictions include (a) the historical dollar amounts of contributions and the income and gains on such contributions which are required by donors to be retained and (b) contributions and the income and gains on these contributions which can be expended but for which restrictions have not yet been met. Such restrictions include purpose restrictions where donors have specified the purpose for which the net assets are to be spent, or time restrictions imposed by donors or implied by the nature of the contribution (capital projects, pledges to be paid in the future and life income funds) or by interpretations of law (gains available for appropriation but not appropriated in the current period). All remaining net assets are considered to be without donor restrictions.

Realized gains and losses are classified as net assets without donor restrictions unless they are restricted by the donor or law. Realized gains and net unrealized appreciation on contributions with donor restrictions are classified as net assets with donor restrictions until appropriated for spending in accordance with policies established by Mass General Brigham and applicable provisions of the Uniform Prudent Management of Institutional Funds Acts (UPMIFA). Net losses on donor endowment funds with donor restrictions are classified as a reduction to net assets with donor restrictions.

Contributed Securities
Our policy is to sell securities contributed by donors upon receipt, unless prevented from doing so by donor request. For the years ended September 30, 2025 and 2024, contributed securities of $227,665 and $146,236, respectively, were received and liquidated. Donors restricted $171,758 and $85,180 of the proceeds received from the sale of these contributed securities for long-term purpose for the years ended September 30, 2025 and 2024, respectively.

Statement of Operations
Activities deemed by management to be ongoing, major and central to the provision of health care services, teaching, research activities and health insurance are reported as operating revenues and expenses. Other activities are deemed to be nonoperating and include contributions without donor restrictions (net of fundraising expenses), external community benefit program support, net change in unexpended research and nonresearch sundry contributions, change in fair value of interest rate swaps, substantially all income from investments, interest on advanced borrowings and nonservice related pension income. Research and nonresearch sundry contributions largely consist of donor contributions (and the related investment income including realized gains and

(in thousands of dollars)

losses) designated to support the clinical, teaching or research efforts of a physician or department as directed by the donor. These contributions are reported as being without donor restrictions, net of related support expenses, when donor restrictions are of a general nature that are inherent in the normal activities of the organization.

The consolidated statements of operations include excess of revenues over expenses. Changes in net assets without donor restrictions, which are excluded from excess of revenues over expenses, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for acquisition of such assets) and change in funded status of defined benefit plans.

Revenues
To determine the appropriate revenue recognition policy, we first assess whether the transaction is an exchange or nonexchange transaction in accordance with accounting guidance. In general, an exchange transaction consists of an exchange of goods and/or services for commensurate value. Transactions that consist of transferring goods and/or services without receiving commensurate value in return are considered nonexchange transactions.

For exchange transactions, revenue is recognized as goods and/or services are provided and is based on the amount expected to be received in exchange for those goods and/or services. Revenue recognized as exchange transactions include net patient service revenue, premium revenue and other revenue.

Nonexchange transactions include contributions and grants for which the service provider does not receive commensurate value in return for the funding.

Contributions
Contributions are generally reported as other nonoperating gains in the consolidated statements of operations. Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give are recognized when the conditions are substantially met and totaled $427,673 and $403,143 as of September 30, 2025 and 2024, respectively. Contributions are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. Contributions with donor restrictions whose restrictions are met within the same year as received are reported as contributions without donor restrictions in the consolidated statements of operations.

Contributions of long-lived assets with explicit restrictions that specify use of assets and contributions of cash or other assets that must be used to acquire long-lived assets are reported as additions to net assets with donor restrictions if the assets are not placed in service during the year.

Grants
Grants and contracts normally provide for the recovery of direct and indirect costs, subject to audit. Revenue associated with direct and indirect costs is recognized as direct costs are incurred. The recovery of indirect costs is based on rates for U.S. Government grants and contracts and negotiated rates for other grants and contracts.

Medical Claims and Related Expenses
The Health Plan contracts with various hospitals, community health centers, primary care and specialty physician practices and other health care providers for the delivery of services to its

(in thousands of dollars)

members and compensates these providers on a capitated, fee-for-service, per diem or diagnosis-related group basis.

The cost of contracted health care services is accrued in the period in which services are provided and include certain estimated amounts. The estimated liability for medical claims and related expenses is actuarially determined based on analysis of historical claims-paid experience, modified for changes in enrollment, inflation and benefit coverage. The liability for medical claims and related expenses represents the anticipated cost of claims incurred but unpaid at the balance sheet date. Estimates for claims expense may be more or less than the amounts ultimately paid when claims are settled. Such changes in estimates are reflected in the current period in the consolidated statements of operations.

In the normal course of business, overpayments are recouped through reductions in future payments made to hospitals and other providers. Such overpayments are the result of, among other things, coordination of benefits and provider claim audits. For the years ended September 30, 2025 and 2024, we recorded a reduction in medical claims expense of $52,568 and $59,115, respectively, for such overpayments. As of September 30, 2025 and 2024, respectively, approximately $1,769 and $1,767 are recorded as receivables related to such overpayments.

Reinsurance
Reinsurance premiums are reported as reductions in premium revenue and reinsurance recoveries are reported as reductions in medical claims and related expenses.

Settlements
The Health Plan contracts with certain providers at negotiated rates based on historical and anticipated experience. This method of reimbursement results in year-end settlements based on actual versus anticipated experience. The settlements are intended to include both reported and unreported incurred claims as of September 30, 2025 and 2024.

In certain instances, base premium revenue is subject to risk adjustment based on demographic factors and health status of covered members. Our estimated net receivable due from the federal government for the risk adjustment program under the Patient Protection and Affordable Care Act (ACA) was $122,295 and $79,841 as of September 30, 2025 and 2024, respectively. Similar to the federal program, EOHHS has risk-sharing arrangements, and our estimated net receivable from EOHHS was $121,071 as of September 30, 2025 and our estimated net payable to EOHHS was $10,712 as of September 30, 2024.

The ACA requires certain health plans with medical loss ratios (MLR) on fully insured products that fall below required minimum percentages to rebate ratable portions of their premium annually. The Health Plan's management thereby regularly monitors MLR calculations by market type and records the applicable liability and reduction to premium revenue if the MLR falls below the minimum requirements. The Health Plan's estimated payable for MLR rebates as of September 30, 2025 and 2024 was $5,043 and $7,936, respectively.

(in thousands of dollars)

Premium Deficiency Reserves
Premium deficiency reserves are assessed and recognized on a product line basis based upon expected premium revenue, medical expense and administrative expense levels, and remaining contractual obligations using historical experience. As of September 30, 2025 and 2024, a premium deficiency reserve of $7,894 and $33,254, respectively, is included in accrued medical claims and related expenses in the accompanying consolidated financial statements.

Claims Adjustment Expenses
Claims adjustment expenses (CAE) are those costs expected to be incurred in connection with the adjustment and recording of health claims. We have recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in medical claims and related expenses in the accompanying consolidated statements of operations. Management believes the amount of the liability for unpaid CAE as of September 30, 2025, is adequate to cover the cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified.

Reclassification
Within the accompanying notes certain amounts for 2024 have been presented to conform with the 2025 presentation.

3. Operating Revenues

Net Patient Service Revenue
Mass General Brigham's providers maintain agreements with CMS under the Medicare program, the Commonwealth under the Medicaid program and various managed care payers that govern payment for services rendered to patients covered by these agreements. The agreements generally provide for per case or per diem rates or payments based on discounted charges for inpatient care and discounted charges or fee schedules for outpatient care. Certain contracts also provide for payments that are contingent upon meeting agreed upon quality and efficiency measures.

(in thousands of dollars)

We recognize net patient service revenue for services provided to patients who have third-party payer coverage based on contractual rates for the services rendered. For uninsured patients that do not qualify for charity care, we recognize revenue based on our standard rates (subject to discounts) for services provided. Based on our historical experience, a significant portion of uninsured patients are unable or fail to pay for the services provided. Consequently, we have provided implicit discounts to uninsured patients. These discounts represent the difference between amounts billed to patients and amounts expected to be collected based on historical experience. The following summarizes net patient service revenue, net of contractual adjustments and discounts by significant payer:

	Years Ended September 30,			
	2025		2024	
Net patient service revenue (net of contractual adjustments and discounts)				
Medicare	$ 3,204,501	22.1%	$ 2,957,873	22.0%
Medicare managed care	1,313,802	9.1%	1,152,455	8.6%
Medicaid	409,525	2.8%	449,718	3.4%
Medicaid managed care	955,589	6.6%	835,802	6.2%
Massachusetts managed care organizations	4,954,040	34.2%	4,710,345	35.0%
Other commercial	3,287,547	22.7%	2,989,867	22.2%
All others	355,060	2.5%	343,896	2.6%
Total all payers	$ 14,480,064	100.0%	$ 13,439,956	100.0%

Net patient service revenue includes estimated retroactive revenue adjustments due to future audits, reviews and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews and investigations. Contracts, laws and regulations governing the Medicare, Medicaid and charity care programs and managed care payer arrangements are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. A portion of the accrual for settlements with third-party payers has been classified as long-term because such amounts, by their nature or by virtue of regulation or legislation, will not be paid within one year.

Third-party payers (accrual) receivable consists of the following:

	Balance Sheet Classification	September 30, 2025	September 30, 2024
Current portion			
Receivable for settlements with third-party payers	Other current assets	$ 167,811	$ 153,064
Payable for settlements with third-party payers	Accounts payable and accrued expenses	(92,740)	(115,461)
		75,071	37,603
Long-term portion			
Receivable for settlements with third-party payers	Other assets	53,353	26,956
Payable for settlements with third-party payers	Accrued other	(21,124)	(10,141)
		32,229	16,815
Third-party payers receivable, net		$ 107,300	$ 54,418

(in thousands of dollars)

We recognize changes in third-party payer settlements and other estimates in the year of the change in estimate. For the years ended September 30, 2025 and 2024, adjustments to prior year estimates resulted in an increase to net patient service revenue of $45,711 and $120,290, respectively. Subsequent changes to estimated discounts are generally recorded as adjustments to net patient service revenue in the period of change.

We provide either full or partial charity care to patients who cannot afford to pay for their medical services based on income and family size. Charity care is generally available to qualifying patients for medically necessary services. We report certain bad debts related to emergency services as charity care. As there is no expectation of collection, there is no net patient service revenue recorded related to charity care.

Premium Revenue
Premiums are due monthly and are recorded as earned during the period in which members are eligible to receive services. Premiums received prior to the first day of the coverage period are recorded as unearned premiums in accounts payable and accrued expenses.

Research and Nonresearch Sundry Revenue
Research and nonresearch sundry revenue is recognized as either an exchange or nonexchange transaction, depending on the contract type. The following table sets forth total research and nonresearch sundry revenue received by funding source:

	Years Ended September 30,			
	2025		2024	
National Institute of Health and other federal agencies	$ 1,310,802	43.1%	$ 1,256,379	43.3%
Federal subcontracts	286,763	9.4%	289,876	10.0%
Industry/corporate	224,282	7.4%	233,689	8.1%
Foundations/nonprofits and other sponsors	1,218,596	40.1%	1,120,806	38.6%
Total research and nonresearch sundry revenue	$ 3,040,443	100.0%	$ 2,900,750	100.0%

Other Revenue
Other revenue includes all other operating revenue sources, the most significant being the following:

	Years Ended September 30,	
	2025	2024
Specialty and retail pharmacy operations	$ 1,892,341	$ 1,211,649
Contract services	192,451	193,706
Ancillary revenue	118,089	121,011
Tuition	70,067	66,570
Blood factor revenue	76,704	57,482
International contracts	11,004	16,458
Income (loss) on intellectual property investments and royalties	(6,988)	40,713
Investment income	13,795	13,482
Other	382,398	318,533
Total other revenue	$ 2,749,861	$ 2,039,604

Ancillary revenue includes cafeteria and parking revenue.

(in thousands of dollars)

COVID-19 Economic Support
We received Provider Relief Funds (PRF) in 2020 and 2021 that were used to prevent, prepare for and respond to COVID-19. As of September 30, 2025 and 2024, we have deferred $32,487 and $86,487, respectively, of PRF received.

We submitted applications to the Federal Emergency Management Agency (FEMA) for the reimbursement of COVID-19 expenses and recognized grant revenue totaling $0 and $19,699, in 2025 and 2024, respectively, as other operating revenue in the consolidated statements of operations. As of September 30, 2025 and 2024, we have deferred $53,367 and $54,792, respectively, of FEMA payments received.

4. Liquidity and Availability

Cash and investments are managed centrally under policies developed by the Investment Committee of the Company's Board of Directors. Wherever possible, funds are commingled and are assigned to one of three investment pools (the Money Market Pool, the Aggregate Bond Pool and the Long Term Pool, collectively, the Pools) which have been structured to provide a range of investment objectives, risk profiles and rates of return appropriate for our assets. Funds are allocated among the Pools based on expected liquidity needs as determined by multi-year financial plans, restrictions and management judgment.

The tiered time horizon structure of the Pools is designed to meet anticipated and contingent liquidity needs. The following tables set forth the periods within which funds are available to meet liquidity needs and based on redemption provisions with investment managers, the specific Pools from which such funds would be drawn as of:

	September 30, 2025						
Investment Pool	**Same Day**	**1 Week**	**1 Month**	**3 Months**	**1 Year**	**> 1 Year**	**Total**
Money Market Pool	$ 426,548	$ -	$ -	$ -	$ -	$ -	$ 426,548
Aggregate Bond Pool	419,423	3,044	-	-	-	-	422,467
Long Term Pool	1,162,871	419,308	2,077,049	4,545,516	1,440,366	7,764,339	17,409,449
Total	$ 2,008,842	$ 422,352	$ 2,077,049	$ 4,545,516	$ 1,440,366	$ 7,764,339	$ 18,258,464
Cumulative total	$ 2,008,842	$ 2,431,194	$ 4,508,243	$ 9,053,759	$ 10,494,125	$ 18,258,464	

	September 30, 2024						
Investment Pool	**Same Day**	**1 Week**	**1 Month**	**3 Months**	**1 Year**	**> 1 Year**	**Total**
Money Market Pool	$ 2,314	$ -	$ -	$ -	$ -	$ -	$ 2,314
Aggregate Bond Pool	404,374	3,311	-	-	-	-	407,685
Long Term Pool	851,883	807,904	2,285,293	4,204,208	1,425,925	6,299,312	15,874,525
Total	$ 1,258,571	$ 811,215	$ 2,285,293	$ 4,204,208	$ 1,425,925	$ 6,299,312	$ 16,284,524
Cumulative total	$ 1,258,571	$ 2,069,786	$ 4,355,079	$ 8,559,287	$ 9,985,212	$ 16,284,524	

As of September 30, 2025 and 2024, we had cash and equivalents not included in the Pools of $103,100 and $105,823, respectively. As of September 30, 2025 and 2024, we had net patient accounts receivable of $1,774,269 and $1,731,496, respectively, that would be available for general expenditures within one year of the balance sheet dates.

5. Investments and Investments Limited as to Use

Investments are either invested in the Pools or separately managed. Substantially all affiliates participate in the Pools. Their respective ownership interests are tracked and updated monthly and

(in thousands of dollars)

are accounted for using the fair value method. Income (including realized gains and losses) from the Pools is allocated to each participant on a monthly basis based on its proportionate interest in the Pools.

Oversight of the management of the investable assets, including the Pools and pension assets, is provided by the Investment Committee of the Company's Board of Directors which seeks to achieve incremental returns by external manager selection and asset allocation (increasing/decreasing allocations within allowable ranges based on current and projected valuations). The Committee is supported by a professional staff of the Company's employees and an external pension actuarial consultant.

The Pools invest in a variety of assets which include private partnerships whose assets include equity, fixed income and other investments. The Pools have unfunded commitments to such private partnerships as follows:

	September 30,	
	2025	**2024**
Private equity	$ 1,644,081	$ 1,676,110
Private energy	89,788	89,816
Private real estate	106,592	102,876
Timber and agriculture	1,587	1,524
Private alternatives and hedge funds	291,708	195,972
	$ 2,133,756	$ 2,066,298

The unfunded commitments will be drawn down by the various general partners of such partnerships over the next several years. The maximum annual drawdown is expected to be 3% to 5% of investments and investments limited as to use, however the actual amount may vary.

Short-term Investments in Investment Pools

Within the Aggregate Bond Pool and the Long Term Pool, there are assets that meet the definition of short-term investments. These short-term investments are considered part of the Aggregate Bond Pool and the Long Term Pool and are not included in cash equivalents on the consolidated balance sheets. Accordingly, transactions within the Aggregate Bond Pool and the Long Term Pool that result in the purchase of investments or result in proceeds from the sales of investments are excluded from the statements of cash flows purchases of investments and proceeds from the sales of investments. Within the Aggregate Bond Pool, purchases of investments and proceeds from the sales of investments not included in the statements of cash flows were $161,119 and $128,440 for the year ended September 30, 2025, and $247,387 and $187,061 for the year ended September 30, 2024, respectively. Within the Long Term Pool, purchases of investments and proceeds from the sales of investments not included in the statements of cash flows were $2,767,455 and $3,216,543 for the year ended September 30, 2025, and $1,632,747 and $1,966,849 for the year ended September 30, 2024, respectively.

(in thousands of dollars)

Investments limited as to use consist of the following:

	September 30, 2025		September 30, 2024	
	Current Portion	Long-Term Portion	Current Portion	Long-Term Portion
Internally designated funds				
Reserved for capital expenditures	$ 1,289,839	$ -	$ 1,244,666	$ -
Unexpended research and nonresearch sundry gifts	-	5,926,993	-	5,131,842
Deferred compensation	-	927,390	-	798,484
Other	1,603,223	490,846	2,030,166	461,821
	2,893,062	7,345,229	3,274,832	6,392,147
Externally limited funds				
Unexpended funds on research	469,114	-	369,851	-
Contributions held for others	1,540	-	1,519	-
Professional liability trust fund	-	58,887	-	50,886
Held by trustees under debt and other agreements	424	-	5,525	-
	471,078	58,887	376,895	50,886
	$ 3,364,140	$ 7,404,116	$ 3,651,727	$ 6,443,033

Investment activity included in excess of revenues over expenses consists of the following:

	Years Ended September 30,	
	2025	2024
Investment income included in operations and reported in other revenue	$ 13,795	$ 13,482
Investment income included in nonoperating gains and reported in		
Income from investments		
Investment income and realized gains on investments	646,313	327,105
Unrealized change in investments	1,104,819	1,622,965
Research and nonresearch sundry gifts net of spending	419,998	291,979
Total investment activity included in excess of revenues over expenses	$ 2,184,925	$ 2,255,531

6. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (also referred to as exit price). Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. In determining fair value, the use of various valuation approaches, including market, income and cost approaches, is permitted.

(in thousands of dollars)

Fair Value Hierarchy
A fair value hierarchy has been established based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the reporting entity's assumptions about the inputs market participants would use. The fair value hierarchy requires the reporting entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. In addition, for hierarchy classification purposes, the reporting entity should not look through the form of an investment to the nature of the underlying securities held by an investee.

The hierarchy is described below:

Level 1 Valuations using quoted prices in active markets for identical assets or liabilities. Valuations of these products do not require a significant degree of judgment. Level 1 assets and liabilities primarily include debt and equity securities that are traded in an active exchange market.

Level 2 Valuations using observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; broker or dealer quotations; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities primarily include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities and derivative contracts whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.

Level 3 Valuations using unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the reporting entity's assumptions about the assumptions market participants would use as well as those requiring significant management judgment.

Valuation Techniques
Pooled investments, separately invested short-term investments and debt and equity securities are classified within Level 1 or Level 2 of the fair value hierarchy as they are valued using quoted market prices, broker or dealer quotations, or other observable pricing sources. Certain types of investments are classified within Level 3 of the fair value hierarchy because they have little or no market activity and therefore have little or no observable inputs with which to measure fair value.

The valuation of interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities.

(in thousands of dollars)

The following tables summarize financial assets and liabilities measured at fair value on a recurring basis as of:

	September 30, 2025				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	Total
Assets					
Pooled investments					
Short-term investments	$ 699,500	$ -	$ -	$ -	$ 699,500
Separately managed investments	1,386,099	554,983	-	-	1,941,082
Mutual funds	3,044	-	-	-	3,044
Private partnerships, commingled funds and other	-	-	-	15,614,838	15,614,838
	2,088,643	554,983	-	15,614,838	18,258,464
Separately invested					
Short-term investments	31,652	-	-	-	31,652
Equities	21,643	-	-	-	21,643
Mutual funds	927,554	83,603	-	-	1,011,157
Private partnerships, commingled funds and other	-	-	-	199,788	199,788
Beneficial interests in perpetual assets	-	-	58,614	-	58,614
	980,849	83,603	58,614	199,788	1,322,854
	$ 3,069,492	$ 638,586	$ 58,614	$ 15,814,626	$ 19,581,318
Interest rate swaps					
Assets		$ 48,376			$ 48,376
Liabilities		(85,312)			(85,312)
Net interest rate swaps		$ (36,936)			$ (36,936)

(in thousands of dollars)

	September 30, 2024				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	Total
Assets					
Pooled investments					
Short-term investments	$ 756,519	$ -	$ -	$ -	$ 756,519
Separately managed investments	1,199,960	119,041	-	-	1,319,001
Mutual funds	3,310	-	-	-	3,310
Private partnerships, commingled funds and other	-	-	-	14,205,694	14,205,694
	1,959,789	119,041	-	14,205,694	16,284,524
Separately invested					
Short-term investments	31,248	-	-	-	31,248
Equities	41,395	-	-	-	41,395
Mutual funds	838,661	68,469	-	-	907,130
Private partnerships, commingled funds and other	-	-	-	223,540	223,540
Beneficial interests in perpetual assets	-	-	56,033	-	56,033
	911,304	68,469	56,033	223,540	1,259,346
	$ 2,871,093	$ 187,510	$ 56,033	$ 14,429,234	$ 17,543,870
Interest rate swaps					
Assets		$ 43,855			$ 43,855
Liabilities		(139,170)			(139,170)
Net interest rate swaps		$ (95,315)			$ (95,315)

(in thousands of dollars)

7. Pledges and Contributions Receivable

Pledges receivables represent unconditional promises to give and are net of allowances for uncollectible amounts. Pledges are recorded at the present value of their estimated future cash flows. Pledges collectible within one year are classified as other current assets, net of allowances, and total $199,430 and $221,076 as of September 30, 2025 and 2024, respectively. Pledges collectable in one year or greater are classified as other assets. Estimated cash flows due after one year are discounted using published treasury bond and note yields that are commensurate with estimated collection risks. The blended discount rate was 3.7% and 3.6% for 2025 and 2024, respectively. Pledges are expected to be collected as follows:

	September 30, 2025	September 30, 2024
Amounts due		
Within one year	$ 220,743	$ 240,290
In one to five years	332,654	330,412
In more than five years	173,052	112,107
Total pledges receivable	726,449	682,809
Less: Unamortized discount	58,399	45,623
	668,050	637,186
Less: Allowance for uncollectibles	33,839	27,441
Net pledges receivable	634,211	609,745
Contributions receivable from trusts	43,721	51,932
	$ 677,932	$ 661,677

8. Property and Equipment

Property and equipment consists of the following:

	September 30, 2025	September 30, 2024
Land and land improvements	$ 355,497	$ 355,891
Buildings and building improvements	10,879,593	10,244,802
Equipment	3,346,428	2,961,248
Construction in progress	1,646,920	1,545,009
Finance right-of-use lease assets	118,665	108,623
	16,347,103	15,215,573
Less: Accumulated depreciation	8,517,223	7,743,833
Property and equipment, net	$ 7,829,880	$ 7,471,740

(in thousands of dollars)

Depreciation expense for the years ended September 30, 2025 and 2024 was $791,200 and $777,893, respectively. Interest costs, net of interest earned, aggregating $40,266 and $12,322 were capitalized in 2025 and 2024, respectively.

For the years ended September 30, 2025 and 2024, fully depreciated assets with an original cost of $21,863 and $393,357, respectively, were written off.

9. Level of Capital and Surplus

Risk-based capital (RBC) is a methodology adopted by the National Association of Insurance Commissioners for determining the minimum level of capital and surplus deemed necessary for an insurer based upon the types of assets held and business written. The Company has guaranteed to the Massachusetts Division of Insurance (DOI) (the RBC Guaranty) to maintain the Health Plan's capital and surplus at a specified minimum level, measured quarterly in accordance with an RBC methodology permitted by DOI. The RBC Guaranty may be enforced by the DOI. The Company provided capital to the Health Plan of $75,000 and $0 in 2025 and 2024, respectively. Mass General Brigham Health Plan, Inc.'s current contract with EOHHS requires it to maintain a minimum net worth as defined under GAAP and/or financial insolvency insurance in an amount equal to the Minimum Net Worth calculation as defined in Massachusetts General Law 176G, Section 25. At December 31, 2024 and 2023 (Mass General Brigham Health Plan, Inc.'s statutory year end), the minimum net worth requirement, as determined in accordance with EOHHS guidelines, was $71,846 and $69,306, respectively. Mass General Brigham Health Plan, Inc.'s GAAP net worth was $205,175 and $212,686 at December 31, 2024 and 2023, respectively, and thus exceeded the EOHHS requirements by $133,329 and $143,380, respectively.

10. Accrued Medical Claims and Related Expenses

Accrued medical claims and related expenses include estimates of expected trends in claims severity, frequency, and other factors, which could vary as the claims are ultimately settled. In establishing this reserve, the Company has utilized the services of actuaries to review the reasonableness of the reserves based upon the historical experience of the Company.

(in thousands of dollars)

The changes in accrued medical claims and related expenses for the years ended September 30, 2025 and 2024 are as follows:

	2025	2024
Balance at beginning of year	$ 258,520	$ 192,435
Less		
Premium deficiency reserve	(33,254)	(24,071)
Accrual for claims adjustment expenses	(4,204)	(2,962)
Accrued medical payables - other	(30,414)	(19,646)
Plus: Settlements payable, net	164,178	135,763
Net balance at beginning of year	354,826	281,519
Incurred related to		
Current year	1,802,086	1,487,755
Prior years	17,387	17,283
Total incurred	1,819,473	1,505,038
Paid related to		
Current year	1,631,586	1,270,729
Prior years	211,604	161,002
Total paid	1,843,190	1,431,731
Net balance at end of year	331,109	354,826
Plus		
Premium deficiency reserve	7,894	33,254
Accrual for claims adjustment expenses	3,804	4,204
Accrued medical payables - other	61,868	30,414
Less: Settlements payable, net	(189,094)	(164,178)
Balance at end of year	$ 215,581	$ 258,520

As a result of changes in estimates of insured events in prior years and recoveries, the liability on claims existing on October 1, 2024 and 2023, increased $17,387 and $17,283, respectively, for the years ended September 30, 2025 and 2024, respectively. Changes of this nature occur as the result of claim settlements and recoveries during the current year and as additional information is received regarding individual claims, causing changes from the original estimates of the cost of these claims. Ongoing analysis of the recent loss development trends is also taken into account in evaluating the overall adequacy of the reserves. The increase in incurred claims related to prior years is primarily the result of higher than anticipated utilization of health care services across the industry and for the Company.

Medical claims and related expenses in the accompanying consolidated statements of operations include other nonclaims related costs. These nonclaims related expenses were for statewide assessments, totaling approximately $87,892 and $14,962 for the years ended September 30, 2025 and 2024, respectively.

(in thousands of dollars)

11. Long-Term Obligations

Mass General Brigham's long-term obligations consist of the following:

	Final Maturity	September 30, 2025	September 30, 2024
Massachusetts Health and Educational Facilities Authority Revenue Bonds			
Series 1997 P*, variable interest rate of 2.55% and 2.99%	2027	$ 60,000	$ 90,000
Series 2005 F*, variable interest rate of 2.99% and 3.03%	2040	220,100	222,250
Series 2007 G*, variable interest rate of 3.00% and 3.00%	2042	75,000	75,000
Series 2008 H*, variable interest rate of 2.75% and 3.44%	2042	150,370	153,675
Massachusetts Development Finance Agency (Agency) Revenue Bonds			
Series 2011 K*, variable interest rate of 2.55% and 3.03%	2046	100,000	100,000
Series 2014 M*, average fixed interest rate of 3.63%	2026	560	1,835
Series 2014 N*, variable interest rate of 4.07% and 4.86%	2044	120,100	122,250
Series 2015 O*, average fixed interest rate of 4.34%	2045	149,545	159,870
Series 2016 Q*, average fixed interest rate of 4.81%	2047	373,665	384,395
Series 2017 S*, average fixed interest rate of 4.47%,	2047	573,785	652,785
Series 2019 T*, variable interest rate of 3.49% and 3.72%	2049	80,000	108,250
Series 2020 A*, average fixed interest rate of 4.80%	2050	252,795	268,130
Series 2022 B*, variable interest rate of 3.85% and 4.67%	2052	100,230	100,230
Series 2023 C, variable interest rate of 4.03% and 4.78%	2038	69,870	69,870
Series 2024 D, average fixed interest rate of 5.00%	2054	309,185	309,185
Series 2024 E*, variable interest rate of 2.48% and 3.50%	2052	150,000	150,000
New Hampshire Health and Education Facilities Authority Revenue Bonds			
Series 2017, average fixed interest rate of 5.00%	2041	80,875	84,445
Mass General Brigham Taxable Debt			
Series 2007 Bonds, fixed interest rate of 6.26%	2037	100,000	100,000
2012 Senior Notes, fixed interest rate of 4.11%	2052	400,000	400,000
2014 Senior Notes, fixed interest rate of 4.73%	2044	150,000	150,000
Series 2015 Bonds, fixed interest rate of 4.12%	2055	300,000	300,000
2016 Senior Notes, fixed interest rate of 3.89%	2046	225,000	225,000
Series 2017 Bonds, fixed interest rate of 3.77%	2048	303,644	303,644
2018 Senior Notes, fixed interest rate of 4.60%	2049	400,000	400,000
Series 2020 Bonds, average fixed interest rate of 3.29%	2060	1,017,135	1,017,135
Series B-1 Commercial Paper Notes, variable interest rate of 4.33% and n/a	2025	61,935	-
Other obligations		1,284	1,880
Total long-term obligations, par value		5,825,078	5,949,829
Net unamortized bond premiums		246,636	265,952
Deferred financing costs		(23,499)	(24,953)
Total long-term obligations, net		6,048,215	6,190,828
Less			
Current portion		448,435	353,249
		$ 5,599,780	$ 5,837,579

* Denotes series is issued in multiple subseries

Variable interest rates are presented at September 30, 2025 and 2024, respectively

(in thousands of dollars)

Scheduled maturities of long-term obligations (including the impact of net unamortized bond premiums and deferred financing costs) during the next five years and thereafter and other amounts classified as current liabilities, are as follows:

	Scheduled Maturities	Bonds Supported by Self Liquidity	Bonds Supported by Bank Facilities	Total
2026	$ 155,565	$ 230,370	$ 62,500	$ 448,435
2027	101,148	-	-	101,148
2028	89,496	-	-	89,496
2029	91,785	-	-	91,785
2030	102,495	-	-	102,495
Thereafter	5,214,856	-	-	5,214,856
	$ 5,755,345	$ 230,370	$ 62,500	$ 6,048,215

The scheduled maturities represent annual payments as required under debt repayment schedules. The current portion of long-term obligations includes the payments scheduled to be made in 2026, bonds supported by self-liquidity that can be tendered prior to September 30, 2026, and bonds supported by bank facilities with financial institutions (standby bond purchase agreements or letters of credit) that expire prior to September 30, 2026 or have potential principal amortization under bank facilities' term out provisions due during 2026. The bonds supported by self-liquidity provide the bondholder with an option to tender the bonds to the Company. Accordingly, these bonds are classified as a current liability. The bonds supported by bank facilities provide the bondholder with an option to tender the bonds to the liquidity provider. Generally accepted accounting principles require bonds backed by bank facilities expiring within one year of the balance sheet date as well as potential principal amortization under bank facilities' term out provisions due within one year of the balance sheet date to be classified as a current liability.

If bonds supported by bank facilities cannot be remarketed, the repayment terms of those bank facilities would result in repayments of $35,000 in 2026, $157,533 in 2027, $135,033 in 2028, $52,533 in 2029, and $0 thereafter. If the bonds supported by self-liquidity cannot be remarketed, the bonds would be tendered to the Company on their respective earliest tender dates, which differ from scheduled maturity dates, and would result in payments of $230,370 in 2026, $0 in 2027, $0 in 2028, $0 in 2029, $76,020 in 2030 and $163,495 thereafter.

(in thousands of dollars)

Scheduled payments of long-term debt (excluding the impact of net unamortized bond premiums and deferred financing costs) for each of the next five years, assuming bonds backed by bank facilities are remarketed and the standby purchase agreements are renewed and bonds supported by self-liquidity are remarketed, are as follows:

2026	$ 93,630
2027	101,148
2028	99,031
2029	100,945
2030	111,820
Thereafter	5,318,504
	$ 5,825,078

Interest expense paid during the years ended September 30, 2025 and 2024 was $249,466 and $247,287, respectively.

In January 2024, we issued $309,185 of Mass General Brigham Series 2024 D Revenue Bonds, plus bond premium of $34,049. The bond proceeds, net of issuance costs of $2,594, were used to refund Partners HealthCare System Series 2017 S-4 Bonds ($69,481) and to finance certain capital projects ($271,158).

In January 2024, we issued $150,000 of Mass General Brigham Series 2024 E Revenue Bonds. The bond proceeds, net of issuance costs of $1,659, were used to refund Taxable Commercial Paper Notes ($50,000) that refinanced, on an interim basis, Partners HealthCare System Series 2016 R-2 Revenue Bonds, and to finance certain capital projects ($98,341).

In December 2023, we issued $69,870 of Mass General Brigham Series 2023 C Revenue Bonds. The bond proceeds were used to refund Taxable Commercial Paper Notes that refinanced, on an interim basis, Partners HealthCare System Series 2017 S-3 Revenue Bonds.

Mass General Brigham bonds are general obligations of the Company supported by guarantees from Brigham, Inc., The Brigham and Women's Hospital, Inc., The Massachusetts General Hospital and The General Hospital Corporation (the General) which may be suspended under certain conditions.

Our debt agreements contain certain covenants, including a minimum debt service coverage ratio and limitations on additional indebtedness and asset transfers.

(in thousands of dollars)

Lines of Credit
The Company maintains two lines of credit aggregating $375,000 that provide access to same day funds. Advances under the lines of credit bear a variable rate of interest based on the Secured Overnight Financing Rate (SOFR). As of September 30, 2025 and 2024, there were no amounts outstanding under the lines of credit. The $250,000 line of credit expires in July 2028. The $125,000 line of credit expires in July 2027.

Taxable Commercial Paper
The Company maintains a $500,000 Taxable Commercial Paper (CP) program. As of September 30, 2025 and 2024, there was $61,935 and $0, respectively, outstanding under the CP program.

12. Derivatives

Interest Rate Swaps
We utilize swap contracts to lock in long-term synthetic fixed rates and manage fluctuations in cash flows resulting from interest rate risk on certain of our variable rate bonds. These bonds expose us to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit this variability. To meet this objective and to take advantage of low interest rates, we have entered into various swap contracts involving the exchange of fixed rate payments by us for variable rate payments from several counterparties. These variable rate payments are currently based on a percentage of SOFR (based on compound average of daily SOFR in arrears) plus a spread.

By using swap contracts to manage the risk of changes in interest rates, we expose ourselves to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the swap contracts. When the fair value of a swap contract is positive, the counterparty has a liability to us, which creates credit risk. We minimize our credit risk by entering into swap contracts with several counterparties and requiring the counterparty to post collateral for our benefit based on the credit rating of the counterparty and the fair value of the swap contract. Conversely, when the fair value of a swap contract is negative, we have a liability to the counterparty and, therefore, we do not have credit risk. Under certain circumstances, we may be required to post collateral for the benefit of the counterparty. Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degree of market risk that we may undertake.

(in thousands of dollars)

In 2025, we terminated various swap contracts with a total notional amount of $243,750 and received $25,788 net proceeds. The following is a summary of the outstanding positions under our swap contracts as of September 30, 2025:

Effective Date	Notional Amount	Maturity	Rate Paid	Rate Received
5/1/03	$ 44,081	7/1/35	4.45%	67% 1M SOFR + 0.0767%
10/15/03	7,360	1/1/31	3.85%	70% 1M SOFR + 0.08014%
7/1/05	150,000	7/1/50	3.09%	67% 1M SOFR + 0.0767%
7/1/07	150,000	7/1/52	2.96%	67% 1M SOFR + 0.0809%
7/1/09	100,000	7/1/50	3.58%	67% 1M SOFR + 0.0767%
7/1/11	100,000	7/1/50	3.66%	67% 1M SOFR + 0.0767%
7/1/13	100,000	7/1/48	3.80%	67% 1M SOFR + 0.0767%
7/1/15	50,000	7/1/50	3.80%	67% 1M SOFR + 0.0767%
4/1/16	100,000	7/1/52	3.76%	67% 1M SOFR + 0.0767%
7/1/17	50,000	7/1/52	3.74%	67% 1M SOFR + 0.083%
7/1/27	100,000	7/1/57	1.79%	67% 1M SOFR + 0.07985%
7/1/29	50,000	7/1/49	1.41%	67% 1M SOFR + 0.0767%
7/1/29	50,000	7/1/54	1.51%	67% 1M SOFR + 0.0767%
7/1/31	50,000	7/1/55	1.50%	67% 1M SOFR + 0.083%
7/1/31	50,000	7/1/56	1.55%	67% 1M SOFR + 0.0767%
7/1/33	50,000	7/1/51	1.03%	67% 1M SOFR + 0.0767%
	$ 1,201,441			

Our swap contracts contain provisions that require collateral to be posted if the fair value of the swap exceeds certain thresholds. The collateral thresholds reflect the current credit ratings issued by major credit rating agencies on our and the counterparty's debt. Declines in our or the counterparty's credit ratings would result in lower collateral thresholds and, consequently, the potential for additional collateral postings by us or the counterparty. As of September 30, 2025, we posted collateral of $0 and held collateral of $11,900 and as of September 30, 2024, we posted collateral of $5,320 and held collateral of $850. We have established procedures to ensure that liquidity and securities are available to meet collateral posting requirements.

Upon the occurrence of certain events of default or termination events identified in the swap contracts, either the Company or the counterparty could terminate the contracts in accordance with their respective terms. Termination results in the payment of a termination amount by one party that attempts to compensate the other party for its economic losses. If interest rates at the time of termination are lower than those specified in the swap contract, we would make a payment to the counterparty. Conversely, if interest rates at such time are higher, the counterparty would make a payment to us.

13. Leases

We lease property and equipment under both finance and operating lease agreements. We recognize leases with a term greater than twelve months on the balance sheets.

(in thousands of dollars)

Some lease agreements require us to pay variable costs including property taxes, insurance, maintenance and repairs. Variable costs are excluded from the right-of-use asset and liability. Lease and nonlease components of agreements are not separated. Some leases contain rental escalation clauses and renewal options that are included in lease payment calculations when appropriate. The estimated incremental borrowing rate is used to discount the lease payment amounts.

The components of lease expense consist of the following:

	Year Ended September 30, 2025		
	Supplies and Other Expenses	Research and Nonresearch Sundry Gifts, Net of Expenses	Total
Operating lease expense	$ 206,602	$ 2,064	$ 208,666
Short-term lease expense	13,379	181	13,560
Variable lease expense	77,139	1,416	78,555
Finance lease expense			
Amortization of leased assets	17,158	179	17,337
Interest on lease liabilities	3,705	28	3,733
Total lease expense	$ 317,983	$ 3,868	$ 321,851

	Year Ended September 30, 2024		
	Supplies and Other Expenses	Research and Nonresearch Sundry Gifts, Net of Expenses	Total
Operating lease expense	$ 218,534	$ 2,217	$ 220,751
Short-term lease expense	14,059	251	14,310
Variable lease expense	78,914	968	79,882
Finance lease expense			
Amortization of leased assets	16,088	174	16,262
Interest on lease liabilities	3,633	16	3,649
Total lease expense	$ 331,228	$ 3,626	$ 334,854

(in thousands of dollars)

Lease related assets and liabilities are as follows:

	Balance Sheet Classification	September 30, 2025	September 30, 2024
Operating lease assets	Right-of-use operating lease assets	$ 801,815	$ 920,702
Finance lease assets	Property and equipment, net	70,368	62,646
Total lease assets		$ 872,183	$ 983,348
Current operating lease liability	Current portion of operating lease obligations	$ 155,897	$ 203,879
Current finance lease liability	Accounts payable and accrued expenses	14,355	16,808
Noncurrent operating lease liability	Operating lease obligation, less current portion	545,738	598,065
Noncurrent finance lease liability	Accrued other	62,579	68,333
Total lease liabilities		$ 778,569	$ 887,085

Supplemental cash flow and other information related to leases are as follows:

	Years Ended September 30, 2025	2024
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flow for operating leases	$ 212,888	$ 213,333
Operating cash flow for finance leases	3,908	3,453
Financing cash flows for finance leases	16,698	14,249
Weighted-average remaining term (years)		
Operating leases	6.7	12.0
Finance leases	21.0	15.0
Weighted-average discount rate		
Operating leases	4.07 %	4.07 %
Finance leases	4.07 %	4.07 %

(in thousands of dollars)

Commitments related to noncancelable operating and finance leases for each of the next five years and thereafter are as follows:

	Operating Leases	Finance Leases
2026	$ 186,072	$ 16,148
2027	153,772	9,298
2028	130,837	6,672
2029	80,205	4,211
2030	52,441	3,616
Thereafter	171,595	111,303
Total minimum future payments	774,922	151,248
Less: Amount representing interest	(73,287)	(74,314)
Present value of minimum future payments	701,635	76,934
Less: Current portion	(155,897)	(14,355)
Long-term lease obligations	$ 545,738	$ 62,579

We are also a lessor and sublessor of real estate under operating leases. Lease income for the years ended September 30, 2025 and 2024 was $7,118 and $15,488, respectively, and is included in other revenue in the consolidated statements of operations. Some of these leases include expenses such as utilities and maintenance costs in rent charges, however, this variable lease income is not considered material. We do not separate lease and nonlease components by class of underlying asset for all asset classes. The underlying real estate assets are included in property and equipment, net in the consolidated balance sheets.

The future undiscounted cash flows to be received from these leases for each of the next five years and thereafter is as follows:

2026	$ 10,514
2027	8,263
2028	7,190
2029	6,499
2030	5,825
Thereafter	51,158
	$ 89,449

14. Construction Projects

The General is constructing a new clinical building, the Phillip and Susan Ragon Building, that will occupy approximately one million square feet and will contain 482 private medical/surgical and intensive care unit beds, exam and infusion bays associated with a relocated and expanded outpatient oncology service, hybrid and conventional cardiovascular operating rooms, and associated imaging modalities as well as below-grade parking. As of September 30, 2025, accumulated costs incurred related to the new clinical building are approximately $1,064,024 with

(in thousands of dollars)

approximately $580,447 in outstanding construction project contracts. The total cost of the project is expected to be approximately $3,311,000 with occupancy scheduled for 2027 for Phase 1 and 2030 for Phase 2.

15. Pension and Postretirement Health Care Benefit Plans

Substantially all Mass General Brigham employees are covered under noncontributory defined benefit pension plans and various defined contribution pension plans. In addition, certain affiliates provide subsidized health care benefits for retired employees on a self-insured basis, with the benefit obligation being partially funded. These retiree health care benefits are administered through a third-party administrator and are accounted for on the accrual basis, which includes an estimate of future payments for claims incurred.

Total net periodic pension and postretirement costs for Mass General Brigham plans consists of the following:

	Years Ended September 30,	
	2025	2024
Defined benefit plans	$ 188,907	$ 106,335
Defined contribution plans	220,993	213,275
Postretirement healthcare benefit plans	(1,253)	1,539
	$ 408,647	$ 321,149

Information regarding benefit obligations, plan assets, funded status, expected cash flows and net periodic benefit cost is as follows:

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
Change in benefit obligations				
Benefit obligations at beginning of year	$ 9,140,819	$ 7,433,676	$ 248,847	$ 213,043
Service cost	421,338	327,945	3,092	2,887
Interest cost	491,097	472,110	11,844	12,535
Plan amendments (gain)/loss	56,665	(1,197)	-	-
Actuarial (gain)/loss	(362,825)	1,314,353	(6,310)	20,020
Benefits paid	(441,413)	(393,190)	(10,893)	(9,950)
Expenses paid	(13,512)	(12,969)	(1,607)	(1,534)
Employee contributions	87	91	13,366	11,846
Benefit obligations at end of year	$ 9,292,256	$ 9,140,819	$ 258,339	$ 248,847

The estimated actuarial gain in the change in benefit obligation for 2025 and 2024 is due primarily to the change in discount rate.

The accumulated benefit obligation for all defined benefit pension plans at the end of 2025 and 2024 was $8,816,878 and $8,739,071, respectively.

(in thousands of dollars)

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
Weighted-average assumptions used to determine end of year benefit obligation				
Discount rate	5.56%	5.25%	5.08%-5.31%	4.91%-5.05%
Rate of compensation increase	3.00%-5.00%	3.00%-5.00%	N/A	N/A
Interest crediting rate	5.50%	5.50%	5.50%	5.50%
Postretirement healthcare cost trend rate for next year	N/A	N/A	7.25%	7.50%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2035	2035

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
Change in plan assets				
Fair value of plan assets at beginning of year	$ 10,325,857	$ 9,075,320	$ 225,985	$ 178,090
Actual return on plan assets	1,525,760	1,549,878	37,866	44,783
Employer contributions	189,514	106,727	2,665	2,750
Employee contributions	87	91	13,366	11,846
Benefits paid	(441,413)	(393,190)	(10,893)	(9,950)
Expenses paid	(13,512)	(12,969)	(1,607)	(1,534)
Fair value of plan assets at end of year	$ 11,586,293	$ 10,325,857	$ 267,382	$ 225,985

The assets of the defined benefit pension plans are aggregated in a single master trust (Master Trust) and managed as one asset pool. The investment objective for the Master Trust is to achieve the highest reasonable total return after considering (i) plan liabilities, (ii) funding status and projected cash flows, (iii) projected market returns, valuations and correlations for various asset classes and (iv) ability and willingness to incur market risk.

Within the Master Trust, assets are allocated to managers with investment mandates that may range from a single sub-asset class to very broad mandates; with restrictions that range from long-only to unconstrained; and with management structures ranging from separately managed funds to mutual/commingled funds to private partnerships. Less market sensitive managers employ long/short equity and diversified strategies. Investment risks (concentration, correlation, valuation, liquidity, leverage, mandate compliance, etc.) are monitored at the manager level as well as the pool level.

(in thousands of dollars)

The following table presents the capital allocations and reported exposures by manager mandate within the Master Trust. Some managers, particularly less market sensitive managers, invest capital among multiple asset classes. The Long-Term Policy Benchmark is 70% Morgan Stanley Capital International All Country World Index and 30% Barclays Global Aggregate Bond.

	September 30, 2025		September 30, 2024	
	Dollars	Reported Exposures	Dollars	Reported Exposures
Global equity	$ 2,698,413	23.3 %	$ 1,805,994	17.6 %
Traditional U.S. equity	1,220,395	10.5 %	1,400,147	13.7 %
Traditional foreign developed equity	223,717	1.9 %	195,010	1.9 %
Traditional emerging markets equity	238,931	2.1 %	316,856	3.1 %
Private equity	3,817,388	32.9 %	2,575,951	24.3 %
Real assets	564,024	4.9 %	571,069	5.5 %
Diversifying equity	2,248,278	19.4 %	2,942,049	28.8 %
Fixed income managers	575,147	5.0 %	518,781	5.1 %
	$ 11,586,293	100.0 %	$ 10,325,857	100.0 %

The postretirement health care benefit plans' assets are invested in commingled funds with the objective of achieving returns to satisfy plan obligations and with a level of volatility commensurate with our overall financial profile. For the years ended September 30, 2025 and 2024, the defined benefit plans had unfunded commitments of $1,242,626 and $1,275,295, respectively.

The following tables summarize plan assets measured at fair value on a recurring basis (using the fair value hierarchy defined in Note 6) as of:

	September 30, 2025			
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	Total
Defined benefit pension plans				
Short-term investments	$ 360,327	$ -	$ -	$ 360,327
Separately managed investments	1,003,430	3,893	-	1,007,323
Private partnerships and commingled funds	-	-	10,218,643	10,218,643
	1,363,757	3,893	10,218,643	11,586,293
Postretirement healthcare benefit plans				
Separately managed investments	45,149	-	222,233	267,382
Total plan assets	$ 1,408,906	$ 3,893	$ 10,440,876	$ 11,853,675

(in thousands of dollars)

	September 30, 2024			
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	Total
Defined benefit pension plans				
Short-term investments	$ 320,651	$ -	$ -	$ 320,651
Separately managed investments	710,149	-	-	710,149
Private partnerships and commingled funds	-	-	9,295,057	9,295,057
	1,030,800	-	9,295,057	10,325,857
Postretirement healthcare benefit plans				
Separately managed investments	47,332	-	178,653	225,985
Total plan assets	$ 1,078,132	$ -	$ 9,473,710	$ 10,551,842

In evaluating the Level at which private partnerships have been classified within the fair value hierarchy, management has assessed factors including but not limited to price transparency, the ability to redeem these investments at net asset value at the measurement date and the existence or absence of certain restrictions at the measurement date. Investments in private partnerships generally have limited redemption options for investors and, subsequent to final closing, may or may not permit subscriptions by new or existing investors. These entities may also have the ability to impose gates, lockups and other restrictions on an investor's ability to readily redeem out of their investment interest in the fund. As of September 30, 2025 and 2024, we have excluded all assets from the fair value hierarchy for which fair value is measured using net asset value per share as a practical expedient.

(in thousands of dollars)

Funded Status

The funded status of the plans recognized in the balance sheet and the amounts recognized in net assets without donor restrictions is as follows:

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
End of year				
Fair value of plan assets at measurement date	$ 11,586,293	$ 10,325,857	$ 267,382	$ 225,985
Benefit obligations at measurement date	(9,292,256)	(9,140,819)	(258,339)	(248,847)
Funded status	$ 2,294,037	$ 1,185,038	$ 9,043	$ (22,862)
Amounts recognized in the balance sheet consist of				
Noncurrent asset	$ 2,315,294	$ 1,206,988	$ 23,709	$ 257
Current liabilities	(4,132)	(1,650)	(1,125)	(1,166)
Long-term liabilities	(17,125)	(20,300)	(13,541)	(21,953)
	$ 2,294,037	$ 1,185,038	$ 9,043	$ (22,862)
Amounts not yet recognized in net periodic benefit cost and included in net assets without donor restrictions consist of				
Actuarial net gain	$ (1,376,912)	$ (184,574)	$ (47,915)	$ (19,451)
Prior service (cost)/credit	49,748	(34,197)	(924)	(1,331)
	$ (1,327,164)	$ (218,771)	$ (48,839)	$ (20,782)
Amounts recognized in net assets without donor restrictions consist of				
Current year actuarial (gain)/loss	$ (1,192,338)	$ 422,524	$ (30,684)	$ (14,463)
Amortization of actuarial loss	-	8,544	2,679	3,582
Current year prior service cost/(credit)	56,665	(1,197)	-	-
Amortization of prior service credit	27,280	27,127	407	-
	$ (1,108,393)	$ 456,998	$ (27,598)	$ (10,881)

As of September 30, 2025 and 2024, the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation below plan assets were as follows:

	September 30,	
	2025	2024
Accumulated benefit obligation below plan assets		
Projected benefit obligation	$ 9,292,256	$ 9,140,819
Accumulated benefit obligation	8,816,878	8,739,071
Fair value of plan assets	11,586,293	10,325,857

(in thousands of dollars)

Expected Cash Flows

Information about the expected cash flows for the defined benefit and postretirement health care benefit plans is as follows:

	Defined Benefit Pension Plans	Postretirement Healthcare Benefit Plans	
Expected employer contributions			
2026	$ 192,145	$ 4,333	
			Medicare Subsidy
Expected benefit payments (receipts)			
2026	422,915	19,915	$ (2)
2027	456,350	20,284	(2)
2028	483,200	20,833	(2)
2029	514,495	21,380	(2)
2030	543,017	21,734	(1)
2031-2034	3,117,186	107,140	(5)

Net Periodic Benefit Cost

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
Service cost	$ 421,338	$ 327,945	$ 3,092	$ 2,887
Interest cost	491,097	472,110	11,844	12,535
Expected return on plan assets	(696,248)	(658,049)	(13,103)	(10,301)
Amortization of				
Prior service credit	(27,280)	(27,127)	(407)	-
Actuarial net gain	-	(8,544)	(2,679)	(3,582)
Nonservice related pension income	(232,431)	(221,610)	(4,345)	(1,348)
Net periodic benefit cost	$ 188,907	$ 106,335	$ (1,253)	$ 1,539

(in thousands of dollars)

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
Weighted-average assumptions used to determine net periodic pension and postretirement cost				
Discount rate	5.25%	6.22%	4.91%-5.05%	6.07%-6.10%
Expected return on plan assets	7.00%	7.00%	6.00%	6.00%
Interest crediting rate	5.50%	5.25%	5.50%	5.25%-6.50%
Rate of compensation increase	3.00%-5.00%	3.00%-5.00%	N/A	N/A
Healthcare cost trend rate for this year	N/A	N/A	7.50%	6.75%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2035	2031

We use a long-term return assumption which is validated annually by obtaining long-term asset return, volatility and correlation projections for relevant asset class indexes; modifying volatility and correlations to reflect the actual historical experience of the active managers; calculating the expected return using benchmark weights and indexes; and comparing the return assumption to the sum of the expected return and the historical outperformance of the actual return versus the benchmark. We regularly monitor the active risk of the Master Trust by a statistical regression of the return series of the actual portfolio to that of the policy benchmark.

16. Professional Liability Insurance

We insure substantially all of our professional and general liability risk on a claims-made basis in cooperation with other health care organizations in the Greater Boston area through a reciprocal risk-retention group, Controlled Risk Insurance Company of Vermont, Inc. (CRICO). The Company owns 11% of CRICO. The policies cover claims made during their respective terms, but not those occurrences for which claims may be made after expiration of the policy. Management intends to renew its coverage on a claims-made basis and has no reason to believe that it will be prevented from such renewal. During 2025, CRICO announced and paid a dividend to member organizations. As a result, we recorded dividend income of $120,595 in other nonoperating expenses.

We follow the accounting policy of establishing reserves to cover the ultimate costs of medical malpractice claims, which include costs associated with litigating or settling claims. The liability also includes an estimated tail liability, established to cover all malpractice claims incurred but not reported to the insurance company as of the end of the year. The total malpractice liability of $594,421 and $573,796 as of September 30, 2025 and 2024, respectively, is presented as an accrued professional liability in the consolidated balance sheets. These reserves have been recorded on a discounted basis using an interest rate of 5.0% as of September 30, 2025 and 2024.

We also recognize an insurance receivable from CRICO at the same time that we recognize the liability, measured on the same basis as the liability, subject to the need for a valuation allowance for uncollectible amounts. The insurance receivable of $464,510 and $442,072 as of September 30, 2025 and 2024, respectively, is reported as a component of other assets in the consolidated balance sheets.

(in thousands of dollars)

Management is not aware of any claims against us or factors affecting CRICO that would cause the expense for professional liability risks to vary materially from the amount provided.

17. Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist of patient accounts receivable, research grants receivable, pledges receivable, premiums receivable, certain investments and interest rate swaps.

Mass General Brigham provider organizations receive a significant portion of payments for services rendered from a limited number of government and commercial third-party payers, including Medicare, Medicaid, Blue Cross and Blue Shield of Massachusetts, and Point32Health. Research funding is provided through many government and private sponsors. The Health Plan receives a portion of premium revenue from the Commonwealth.

Pledges receivable are due from multiple donors. We assess the credit risk for pledges based on history and the financial wherewithal of donors, most of which are individuals or organizations well known to us.

Investments, which include government and agency securities, stocks and corporate bonds, private partnerships and other investments, are not concentrated in any corporation or industry or with any single counterparty. Alternative investments are less liquid than other investments. The reported values of the alternative investments may differ significantly from the values that would have been used had a ready market for those securities existed. These instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of oversight, dependence upon key individuals, emphasis on speculative investments and nondisclosure of portfolio composition.

We minimize our credit risk exposure under interest rate swap agreements by utilizing several counterparties and requiring the counterparties to post collateral for our benefit when the fair value of the swap is positive. We minimize our counterparty risk by contracting with nine counterparties, none of which accounts for more than 21% of the aggregate notional amount of the swap contracts.

(in thousands of dollars)

18. Net Assets

Net assets without donor restrictions

The following table reconciles the changes in consolidated net assets without donor restrictions that are attributable to the Company and noncontrolling interests:

	Controlling Interest	Noncontrolling Interest	Total
Net assets without donor restrictions at September 30, 2023	$ 13,266,506	$ 95,939	$ 13,362,445
Excess of revenues over expenses	2,051,883	(4,204)	2,047,679
Funds utilized for property and equipment	434,073	-	434,073
Change in funded status of defined benefit plans	(445,729)	-	(445,729)
Other changes in net assets	69	15,053	15,122
Increase in net assets without donor restriction	2,040,296	10,849	2,051,145
Net assets without donor restrictions at September 30, 2024	15,306,802	106,788	15,413,590
Excess of revenues over expenses	2,396,553	(10,911)	2,385,642
Funds utilized for property and equipment	36,549	-	36,549
Change in funded status of defined benefit plans	1,135,994	-	1,135,994
Other changes in net assets	(1,253)	(2,224)	(3,477)
Increase in net assets without donor restriction	3,567,843	(13,135)	3,554,708
Net assets without donor restrictions at September 30, 2025	$ 18,874,645	$ 93,653	$ 18,968,298

Net assets with donor restrictions

Net assets with donor restrictions are available for the following purposes:

	September 30, 2025	September 30, 2024
Net assets with donor restrictions		
Charity care	$ 233,182	$ 223,251
Buildings and equipment	682,102	506,830
Clinical care, research and academic	3,727,987	3,216,044
	$ 4,643,271	$ 3,946,125

(in thousands of dollars)

Endowment

Our endowment consists of numerous individual funds established for a variety of purposes and includes both endowment funds with donor restrictions and funds designated by boards to function as endowment. We have interpreted UPMIFA as requiring the preservation of the value of the original contribution of the endowment funds with donor restrictions absent explicit donor stipulations to the contrary. As a result of this interpretation, we classify net assets with donor restrictions, the original value of all contributions with donor stipulations to maintain in perpetuity, accumulated gains required to be maintained in perpetuity by explicit donor stipulation or accumulated gains which have been appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, we consider several factors in making a determination to appropriate or accumulate endowment funds with donor restrictions. These factors include: the duration and preservation of the fund; the purposes of the organization and the endowment fund with donor restrictions; general economic conditions; the possible effect of inflation and deflation; the expected total return from income and the appreciation of investments; other resources of the organization; and the investment policies of the organization.

Endowment Funds with Deficits

From time to time, the value of assets associated with individual endowment funds with donor restrictions may fall below the value of the initial and subsequent donor contribution amounts. These deficits generally result from unfavorable market fluctuations that occurred after the investment of new contributions with donor restrictions or subsequent endowment additions. When such endowment deficits exist, they are classified as a reduction to net assets with donor restrictions.

The following presents the endowment net asset composition by type of fund as of September 30, 2025 and 2024 and the changes in endowment assets for the years ended September 30, 2025 and 2024:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net asset composition by type of fund as of September 30, 2025			
Endowment funds with donor restrictions	$ -	$ 3,356,694	$ 3,356,694
Endowment funds with board designations	1,936,933	-	1,936,933
Total funds	$ 1,936,933	$ 3,356,694	$ 5,293,627

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
Changes in endowment net assets			
Endowment net assets at September 30, 2024	$ 1,662,338	$ 2,929,226	$ 4,591,564
Investment return			
Investment income	3,508	6,078	9,586
Net realized and unrealized appreciation	251,118	436,482	687,600
Total investment return	254,626	442,560	697,186
Contributions	30,447	150,736	181,183
Appropriation of endowment assets for expenditure	(8,922)	(163,618)	(172,540)
Other changes	(1,556)	(2,210)	(3,766)
Total changes	274,595	427,468	702,063
Endowment net assets at September 30, 2025	$ 1,936,933	$ 3,356,694	$ 5,293,627

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net asset composition by type of fund as of September 30, 2024			
Endowment funds with donor restrictions	$ -	$ 2,929,226	$ 2,929,226
Endowment funds with board designations	1,662,338	-	1,662,338
Total funds	$ 1,662,338	$ 2,929,226	$ 4,591,564

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
Changes in endowment net assets			
Endowment net assets at September 30, 2023	$ 1,368,005	$ 2,441,991	$ 3,809,996
Investment return			
Investment income	1,660	2,851	4,511
Net realized and unrealized appreciation	261,492	452,078	713,570
Total investment return	263,152	454,929	718,081
Contributions	10,624	142,349	152,973
Appropriation of endowment assets for expenditure	(61,076)	(107,076)	(168,152)
Other changes	81,633	(2,967)	78,666
Total changes	294,333	487,235	781,568
Endowment net assets at September 30, 2024	$ 1,662,338	$ 2,929,226	$ 4,591,564

19. Functional Expenses

Expenses by functional classification are allocated based on management's judgement, the nature of the expense and historical experience. Such classifications and allocations are as follows:

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2025
Operating expenses					
Employee compensation and benefit expense	$ 9,461,923	$ -	$ 69,376	$ 1,591,615	$ 11,122,914
Supplies and other expenses	6,115,688	-	101,667	307,546	6,524,901
Medical claims and related expenses	-	-	1,819,473	-	1,819,473
Direct research and noresearch sundry expenses	-	2,324,147	-	-	2,324,147
Depreciation and amortization expenses	704,019	-	53	87,680	791,752
Interest expense	103,486	-	-	61,920	165,406
Total operating expenses	$ 16,385,116	$ 2,324,147	$ 1,990,569	$ 2,048,761	$ 22,748,593

Direct research and nonresearch sundry expenses include $1,432,864 of employee compensation and benefit expense and $891,283 of supplies and other expenses for the year ended September 30, 2025.

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2025
Nonoperating expenses					
Employee compensation and benefit expense	$ -	$ -	$ -	$ 84,342	$ 84,342
Supplies and other expenses	-	-	-	35,950	35,950
Interest expense	-	-	-	19,010	19,010
Pension related interest costs	384,125	51,401	-	67,415	502,941
Total nonoperating expenses	$ 384,125	$ 51,401	$ -	$ 206,717	$ 642,243

(in thousands of dollars)

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2024
Operating expenses					
Employee compensation and benefit expense	$ 8,762,016	$ -	$ 82,892	$ 1,419,870	$ 10,264,778
Supplies and other expenses	5,182,240	-	94,827	263,209	5,540,276
Medical claims and related expenses	-	-	1,505,038	-	1,505,038
Direct research and noresearch sundry expenses	-	2,240,832	-	-	2,240,832
Depreciation and amortization expenses	691,739	-	-	86,598	778,337
Interest expense	100,276	-	-	75,003	175,279
Total operating expenses	$ 14,736,271	$ 2,240,832	$ 1,682,757	$ 1,844,680	$ 20,504,540

Direct research and nonresearch sundry expenses include $1,339,705 of employee compensation and benefit expense and $901,127 of supplies and other expenses for the year ended September 30, 2024.

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2024
Nonoperating expenses					
Employee compensation and benefit expense	$ -	$ -	$ -	$ 85,449	$ 85,449
Supplies and other expenses	-	-	-	24,244	24,244
Interest expense	-	-	-	57,567	57,567
Pension related interest costs	368,476	52,972	-	63,197	484,645
Total nonoperating expenses	$ 368,476	$ 52,972	$ -	$ 230,457	$ 651,905

20. Contingencies

We are subject to complaints, claims and litigation which arise in the normal course of business. In addition, we are subject to reviews and investigations by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. Governmental review of compliance by health care organizations has increased.

21. Subsequent Events

We have assessed the impact of subsequent events through December 19, 2025, the date the audited financial statements were issued. During this period, there were no subsequent events that require adjustment to the audited financial statements.

Schedule of Expenditures of Federal Awards

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number		Total Expenditures	Subrecipient Expenditures
Research and Development and Research Training						
Research and Development						
ADMINISTRATION FOR CHILDREN AND FAMILIES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Assistance for Torture Victims	93.604	Center for Victims of Torture	90ZT0214-03-00		$ 203,073	$ -
				Subtotal	203,073	-
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Direct			2,060,526	356,564
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Shepherd Center Inc.	90DPHF0004		28,793	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPBU0008-03-00		50,468	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPCP0008-04-00		12,547	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPKT0013-01-00		9,680	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPTB0027-03-00		16,108	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPTB0027-04		15,958	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90SIMS0017-01-04		23,882	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Trustees of Indiana University	90DPHF0006-05-00		2,079	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Trustees of Indiana University	90DPTB0035-02-00		84,949	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	University of Alabama, Birmingham	90REGE0019-03-00		7,920	-
Special Programs for the Aging, Title III, Part D, Disease Prevention and Health Promotion Services	93.043	Direct			69,594	-
				Subtotal	2,382,504	356,564
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	5P30HS029762-02		131,832	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	5R01HS029781-02		19,430	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Boston Medical Center	5R13HS028936-03		2,530	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Brigham and Women's Hospital, Inc.	5R01HS029470-02		18,812	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Cincinnati Children's Hospital Medical Center	5R01HS028976-03		13,818	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Direct			8,146,051	2,098,312
Research on Healthcare Costs, Quality and Outcomes	93.226	Harvard Pilgrim Health Care	5R01HS027170-04		38,725	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Massachusetts General Hospital	1R01HS030245-01		39,148	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Oregon Health & Science University (OHSU)	5R18HS029345-03		248,226	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	1R01HS026753-05		(1,850)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	5R01HS029454-02		36,550	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	5R18HS027282-04		(2)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of California, San Francisco	5R18HS029366-03		158,319	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of Michigan	5R01HS028975-02		128,505	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Tufts Medical Center, Inc.	5R01HS029319-02		(27,541)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Colorado at Denver	1R21HS029991-01		70,979	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Utah	5R18HS027960-03		1,785	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Yale University	5U18HS029307-03		251,963	-
				Subtotal	9,277,280	2,098,312
AGRICULTURAL RESEARCH SERVICE, AGRICULTURE, DEPARTMENT OF						
Agricultural Research Basic and Applied Research	10.001	Direct			74,512	-
				Subtotal	74,512	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	Children's Hospital Corporation dba Boston Children's Hospital	NU27DD000020-05-00		12,875	-
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	Trustees of Columbia University in the City of New York (The)	6U01DP006436-01-02		4,325	-
Centers for Diseases Control and Prevention Contracts	93.RD7	American Society for Microbiology	P01145		19,862	-
Centers for Diseases Control and Prevention Contracts	93.RD7	American Society for Microbiology	P01146		6,496	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Direct			1,070,203	575,879
Centers for Diseases Control and Prevention Contracts	93.RD7	The Broad Institute, Inc.	75D30122C15113		(1,978)	-
Centers for Diseases Control and Prevention Contracts	93.RD7	University of Maryland, Baltimore	75D30122C15467		193,865	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	Emory University	6U48DP006377-05-03		35,419	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	President and Fellows of Harvard College	6U48DP006785-01-01		6,648	-
Chronic Diseases: Research, Control, and Prevention	93.068	Direct			568,270	89,189
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	Vanderbilt University Medical Center	5NU58DP007307 02 00		60,624	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Brown University	200-2016-91773-T.O.2		(12,448)	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Direct			(8)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number		Total Expenditures	Subrecipient Expenditures
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 The Broad Institute, Inc.	75D30123C17983		217,722	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Wayne State University	75D30121C11813		66,416	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 Olive View/UCLA Education and Research Institute, Inc.	U01CK000643-01-03		(76,435)	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 Regents of the University of California, Los Angeles, The	5U01CK000643-02		(5,242)	-
COVID-19 Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	COVID-19 Direct			(2,038)	1,289
COVID-19 Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases	93.083	COVID-19 Beth Israel Deaconess Medical Center	1U011P001257-01-00		385,390	-
COVID-19 Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases	93.083	COVID-19 Beth Israel Deaconess Medical Center	1U01IP001257-01-00		232,182	-
Global AIDS	93.067	Beth Israel Deaconess Medical Center	5NU2GGH002212-02-00		(333)	-
Global AIDS	93.067	Beth Israel Deaconess Medical Center	5NU2GGH002212-04-00		(199)	-
HIV Demonstration, Research, Public and Professional Education Projects	93.941	Vanderbilt University Medical Center	5U01PS005240-04-00		109,303	-
Injury Prevention and Control Research and State and Community Based Programs	93.136	Direct			313,194	64,310
Occupational Safety and Health Program	93.262	Icahn School of Medicine at Mount Sinai	1U01OH012782-01-00		26,707	-
Occupational Safety and Health Program	93.262	Icahn School of Medicine at Mount Sinai	5U01OH010401-11-00		14,302	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5R01OH002421-26		25,461	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5U19OH008861-18		11,545	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5U19OH008861-18-00		34,770	-
Occupational Safety and Health Program	93.262	The Broad Institute, Inc.	R01MH132968		80,215	-
Packaging and Spreading Proven Pediatric Weight Management Interventions for Use by Low-Income Families	93.349	Direct			86,153	15,771
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Direct			1,118,672	339,592
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Health Care	5U54CK000611-02		(99)	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Health Care	5U54CK000611-02-00		8,690	-
Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases	93.083	Beth Israel Deaconess Medical Center	1U01IP001257-01-00		707,917	-
Public Health Preparedness Science	93.316	President and Fellows of Harvard College	1NH78TU000001-01-00		19,675	-
Sexually Transmitted Diseases (STD) Prevention and Control Grants	93.977	Direct			261,169	-
Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention	93.326	Direct			40,959	40,000
Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement	93.772	Rosebud Sioux Tribe	6NU38TO000024-02-02		94,258	-
				Subtotal	5,734,507	1,126,030
CONSUMER PRODUCT SAFETY COMMISSION, CONSUMER PRODUCT SAFETY COMMISSION						
Consumer Product Safety Commission Contracts	93.RD5	Direct			38,748	-
				Subtotal	38,748	-
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA), DEPT OF DEFENSE						
Research and Technology Development	12.910	Charles Stark Draper Laboratory, Inc (The)	N66001-23-C-4018		652,170	-
Research and Technology Development	12.910	Direct			2,720,300	1,042,981
Research and Technology Development	12.910	Johns Hopkins University	N660012424024		1,207,700	-
Research and Technology Development	12.910	President and Fellows of Harvard College	HR00111920022		(222)	-
				Subtotal	4,579,948	1,042,981
DEFENSE THREAT REDUCTION AGENCY (DTRA), DEPT OF DEFENSE						
Scientific Research - Combating Weapons of Mass Destruction	12.351	Direct			359,764	-
				Subtotal	359,764	-
DEPARTMENT OF DEFENSE, DEPT OF DEFENSE						
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Advanced Technology International	2017-605		10,569	-
Department of Defense Contracts	93.RD10	Coalesenz, Inc	W81XWH20C0119		(403)	-
Department of Defense Contracts	93.RD10	Dana-Farber Cancer Institute, Inc.	HT94252410457		33,844	-
Department of Defense Contracts	93.RD10	Dana-Farber Cancer Institute, Inc.	HT94252410799		9,526	-
Department of Defense Contracts	93.RD10	Direct			5,419,895	502,789
Department of Defense Contracts	93.RD10	Geneva Foundation, The	HU00011920056		916,607	32
Department of Defense Contracts	93.RD10	Lumia Health, Inc.	FA864924P0525		134,632	-
Department of Defense Contracts	93.RD10	Massachusetts General Hospital	HT94252310948		83,994	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology	FA8702-15-D-0001		121,845	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology Lincoln Laboratories	FA8702-15-D-0001		306,612	-
Department of Defense Contracts	93.RD10	Medical Technology Enterprise Consortium (MTEC)	HT94252490023		485,552	-
Department of Defense Contracts	93.RD10	Medical Technology Enterprise Consortium (MTEC)	W81XWH189000411		1,356,202	-
Department of Defense Contracts	93.RD10	Medical Technology Enterprise Consortium (MTEC)	W81XWH2290004		(31,560)	-
Department of Defense Contracts	93.RD10	Meso Scale Diagnostics, LLC	HT94252310312		86,947	-
Department of Defense Contracts	93.RD10	Metro International Biotech, LLC	H924051890002		1,813,939	-
Department of Defense Contracts	93.RD10	President and Fellows of Harvard College	W81XWH22C0128		16,519	-
Department of Defense Contracts	93.RD10	Rector and Visitors of the University of Virginia, The	HT94252310219		22,519	-
Department of Defense Contracts	93.RD10	Regents of the University of California, San Diego	W81XWH2220027		12,118	-
Department of Defense Contracts	93.RD10	Regents of the University of California, San Francisco	W81XWH1590001		136,152	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Department of Defense Contracts	93.RD10	Solventum Intellectual Properties Company	HT942524C0066	550,953	-
Department of Defense Contracts	93.RD10	STAT Health Informatics, Inc.	FA86492490814	26,705	-
Department of Defense Contracts	93.RD10	The Broad Institute, Inc.	HR0012120010	9,862	-
Department of Defense Contracts	93.RD10	The Henry M. Jackson Foundation for the Advancement of Military Medicine	HT942524C0053	67,264	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	HT942523C0012	84,165	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	W81XWH21C0023	93,102	-
Department of Defense Contracts	93.RD10	University of North Carolina at Chapel Hill, The	W81XWH22C0122	222,272	-
Department of Defense Contracts	93.RD10	University of South Florida	H9240520D0001	108,893	-
Department of Defense Contracts	93.RD10	Vivonics, Inc.	W81XWH21900006	47,542	-
Department of Defense Contracts	93.RD10	Wake Forest University Health Sciences	W15QKN1691002	483,510	-
			Subtotal	12,629,777	502,821
DEPT OF THE AIR FORCE, DEPT OF DEFENSE					
Air Force Defense Research Sciences Program	12.800	Direct		7,763,945	-
Air Force Defense Research Sciences Program	12.800	Massachusetts Institute of Technology	FA8702-15-D-0001	4,219	-
Air Force Defense Research Sciences Program	12.800	Massachusetts Institute of Technology Lincoln Laboratories	FA8702-15-D-0001	265,038	-
			Subtotal	8,033,202	-
DEPT OF THE ARMY, DEPT OF DEFENSE					
Basic Scientific Research	12.431	Trustees of Tufts College	W911NF2310276	722,802	-
Basic Scientific Research	12.431	University of Pittsburgh Of the Commonwealth System of Higher Education	W911NF2320022	152,016	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Direct		582,400	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Trustees of the University of Pennsylvania	W81XWH2110422	14,881	-
Military Medical Research and Development	12.420	American Burn Association	W81XWH1910664	5,500	-
Military Medical Research and Development	12.420	American University	W81XWH2220012	426,902	-
Military Medical Research and Development	12.420	Axogen Corporation	W81XWH18PRORPCTRA	(28,781)	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2110471	80,343	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2210349	8,950	-
Military Medical Research and Development	12.420	BioSensics LLC	HT94252410421	17,906	-
Military Medical Research and Development	12.420	Board of Trustees of the Leland Stanford Junior University, The	W81XWH2010855	8,115	-
Military Medical Research and Development	12.420	Board of Trustees of the University of Illinois, The	W81XWH1810661	1,275	-
Military Medical Research and Development	12.420	Boston VA Research Institute Inc	W81XWH1910057	(3,903)	-
Military Medical Research and Development	12.420	Boston VA Research Institute Inc	W81XWH2210568	15,830	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	HT94252310846	160,666	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	HT94252310880	368,308	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	HT94252510003	26,340	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	HT94252510037	52,121	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	HT94252510265	949	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	W81XWH1910219	6,919	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	W81XWH2230001	(7,410)	-
Military Medical Research and Development	12.420	Children's Hospital Los Angeles	W81XWH2110257	(2)	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	HT94251210837	49,029	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	HT94252410799	43,379	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH2210705	25,232	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH2211090P00001	23,400	-
Military Medical Research and Development	12.420	Direct		47,940,463	4,089,611
Military Medical Research and Development	12.420	Duke University	PR221120-HT94252310386	57,196	-
Military Medical Research and Development	12.420	Duke University	W81XWH2120031	7,595	-
Military Medical Research and Development	12.420	HHT Foundation International Inc.	W81XWH2110827	11,726	-
Military Medical Research and Development	12.420	Icahn School of Medicine at Mount Sinai	W81XWH2210999	246,846	-
Military Medical Research and Development	12.420	Joan & Sanford I. Weill Medical College of Cornell University	W81XWH1810667	153,877	-
Military Medical Research and Development	12.420	Johns Hopkins University	10054547-01	(802)	-
Military Medical Research and Development	12.420	Johns Hopkins University	HT94252310589	194,150	-
Military Medical Research and Development	12.420	Kessler Foundation	HT94252410911	76,037	-
Military Medical Research and Development	12.420	Massachusetts Eye and Ear Infirmary	HT94252310284	11,605	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	243076	(1,958)	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	HT94252410311	48,028	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2010293	(2,273)	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2211053	13,732	-
Military Medical Research and Development	12.420	Massachusetts Institute of Technology	W81XWH1910151	46,662	-
Military Medical Research and Development	12.420	Massachusetts Institute of Technology	W81XWH2110235	(45)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Military Medical Research and Development	12.420	Mayo Clinic	W81XWH1510293	25	-
Military Medical Research and Development	12.420	MD Anderson Cancer Center	W81XWH2210890	(5,535)	-
Military Medical Research and Development	12.420	MD Anderson Cancer Center	W81XWH2210952	24,034	-
Military Medical Research and Development	12.420	Melanoma Research Alliance	W81XWH2110819	88,771	-
Military Medical Research and Development	12.420	Metis Foundation, The	HT94252311011	237,386	-
Military Medical Research and Development	12.420	Metis Foundation, The	HT94252330001	18,747	-
Military Medical Research and Development	12.420	MGH INTERNAL SUPPORT	W81XWH2210293	(160,651)	-
Military Medical Research and Development	12.420	Michigan State University	W81XWH2110744	99,304	-
Military Medical Research and Development	12.420	NeuroDex, Inc.	HT94252310077	32,044	-
Military Medical Research and Development	12.420	New York University Grossman School of Medicine	W81XWH2220078	411,318	-
Military Medical Research and Development	12.420	Northwestern University	W81XWH2210166	(19,346)	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	HT94252310226	187,862	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	HT94252310523	42,816	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	HT94252310871	3,200	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH2010303	(5)	-
Military Medical Research and Development	12.420	Rector and Visitors of the University of Virginia, The	HT94252310219	465,989	-
Military Medical Research and Development	12.420	Regents of the University of California, Davis	HT94252310153	166,772	-
Military Medical Research and Development	12.420	Regents of the University of California, Los Angeles, The	2023-508	103,237	-
Military Medical Research and Development	12.420	Regents of the University of California, Los Angeles, The	HT94262411081	36,064	-
Military Medical Research and Development	12.420	Regents of the University of California, Los Angeles, The	W81XWH2110869	(7,727)	-
Military Medical Research and Development	12.420	Regents of the University of California, San Diego	HT94252320013	84,305	-
Military Medical Research and Development	12.420	Regents of the University of California, San Diego	W81XWH1710671	157,374	-
Military Medical Research and Development	12.420	The Broad Institute, Inc.	HT94252310890	6,944	-
Military Medical Research and Development	12.420	Trustees of Boston University	W81XWH1910765	121,736	-
Military Medical Research and Development	12.420	Trustees of Boston University	W81XWH2110980	(21)	-
Military Medical Research and Development	12.420	Trustees of the University of Pennsylvania	W81XWH1910861	(14,399)	-
Military Medical Research and Development	12.420	Trustees of Tufts College	W81XWH2211065	30,722	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1720037	(1,227)	-
Military Medical Research and Development	12.420	University of Kentucky	W81XWH2010449	19,609	-
Military Medical Research and Development	12.420	University of North Carolina at Chapel Hill, The	HT9425230032 0011962393	93,035	-
Military Medical Research and Development	12.420	University of North Carolina at Chapel Hill, The	HT94252411108	62,372	-
Military Medical Research and Development	12.420	University of North Carolina at Chapel Hill, The	W81XWH2220051 00 11788011	200,836	-
Military Medical Research and Development	12.420	University of Pittsburgh Of the Commonwealth System of Higher Education	W81XWH2110542	2,757	-
Military Medical Research and Development	12.420	University of Texas Health Science Center at San Antonio	HT94252311046	91,713	-
Military Medical Research and Development	12.420	University of Texas Health Science Center at San Antonio	w81XWH2120044	36,078	-
			Subtotal	54,172,145	4,089,611
DEPT OF THE NAVY, DEPT OF DEFENSE					
Basic and Applied Scientific Research	12.300	Massachusetts Institute of Technology	N000142412687	45,513	-
Basic and Applied Scientific Research	12.300	National Marrow Donor Program	C10831	(11,210)	-
Basic and Applied Scientific Research	12.300	Ohio State University	N00014-20-1-2163	323,356	-
Basic and Applied Scientific Research	12.300	Regents of the University of Michigan	N00014-20-1-2479	(82,533)	-
			Subtotal	275,126	-
DRUG ENFORCEMENT ADMINISTRATION, JUSTICE, DEPARTMENT OF					
U.S. Drug Enforement Administration Contracts	93.RD19	Direct		89,630	-
			Subtotal	89,630	-
ENERGY, DEPARTMENT OF, ENERGY, DEPARTMENT OF					
Office of Science Financial Assistance Program	81.049	North Carolina State University	DE-SC0023334	293,444	-
U.S. Department of Energy Contracts	93.RD4	Los Alamos National Laboratory		257,212	-
			Subtotal	550,656	-
FEDERAL AVIATION ADMINISTRATION, TRANSPORTATION, DEPARTMENT OF					
Federal Aviation Administration Contracts	93.RD14	Boston University School of Public Health	13-C-AJFE-BU-027	171,882	-
Federal Aviation Administration Contracts	93.RD14	Guidehouse, Inc.	693KA8-23-F-00032	2	-
Federal Aviation Administration Contracts	93.RD14	Guidehouse, Inc.	693KA9-24-C-00016	34,283	-
			Subtotal	206,167	-
FEDERAL COMMUNICATIONS COMMISSION, FEDERAL COMMUNICATIONS COMMISSION					
Federal Communications Commission Contracts	93.RD11	Direct		71,124	-
			Subtotal	71,124	-
FOOD AND DRUG ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 U.S. Food & Drug Administration Contracts	93.RD8	COVID-19 American College of Medical Toxicology, Inc.	75F40122D00028	7,512	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number		Total Expenditures	Subrecipient Expenditures
Food and Drug Administration Research	93.103	Children's Research Institute	5P50FD007965-02		109,140	-
Food and Drug Administration Research	93.103	Direct			2,434,332	117,822
Food and Drug Administration Research	93.103	Duke University	1U01FD007909-01A1		1,521	-
Food and Drug Administration Research	93.103	Johns Hopkins University	1U01FD008129-01		126,671	-
Food and Drug Administration Research	93.103	President and Fellows of Harvard College	5U01FD007929-02		389,810	-
Food and Drug Administration Research	93.103	Regents of the University of California, San Diego	1U01FD007773-01		(1,317)	-
Food and Drug Administration Research	93.103	Regents of the University of Minnesota	1R01FD007630-01		25,424	-
U.S. Food & Drug Administration Contracts	93.RD8	Direct			1,978,576	77,366
U.S. Food & Drug Administration Contracts	93.RD8	Harvard Pilgrim Health Care	75F40119D10037		1,546,942	-
U.S. Food & Drug Administration Contracts	93.RD8	Jaeb Center for Health Research	4050		71,925	-
U.S. Food & Drug Administration Contracts	93.RD8	Regents of the University of Michigan	75F40121C00148		11,767	-
U.S. Food & Drug Administration Contracts	93.RD8	Regents of the University of Michigan	75F40124C00131		33,995	-
				Subtotal	6,736,298	195,188
HEALTH AND HUMAN SERVICES, DEPARTMENT OF, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Congressional Directives	93.493	Direct			990,702	-
				Subtotal	990,702	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
COVID-19 Mental and Behavioral Health Education and Training Grants	93.732	COVID-19 Massachusetts League of Community Health Centers, Inc.	1U3MHP45385 01 00		129,212	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	6TR7HA53199-01-02		8,854	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	6TR7HA53199 01 02		2,887	-
Maternal and Child Health Federal Consolidated Programs	93.110	Ann & Robert H. Lurie Children's Hospital of Chicago	U1IMC45814		6,968	-
Maternal and Child Health Federal Consolidated Programs	93.110	Education Development Center, Inc.	2UF4MC26525		81,206	-
Maternal and Child Health Federal Consolidated Programs	93.110	HHT Foundation International Inc.	1UP4MC46404-03-00		99,999	-
Maternal and Child Health Federal Consolidated Programs	93.110	Icahn School of Medicine at Mount Sinai	5H30MC24048 14 00		4,097	-
Maternal and Child Health Federal Consolidated Programs	93.110	President and Fellows of Harvard College	1U54HD113238-01		26,668	-
Special Projects of National Significance	93.928	Fenway Community Health Center	5U90HA42153-04		57,235	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	5U30CS22742-14-00		52,856	-
Telehealth Programs	93.211	President and Fellows of Harvard College	5U3IRI143510-04		88,695	-
				Subtotal	558,677	-
IMMED OFFICE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Biomedical Advanced Research and Development Authority	93.RD13	Locus Biosciences, Inc.	75A50120C00169		140,961	-
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.360	Children's Research Institute	75A50124C00035		43,600	-
COVID-19 Biomedical Advanced Research and Development Authority	93.RD13	COVID-19 Beckman Coulter, Inc.	75A50122C00036		193,015	-
COVID-19 National Ebola Training and Education Center (NETEC)	93.825	COVID-19 Emory University	6U3REP150549-05-26		113,485	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Advanced Regenerative Manufacturing Institute	IDSEP220058-01-003		1,397,316	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct			1,513,656	240,577
				Subtotal	3,402,033	240,577
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION, NATIONAL AERONAUTICS AND SPACE ADMINISTRATION						
Exploration	43.003	Baylor College of Medicine	80NSSC21K0757		14,220	-
Exploration	43.003	Direct			355,639	141,013
Exploration	43.003	Massachusetts Institute of Technology	7000000324/NNX16A069A		202,316	-
National Aeronautics and Space Administration Contracts	93.RD17	Beth Israel Deaconess Medical Center	80NSSC19K0534		5,684	-
National Aeronautics and Space Administration Contracts	93.RD17	Direct			527,314	147,663
National Aeronautics and Space Administration Contracts	93.RD17	KBRWyle	NNJ15HK11B		58,868	13,463
National Aeronautics and Space Administration Contracts	93.RD17	Wake Forest University Health Sciences	80ARC022CA008P00003		43,483	-
Science	43.001	Beth Israel Deaconess Medical Center	80NSSC23K0774		43,551	-
Science	43.001	Institute for Medical Research, Inc	80NSSC24K1019		106,745	-
Science	43.001	National Aeronautics and Space Administration			233,089	-
Space Operations	43.007	Direct			317,911	93,000
				Subtotal	1,908,820	395,139
NATIONAL INSTITUTE OF FOOD AND AGRICULTURE, AGRICULTURE, DEPARTMENT OF						
Agriculture and Food Research Initiative (AFRI)	10.310	University of New England	2024-68015-42297		43,675	-
				Subtotal	43,675	-
NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY, COMMERCE, DEPARTMENT OF						
Measurement and Engineering Research and Standards	11.609	Direct			(723)	-
				Subtotal	(723)	-
NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Brigham and Women's Hospital, Inc.	1R37CA288557-01		37,392	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	1U01CA274276-03	15,635	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	1U2CCA233195-06	(220)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	1U54CA231637-01	(23,947)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	2U24CA224331-07	28,885	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	3U54CA231637-01S2	(29,814)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	3U54CA274516-02S1	81,747	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Direct		1,179,242	492,008
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	1U2CCA233280	(672)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	3U2CCA233262-01S2	2,612	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	5P50CA244433-05	(3,763)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	P50CA244433-05	(23,480)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	1U01CA294507	9,658	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	5U2CCA252974-04	(220)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	5U2CCA252974-05	17,563	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	U2CCA233238	(2)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	U2CCA252974	3,025	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Trustees of Boston University	1R01CA284133-01A1	15,910	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	University of Texas - Southwestern Medical Center	5UM1CA221940-06	24,728	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Wyss Institute at Harvard University	1U54CA244726-01	(22,797)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Yale University	5U2CCA252979-04	174,064	-
21st Century Cures Act - Precision Medicine Initiative□	93.368	The Broad Institute, Inc.	3OT2OD002750	(6,077)	-
21st Century Cures Act - Precision Medicine Initiative□	93.368	The Broad Institute, Inc.	3OT2OD002750-01S5	47,377	-
21st Century Cures Act - Precision Medicine Initiative□	93.368	The Broad Institute, Inc.	OT20D002750	122,539	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Board of Trustees of the Leland Stanford Junior University, The	1AY2AX000056-01	1,741,735	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Brigham and Women's Hospital, Inc.	1AY2AX000058	48,119	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Case Western Reserve University	1AY2AX000011	629,609	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Direct		5,380,625	2,536,150
Advanced Research Projects Agency for Health (ARPA-H)	93.384	La Jolla Institute for Immunology	1AY1AX000055-01	277,753	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Massachusetts Institute of Technology	140D0425900008	156,161	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Massachusetts Institute of Technology	D24AC00040-00	45,343	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Massachusetts Institute of Technology	D24AC00040-01	57,194	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Mitre Corporation	75N99223F00002	14,765	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	National Collegiate Inventors and Innovators Alliance, Inc. d/b/a VentureWell	AY2AX000007	888,893	182,450
Advanced Research Projects Agency for Health (ARPA-H)	93.384	President and Fellows of Harvard College	152048.5128031.0043	333,398	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	President and Fellows of Harvard College	1AY2AX000031	43,214	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	President and Fellows of Harvard College	1AYSAX000005-01	95,217	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	The Broad Institute, Inc.	D24AC00040-00	1,180,493	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Trustees of Columbia University in the City of New York (The)	140D042490006	496,223	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	University of Washington	D24AC00357-02	700,515	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Vanderbilt University	1AY1AX000039-01	449,741	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	Wyss Institute at Harvard University	1AY2AX000031	324,822	-
Aging Research	93.866	Advanced Brain Monitoring, Inc.	2R44AG050326-03A1	209,240	-
Aging Research	93.866	Albert Einstein College of Medicine	1R01AG080635-02	60,900	-
Aging Research	93.866	Aromha Inc	2R42AG062130-04	171,078	-
Aging Research	93.866	Banner Alzheimer's Institute	5R01AG058468-05	368,429	-
Aging Research	93.866	Banner Health	1R01AG086363-01	40,417	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	1R21AG083421-01	26,325	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	1R56AG075017-01A1	(4)	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG065554-05	(348,289)	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG080598-02	78,699	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG082093-02	438,772	-
Aging Research	93.866	Board of Regents of the University of Wisconsin System, The	5U01AG082350-02	100,948	-
Aging Research	93.866	Board of Regents of the University of Wisconsin System, The	U19AG024904	791	-
Aging Research	93.866	Board of Trustees of the Leland Stanford Junior University, The	5R01AG080678-03	265,413	-
Aging Research	93.866	Boston University School of Medicine	2R01AG063913-02	410,126	-
Aging Research	93.866	Boston University School of Medicine	5R01AG066914-05	(88)	-
Aging Research	93.866	Boston University School of Medicine	5U19AG073172-04	760,180	-
Aging Research	93.866	Boston University School of Medicine	7R01AG069917-04	50,671	-
Aging Research	93.866	Boston VA Research Institute Inc	5R01AG081809-03	199,095	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Aging Research	93.866	Boston VA Research Institute Inc	7RF1AG061774-02	(1,149)	-
Aging Research	93.866	Brain Thrive Technology LLC	1R41AG082591-01	121,485	-
Aging Research	93.866	Brandeis University	5P30AG048785-09	(828)	-
Aging Research	93.866	Brandeis University	5R01AG074330-04	639,045	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1P01AG071463-01A1	173,573	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1P01AG071463-02	407,626	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1R01AG082771-01A1	20,734	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	2P01AG015379-25	(34,674)	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	3R01AG070252-04S2	7,252	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5P01AG015379-25	31,077	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG042512-10	121,329	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG053184-05	143,705	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG058825-05	217,811	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG063689-05	783,863	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG066921-04	46,330	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG067507-05	33,048	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG070252-05	30,534	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG077489-04	38,646	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG080429-03	4,409	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	7R42AG069629-02	17,725	-
Aging Research	93.866	Brown University	5U54AG063546-05	150,998	13,952
Aging Research	93.866	Case Western Reserve University	5R03AG077132-02	8,990	-
Aging Research	93.866	Cedar-Sinai Medical Center	5U54AG065141-05	15,608	-
Aging Research	93.866	Children's Hospital Corporation dba Boston Children's Hospital	5R01AG070921-04	119,220	-
Aging Research	93.866	Children's Hospital Corporation dba Boston Children's Hospital	5R01AG078929-02	32,305	-
Aging Research	93.866	CND Life Sciences	1R44AG076072-01	660	-
Aging Research	93.866	Dimagi, Inc	1R43AG084434-01	20,558	-
Aging Research	93.866	Direct		130,479,434	25,872,137
Aging Research	93.866	Duke University	5R01AG084098-03	151,840	-
Aging Research	93.866	Duke University	5U19AG065188-05	12,663	-
Aging Research	93.866	Einsenca, Inc.	R44AG079734	(18,577)	-
Aging Research	93.866	Einsenca, Inc.	R44AG079734-03	599,848	-
Aging Research	93.866	Emory University	5R01AG066956-04	35,651	-
Aging Research	93.866	Emory University	5R01AG070704-04	37,818	-
Aging Research	93.866	ExQor Technologies Inc	R44AG058343	600,797	-
Aging Research	93.866	Eyenexo LLC	1R43AG090213-01	35,186	-
Aging Research	93.866	Function Promoting Therapies, LLC	1R33AG068234-01	251,857	-
Aging Research	93.866	Function Promoting Therapies, LLC	2R44AG045011-04	157,725	-
Aging Research	93.866	General Biophysics LLC	2R42AG073059-02	262,535	-
Aging Research	93.866	George Washington University	5U19AG078558-03	287,324	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5R01AG076708-03	56,879	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5R03AG075434-02	17,518	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	R01AG044518	1,070	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	R33AG071744	10,615	-
Aging Research	93.866	Hebrew Senior Life	5P01AG031720-10	47,405	-
Aging Research	93.866	Hebrew Senior Life	R56AG084578	26,238	-
Aging Research	93.866	Hennepin Healthcare Research Institute	5U19AG062682-05	101,907	-
Aging Research	93.866	Icahn School of Medicine at Mount Sinai	5P01AG066605-05	(7,508)	-
Aging Research	93.866	Imaginostics, Inc.	1R43AG079732-01	135,015	-
Aging Research	93.866	Johns Hopkins University	1R01AG085712-01	267,567	-
Aging Research	93.866	Johns Hopkins University	5P30AG073104-04	227,352	-
Aging Research	93.866	Johns Hopkins University	5RO1AG062649-05	23,337	-
Aging Research	93.866	Massachusetts AI & Technology Center for Connected Care in Aging & Alzheimer's Disease (MassAITC)	3P30AG073107-04	204,977	-
Aging Research	93.866	Massachusetts Eye and Ear Infirmary	5R01AG075532-02	33,630	-
Aging Research	93.866	Massachusetts General Hospital	1R01AG090302-01	83,638	-
Aging Research	93.866	Massachusetts General Hospital	1RF1AG067744-01	68,688	-
Aging Research	93.866	Massachusetts General Hospital	1RF1AG074008-01	(7,512)	-
Aging Research	93.866	Massachusetts General Hospital	4R01AG067744-02	26,078	-
Aging Research	93.866	Massachusetts General Hospital	4R01AG074008-02	155,990	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Aging Research	93.866	Massachusetts General Hospital	5R01AG057505-07	151,641	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG062667-05	47,769	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG065254-04	30,043	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG071865-05	340,281	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG083777-02	56,051	-
Aging Research	93.866	Massachusetts General Hospital	7R01AG065254-04	23,373	-
Aging Research	93.866	Massachusetts Institute of Technology	5R01AG070135-05	103,657	-
Aging Research	93.866	Massachusetts Institute of Technology	5R01AG081017-03	65,430	-
Aging Research	93.866	Mayo Clinic	5U19AG063911-05	(355,202)	-
Aging Research	93.866	Melax Technologies	1R44AG081006-01	8,812	-
Aging Research	93.866	Methodist Hospital Research Institute dba Houston Methodist Research Institute	R01AG071496	430,995	-
Aging Research	93.866	Michigan State University	1RF1AG072449-01	106,512	-
Aging Research	93.866	New York University Grossman School of Medicine	5U19AG078105-02	155,292	-
Aging Research	93.866	Northeastern University	RF1AG079946	26,041	-
Aging Research	93.866	Northern California Institute for Research and Education, Inc.	5R24AG064025	5,067	-
Aging Research	93.866	Northern California Institute for Research and Education, Inc.	5U19AG024904-18	35,771	-
Aging Research	93.866	Northwestern University	1RF1AG064006-01	28,695	-
Aging Research	93.866	Northwestern University	2U2CAG060426-06	(664)	-
Aging Research	93.866	NYU Langone Health	5R01AG068248-05	194,767	-
Aging Research	93.866	Ohio State University	5R01AG073113-04	32,329	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	3RF1AG069782-01S1	1,766	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	4R01AG069782-02	11,101	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5P30AG024978-20	23,996	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5R01AG082931-03	468,050	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5R01AG083756-02	120,423	-
Aging Research	93.866	Pennsylvania State University	5R01AG077016-03	38,134	-
Aging Research	93.866	Pennsylvania State University	5U2CAG060408-05	(4,456)	-
Aging Research	93.866	President and Fellows of Harvard College	1R01AG085375-01A1	90,582	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG074372-01A1	162,491	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG078377-01	160,235	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG081475-01	239,102	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG088640-01	34,256	-
Aging Research	93.866	President and Fellows of Harvard College	2P01AG032952-13	30,134	-
Aging Research	93.866	President and Fellows of Harvard College	5P01AG041710-10	303,335	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG011085-32	112,578	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG066793-04	15,581	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG066793-05	29,605	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG067420-05	31,879	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG068122-03	22,478	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG081151-02	108,789	-
Aging Research	93.866	Regents of the University of California, San Francisco	1R01AG085029-01	331,776	-
Aging Research	93.866	Regents of the University of California, San Francisco	5R01AG066137-05	100,320	-
Aging Research	93.866	Regents of the University of California, San Francisco	5R01AG078457-02	911,032	-
Aging Research	93.866	Regents of the University of Michigan	1R21AG090819-01	3,828	-
Aging Research	93.866	Regents of the University of Michigan	4R01AG072449-02	56,520	-
Aging Research	93.866	Regents of the University of Michigan	7R01AG061034-06	(63,372)	-
Aging Research	93.866	Regents of the University of Michigan	7R01AG068074-07	10,981	-
Aging Research	93.866	Rip Road, Inc.	7R42AG069629-02	365,976	137,557
Aging Research	93.866	Rush University Medical Center	5R01AG015819-21	(559)	-
Aging Research	93.866	Rush University Medical Center	5R01AG062637-04	612,536	-
Aging Research	93.866	Sanford Burnham Prebys Medical Discovery Institute	5R56AG080525-02	319,300	-
Aging Research	93.866	Seattle Institute for Biomedical and Clinical Research	5R01AG061558-05	354,575	-
Aging Research	93.866	Stanford University Medical Center	5R01AG080678-03	156,546	-
Aging Research	93.866	The University of Texas Health Science Center at Houston	5R01AG082751-02	181,564	-
Aging Research	93.866	Translational Genomics Research Institute	5UH3AG064706-05	(103,593)	-
Aging Research	93.866	Trustees of Boston University	1RF1AG068121-01	30,131	-
Aging Research	93.866	Trustees of Boston University	4R01AG068121-02	20,398	-
Aging Research	93.866	Trustees of Boston University	4R01AG073179-02	(35,267)	-
Aging Research	93.866	Trustees of Boston University	5R01AG066010-05	22,284	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Aging Research	93.866	Trustees of Boston University	5R01AG067394-04	(1,811)	-
Aging Research	93.866	Trustees of Boston University	5R01AG083941-03	11,101	-
Aging Research	93.866	Trustees of Boston University	5U19AG068753-05	276,618	-
Aging Research	93.866	Trustees of Boston University	5U19AG073172-04	475,583	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	1RF1AG072167-01A1	219,286	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5R01AG081155-02	16,015	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5R21AG080464-02	3,732	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5U01AG061356-03S1	(646)	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5U01AG061356-05	(50)	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5U01AG072572-05	118,142	-
Aging Research	93.866	Trustees of Indiana University	5U01AG057195-05	617,479	-
Aging Research	93.866	Trustees of the University of Pennsylvania	1U19AG079774-02	30,013	-
Aging Research	93.866	Trustees of the University of Pennsylvania	5R01AG072796-03	494,147	-
Aging Research	93.866	Trustees of the University of Pennsylvania	5U01AG032984-15	8,571	-
Aging Research	93.866	Tufts Medical Center, Inc.	5R01AG066892-05	33,359	-
Aging Research	93.866	Tufts Medical Center, Inc.	R01AG066892	3,093	-
Aging Research	93.866	Tufts University	5R01AG059011-05	44,290	-
Aging Research	93.866	University of Chicago	5U19AG073153-05	46,450	-
Aging Research	93.866	University of Cincinnati	5R01AG072087-05	70,395	-
Aging Research	93.866	University of Florida Board of Trustees	5R01AG078250-05	10,148	-
Aging Research	93.866	University of Florida Board of Trustees	5R33AG072265-05	38,700	-
Aging Research	93.866	University of Kansas Medical Center Research Institute, Inc.	5R01AG079422-02	171,649	-
Aging Research	93.866	University of Maryland, Baltimore	1RF1AG073236-01	(164,981)	-
Aging Research	93.866	University of Maryland, Baltimore	3P30AG028747-17S1	13,274	-
Aging Research	93.866	University of Maryland, Baltimore	4R01AG073236-02	303,479	-
Aging Research	93.866	University of Massachusetts Amherst	2R01AG051600-06	90,829	-
Aging Research	93.866	University of Massachusetts Amherst	3P30AG073107-03S3AS5	9,604	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-02	(11,795)	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-03	163,053	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-04	161,537	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-05	524,717	-
Aging Research	93.866	University of Massachusetts Amherst	5R01AG082354-02	457,756	-
Aging Research	93.866	University of Massachusetts Amherst	5R21AG083468-02	14,386	-
Aging Research	93.866	University of Massachusetts Amherst	5R21AG087392-02	23,366	-
Aging Research	93.866	University of Massachusetts Amherst	P30AG073107	(7,654)	-
Aging Research	93.866	University of Massachusetts Medical School	5U01AG068221-04	80,006	-
Aging Research	93.866	University of Miami	5R01AG067568-04	250,367	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-02	2,267	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-04	(206,544)	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-05	20,097	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01AG068567	10,995	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	3U19AG068054-03S3	40,314	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AG066198-05	14,359	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	5U19AG063720-04	199,967	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	U19AG068054	1,364,109	-
Aging Research	93.866	University of Rochester	2P01AG047200-11	776,921	-
Aging Research	93.866	University of Rochester	5P01AG047200-09	(118,701)	-
Aging Research	93.866	University of Southern California	1R01AG061848-04	(86,528)	-
Aging Research	93.866	University of Southern California	2U19AG024904-16	49,826	-
Aging Research	93.866	University of Southern California	2U24AG057437-06	7,336	-
Aging Research	93.866	University of Southern California	2U24AG057437-07	812,496	-
Aging Research	93.866	University of Southern California	4R01AG057892-02	53,562	-
Aging Research	93.866	University of Southern California	5R01AG051125-09	33,780	-
Aging Research	93.866	University of Southern California	5R01AG053798-05	(5,878)	-
Aging Research	93.866	University of Southern California	5R01AG054029-02	(4,780)	-
Aging Research	93.866	University of Southern California	5R01AG061848-05	224,443	-
Aging Research	93.866	University of Southern California	5R01AG063689-02	(4,476)	-
Aging Research	93.866	University of Southern California	5R01AG065248-02	89,909	-
Aging Research	93.866	University of Southern California	5R01AG080652-03	11,749	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Aging Research	93.866	University of Southern California	5U24AG057437-07	490,408	-
Aging Research	93.866	University of Tennessee Medical Center	A22-1001-S001-A04	38,407	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG062531-04	65,555	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG066524-02	326,375	-
Aging Research	93.866	University of Texas Southwestern Medical Center	5R01AG056426-05	32,911	-
Aging Research	93.866	University of Washington	5R03AG073990-02	25,448	-
Aging Research	93.866	University of Washington	5U01AG082350-02	40,713	-
Aging Research	93.866	University of Washington	5U24AG072122-02	(601)	-
Aging Research	93.866	University of Washington - Seattle	5U24AG072122-05	24,873	-
Aging Research	93.866	Vanderbilt University Medical Center	5R01AG073439-05	36,798	-
Aging Research	93.866	Virginia Commonwealth University	1RF1AG076912-01A1	300,371	-
Aging Research	93.866	Virginia Commonwealth University	5R01AG076360-04	46,116	-
Aging Research	93.866	Virginia Commonwealth University	5U01AG076481-04	177,839	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG064440-05	131,601	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG074562-03	120,491	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG075959-04	78,500	-
Aging Research	93.866	Washington University in St. Louis	5R01AG089215-02	47,729	-
Aging Research	93.866	Washington University, The	2RF1AG047644-06	(6,288)	-
Aging Research	93.866	Washington University, The	5R01AG084739-03	278,637	-
Aging Research	93.866	Washington University, The	5U19AG032438-12	139,793	-
Aging Research	93.866	Washington University, The	5U19AG071754-03	101,744	-
Aging Research	93.866	Washington University, The	5U19AG071754-04	164,773	-
Aging Research	93.866	Washington University, The	5U19AG073585-04	1,563,317	-
Aging Research	93.866	Yale University	1RF1AG081413-01	104,201	-
Aging Research	93.866	Yale University	5R01AG065403-05	352,349	-
Aging Research	93.866	Yale University	5R01AG071528-04	(21,072)	-
Aging Research	93.866	Yale University	5R01AG076153-04	37,019	-
Alcohol Research Programs	93.273	Brown University	5R01AA027760-05	(468)	-
Alcohol Research Programs	93.273	Clinitech, Inc.	2R44AA026123-02	(292)	-
Alcohol Research Programs	93.273	Direct		2,302,453	753,919
Alcohol Research Programs	93.273	Fenway Community Health Center	5P01AA029544-04	19,747	-
Alcohol Research Programs	93.273	Planned Parenthood League of Massachusetts, Inc.	1R01AA030529-01	13,634	-
Alcohol Research Programs	93.273	President and Fellows of Harvard College	5R01AA029267-04	4,749	-
Alcohol Research Programs	93.273	Regents of the University of California, San Diego	1R21AA031410-01A1	65,644	-
Alcohol Research Programs	93.273	Seton Hall University	R21AA029925	(86,153)	-
Alcohol Research Programs	93.273	University of Texas at Austin	5R01AA029090-04	174,932	-
Alcohol Research Programs	93.273	Vanderbilt University	1R01AA031936-01	107,662	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-11	108,209	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-12	1,067,287	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	4U01AI145801-05	89,584	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5P01AI177687-02	96,248	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5P01AI177687-03	305,015	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5P01AI179405-02	766,600	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5R01AI149670-05	319,106	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5UM1AI164556-05	787,946	-
Allergy and Infectious Diseases Research	93.855	Board of Regents of the University of Wisconsin System, The	1U24AI179612-01	50,441	-
Allergy and Infectious Diseases Research	93.855	Board of Regents of the University of Wisconsin System, The	5R01AI168370-03	84,967	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the Leland Stanford Junior University, The	5R01AI181283-02	333,898	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the Leland Stanford Junior University, The	5U19AI057229-20	(130)	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the University of Alabama for the University of Alabam	5R01AI147727-05	115,137	-
Allergy and Infectious Diseases Research	93.855	Boston University School of Public Health	5R01AI168424-03	251,489	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	1R01AI187513-01	21,259	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI138999-05	21,477	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI150295-04	9,911	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI175582-02	340,292	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI176579-03	130,081	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI181221-02	113,543	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI184094-02	239,919	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI148306-05	10,213	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI170056-02	46,386	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5UM1AI069412-19	530,245	-
Allergy and Infectious Diseases Research	93.855	Brown University	5R01AI167694-04	2,287	-
Allergy and Infectious Diseases Research	93.855	Cedars-Sinai Medical Center	1U01AI170424-03	50,488	-
Allergy and Infectious Diseases Research	93.855	Cedars-Sinai Medical Center	5U01AI170424-02	4,448	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	1K08AI187736-01	6,911	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	1R01AI175556-01	62,338	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5P01AI089618-12	332,677	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5R01AI151180-03	1,644	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5R01AI173142-03	45,515	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI143514-05	149,167	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI160087-05	96,826	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI163072-04	248,979	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI179563-02	123,572	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U19AI168643-04	149,352	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Medical Center	5R01AI148276-04	3,212	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5P01AI143565-04	11,725	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5U01AI165442-04	400,841	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5U01AI165442-04	71,340	-
Allergy and Infectious Diseases Research	93.855	Direct		110,543,249	28,424,864
Allergy and Infectious Diseases Research	93.855	Duke University	5UM1AI104681-13	82,996	-
Allergy and Infectious Diseases Research	93.855	Emory University	3U19AI110483-08S4	227	-
Allergy and Infectious Diseases Research	93.855	Emory University	5R01AI66988-03	19,621	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI110483-12	25,713	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI110483-10	1	-
Allergy and Infectious Diseases Research	93.855	Emory University	5UM1AI164562-04	151,169	-
Allergy and Infectious Diseases Research	93.855	Erasmus University Medical Center	1R01AI147330-01	(306,438)	-
Allergy and Infectious Diseases Research	93.855	Fenway Community Health Center	5UM1AI068619-19	3,480	-
Allergy and Infectious Diseases Research	93.855	FHI 360	5UM1A1068619-16	19,778	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068614-18	(21,108)	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068614-19	146,986	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068614-20	400,015	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068617-20	173,734	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068614-17	13,970	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068614-20	46,653	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Research Center	5UM1AI068614-16	(232)	-
Allergy and Infectious Diseases Research	93.855	GHESKIO Centers	4UM1AI069421-19	53,691	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	5P01AI168258-03	1,034,293	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	5R01AI174902-03	384,758	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	5R21AI178021-02	170,473	-
Allergy and Infectious Diseases Research	93.855	Joan & Sanford I. Weill Medical College of Cornell University	2P01AI129859-07	465,874	-
Allergy and Infectious Diseases Research	93.855	Joan & Sanford I. Weill Medical College of Cornell University	5R01AI171390-02	133,236	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2UM1AI068632-18	19,926	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	3UM1AI182034-02S1	972,601	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U19AI159822-04	549,949	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM1AI164566-04	15,723	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM1AI164566-05	1,405	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM1AI182034-02	253,509	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM2AI130836-07	(9,896)	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UMAI164566-03	231,415	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U01AI167892-03	53,618	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U19AI142790-05	(16,206)	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Eye and Ear Infirmary	5P01AI083214-17	273,200	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	1R01AI182098-01A1	13,083	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R01AI042006-28	62,929	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R01AI155662-05	126,016	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R37AI058736-20	32,779	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R37AI155171-04	348,662	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI136816-04	(174,271)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI163086-04	24,512	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U19AI174967-03	22,354	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Institute of Technology	5R33AI161805-05	517,616	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Institute of Technology	5U19AI167899-03	5,583	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Institute of Technology	5U19AI167899-04	758,831	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	R01AI182419	245,903	-
Allergy and Infectious Diseases Research	93.855	Microbiotix, Inc	1R41AI183900-01	269,825	-
Allergy and Infectious Diseases Research	93.855	New York University Grossman School of Medicine	5U01AI174997-03	18,498	-
Allergy and Infectious Diseases Research	93.855	NYU Langone Health	1R01AI179417-01AI	103,608	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University (OHSU)	5R01AI157807-04	27,232	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	1R01AI177514-01A1	9,041	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-20	2,149	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-21	1,392,542	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	3P30AI060354-20S1	(51,437)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	3P30AI060354-21S1	152,175	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	3P30AI060354-21S2	256,841	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	4U01AI135940-07	(408)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P01AI056299-20	(2,230)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20	9,080	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20S1	(17,245)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI143723-05	(116,552)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI148338-04	(30,385)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI176498-02	16,334	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI135940-07	47,601	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI179561-02	98,429	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U19AI142793-05	308,193	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	P30AI060354	27,122	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	R01AI155345	59,633	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	U01AI135940	960	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	U01AI179561	8,909	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	UM1AI069456-19	112,294	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Berkeley	5R01AI155634-05	10,229	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-16S2	23,866	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-17S2	2,480	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5R01AI166313-04	137,786	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-17	(8)	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-18	68,601	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-19	1,141,407	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI106701-12	354,647	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	UM1AI068636-14	(206)	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Diego	5U19AI070535-19	100,240	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5R25AI154589-04	16,026	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5UM1AI164560-03	75,935	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5UM1AI164560-04	274,317	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5UM1AI164560-05	184,043	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Colorado	R01AI141452	(2,946)	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	3U01AI169587-03S1	270,408	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	5R01AI084913-13	1,560	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	5U01AI169587-03	382,402	-
Allergy and Infectious Diseases Research	93.855	Rutgers, the State University of New Jersey	5R01AI175315-02	26,943	-
Allergy and Infectious Diseases Research	93.855	Sanaria Inc	U01AI155354	1,865	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5P01AI177683-03	213,848	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5R01AI147826-05	(4,716)	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-05	2,828	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-07	1,226,944	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-07	83,126	-
Allergy and Infectious Diseases Research	93.855	SingletO2 Therapeutics LLC	1R41AI183969-01	125,900	-
Allergy and Infectious Diseases Research	93.855	Stellenbosch University	1R01AI175235-02	34,360	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	1U19AI42780-05	707,912	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	2U19AI082630-16	3,614	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	2U19AI110818-11	29,091	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5P01AI148102	9,877	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5R01AI158495	59,778	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5R01AI172147-03	30,246	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5U19AI110818-10	(11,414)	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	CNVA000599421316161	(5,406)	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	GMO190409	172,685	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	R01AI153405	87,618	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	R01AI172147	9,236	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	R21AI178690	11,206	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	U19AI082630	45,970	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	U19AI110818	20,796	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	U19AI142780	23,148	-
Allergy and Infectious Diseases Research	93.855	Trustees of Boston University	5R01AI162850-04	98,944	-
Allergy and Infectious Diseases Research	93.855	Trustees of Columbia University in the City of New York (The)	1R56AI176507-01A1	11,997	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	1R01AI191440-01	12,394	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	4R33AI161818-05	342,139	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	5U01AI163087-04	82,860	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	5U19AI149680-05	307,822	-
Allergy and Infectious Diseases Research	93.855	Trustees of Tufts College	1P01AI181934-02	332,512	-
Allergy and Infectious Diseases Research	93.855	Trustees of Tufts College	1R61AI187098-01	78,233	-
Allergy and Infectious Diseases Research	93.855	Trustees of Tufts College	5P01AI181934-02	1,094,247	-
Allergy and Infectious Diseases Research	93.855	Trustees of Tufts College	5R01AI169786-04	28,572	-
Allergy and Infectious Diseases Research	93.855	University Health Network	5R01AI173319-02	245,993	-
Allergy and Infectious Diseases Research	93.855	University of Alabama, Birmingham	5R37AI179640-02	551,300	-
Allergy and Infectious Diseases Research	93.855	University of Chicago	5R01AI182097-02	125,305	-
Allergy and Infectious Diseases Research	93.855	University of Connecticut	1R01AI167884	6,520	-
Allergy and Infectious Diseases Research	93.855	University of Georgia Research Foundation, Inc. (UGARF)	U01AI148114	38,666	-
Allergy and Infectious Diseases Research	93.855	University of Maryland, Baltimore	R01AI167367	767,964	-
Allergy and Infectious Diseases Research	93.855	University of Maryland, Baltimore	U19AI145825	471,891	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Chan Medical School	5U01AI172987-03	37,057	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Medical School	5R01AI159159-04	67,914	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Medical School	5U01AI165524-03	27,519	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01AI184406-01	71,308	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5P01AI08545-10	234,778	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AI155345-04	167,926	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AI164970-03	80,257	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	R01AI184980	34,334	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19AI142784-05	145,696	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5P30AI110527-10	68,338	-
Allergy and Infectious Diseases Research	93.855	Volatylix, Inc.	5R44AI141264-03	(2,356)	-
Allergy and Infectious Diseases Research	93.855	Washington University in St. Louis	1U19AI181960-01	1,035,527	-
Allergy and Infectious Diseases Research	93.855	Washington University, The	5R01AI184666-02	264,256	-
Allergy and Infectious Diseases Research	93.855	Wayne State University	5R21AI180183-02	104,983	-
Allergy and Infectious Diseases Research	93.855	Wistar Institute of Anatomy and Biology	5UM1AI164570-04	292,662	-
Allergy and Infectious Diseases Research	93.855	Yale University	5P01AI039671-27	623,797	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Beth Israel Deaconess Medical Center	1R44AR083316-01A1	3,758	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Beth Israel Deaconess Medical Center	5R01AR075964-05	52,383	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Board of Trustees of the University of Alabama for the University of Alabam	5P50AR060772-10	(9,682)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	3U01AR070498-04S1	204,070	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR065807-25	(128)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR077607-04	102,229	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR080193-03	38,629	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5U01AR070498-04	281,633	95,908
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brixton Biosciences, Inc.	R44AR084998	233,830	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation dba Boston Children's Hospital	1R01AR080079	50,342	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation dba Boston Children's Hospital	5R01AR065538-10	(552)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Direct		30,650,957	6,862,730

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Hebrew Senior Life	5R01AR075346-03	(18,098)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Highland Instruments	4R44AR076885-02	23,060	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Johns Hopkins University	5U01AR080993-02	4,690	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Johns Hopkins University	5UH3AR077360-05	(165,686)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	2P30AR075042-06	34,430	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR065944-09	61,028	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR077023-05	8,445	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5U01AR070498-04	58,381	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5U01AR080985-02	704,601	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northwestern University	R01AR081854-02	48,927	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Oklahoma Medical Research Foundation	5UC2AR081032-03	477,153	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	President and Fellows of Harvard College	1R21AR083058-01A1	40,388	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of California, Irvine	5R01AR078340-03	(5,373)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Colorado, a body corporate, for and on behalf	5R01AR069060-06	17,302	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Michigan	4U24AR076730-02	77,327	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Spaulding Rehabilitation Hospital	1R21AR084246-01	109,423	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Broad Institute, Inc.	5R21AR080274-02	25,714	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Broad Institute, Inc.	UC2AR081031	28,729	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5P30AR072571-04	1,663	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5R01AR078299-03	121,596	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5R01AR080950-03	6,348	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	5R01AR077187-02	(32,054)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	5R01AR077187-03	35,730	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of the University of Pennsylvania	U01AR079752-03	19,236	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Tufts College	1R21AR085398-01	46,812	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Tufts Medical Center, Inc.	R01AR077146	16,317	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Alabama, Birmingham	1R01AR084827-01	24,859	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Arizona	1R01AR078187-01S1	126,330	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Arizona	5R01AR080742-03	400,061	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Colorado at Denver	2R01AR075033-06	47,619	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Colorado at Denver	5R01AR075033-04	(86)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Massachusetts Chan Medical School	5R21AR079633-03	3,565	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Massachusetts Medical School	5R01AR078230-04	225,352	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of North Carolina at Chapel Hill, The	4U24AR076730-02	8,917	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh Of the Commonwealth System of Higher Education	5UH3AR076568-05	(64,201)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Rochester	5UC2AR081025-04	38,979	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Texas Health Science Center at San Antonio	5R01AR077445-04	26,183	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Wake Forest University	5U01AR082121-03	683,918	-
Biomedical Research and Research Training	93.859	Beth Israel Deaconess Medical Center	7R01GM148745-02	424,384	-
Biomedical Research and Research Training	93.859	Brandeis University	1R01GM152811-02	136,834	-
Biomedical Research and Research Training	93.859	Brandeis University	3R01GM152811-02S1	167,660	-
Biomedical Research and Research Training	93.859	Brigham and Women's Hospital, Inc.	5R01GM132825-04	902	-
Biomedical Research and Research Training	93.859	Dana-Farber Cancer Institute, Inc.	5R01GM136859-05	11,725	-
Biomedical Research and Research Training	93.859	Direct		18,923,742	1,170,493
Biomedical Research and Research Training	93.859	President and Fellows of Harvard College	5R01GM148494-03	37,411	-
Biomedical Research and Research Training	93.859	Regents of the University of California, San Francisco	R01GM117163	16,241	-
Biomedical Research and Research Training	93.859	The Broad Institute, Inc.	1R01GM137606-01A1	21,265	-
Biomedical Research and Research Training	93.859	The Broad Institute, Inc.	R21GM1448826	4,240	-
Biomedical Research and Research Training	93.859	Trustees of the University of Pennsylvania	5R01GM132668-06	276,196	-
Biomedical Research and Research Training	93.859	Trustees of Tufts College	5R21GM141683-02	(2,553)	-
Biomedical Research and Research Training	93.859	Vox Biomedical LLC	1R43GM149051-01A1	19,001	-
Biomedical Research and Research Training	93.859	Wake Forest University Health Sciences	4R33GM144947-03	11,460	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	1P01HL158688-01A1	1,967	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5P01HL046925-25	131,497	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL095791-14	87,710	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL158192-02	(10)	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5T32HL066987-23	5,727	-
Blood Diseases and Resources Research	93.839	Children's Hospital of Philadelphia (The)	5R01HL169401-02	51,669	-
Blood Diseases and Resources Research	93.839	Coalesenz, Inc	1R41HL170886-01A1	27,195	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Blood Diseases and Resources Research	93.839	Dana-Farber Cancer Institute, Inc.	5UG1HL069249-25	35,793	-
Blood Diseases and Resources Research	93.839	Direct		14,742,777	3,054,376
Blood Diseases and Resources Research	93.839	Emory University	1R01HL163637-01A1	31,074	-
Blood Diseases and Resources Research	93.839	Fred Hutchinson Cancer Center	5R01HL148565-07	253,301	-
Blood Diseases and Resources Research	93.839	Joan & Sanford I. Weill Medical College of Cornell University	5R01HL167139-02	61,425	-
Blood Diseases and Resources Research	93.839	Johns Hopkins University	7R01HL138714-04	964,314	-
Blood Diseases and Resources Research	93.839	Massachusetts Institute of Technology	5R01HL158102-04	(10,914)	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL138660-03	774	-
Blood Diseases and Resources Research	93.839	New York University Grossman School of Medicine	4UH3HL155798-03	42,077	-
Blood Diseases and Resources Research	93.839	President and Fellows of Harvard College	1R01HL174679-01	48,450	-
Blood Diseases and Resources Research	93.839	Regents of the University of Minnesota	1R01HL177019-01	177,503	-
Blood Diseases and Resources Research	93.839	Rutgers, the State University of New Jersey	5U01HL133817-05	627	-
Blood Diseases and Resources Research	93.839	The Broad Institute, Inc.	1P01HL158505-01	2,078	-
Blood Diseases and Resources Research	93.839	University of Minnesota	5R01HL132906-08	1,197	-
Blood Diseases and Resources Research	93.839	University of Southern California	5U19HL156247-05	26,541	-
Blood Diseases and Resources Research	93.839	University of Washington	5R01HL154385-04	24,395	-
Blood Diseases and Resources Research	93.839	University of Washington - Seattle	5R01HL147894-04	17,769	-
Blood Diseases and Resources Research	93.839	Washington University, The	5UH3HL138325-06	7,638	-
Cancer Biology Research	93.396	Aperture Bio Inc	1R42CA290912-01	96,364	-
Cancer Biology Research	93.396	Beth Israel Deaconess Medical Center	1R01CA285395-01A1	103,743	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	5U19CA264504-04	6,139	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	5U19CA264504-05	107,880	-
Cancer Biology Research	93.396	Brown University	5R01CA263324-02	32,195	-
Cancer Biology Research	93.396	Cincinnati Children's Hospital Medical Center	5R01CA240317-05	13,684	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	1R01CA279221-01A1	27,866	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	1R01CA289304-02	99,030	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	2R01CA181217-09	13,420	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5P01CA233412-05	(27,235)	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA246653-05	159,524	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA251589-05	5,745	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA251599-05	7,570	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5U01CA286537-02	105,466	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	P01CA250959	80,991	-
Cancer Biology Research	93.396	Direct		18,723,793	4,166,873
Cancer Biology Research	93.396	Jackson Laboratory, The	3U01AG077925-04S2	12,190	-
Cancer Biology Research	93.396	Joan & Sanford I. Weill Medical College of Cornell University	5U01CA275301-03	257,772	-
Cancer Biology Research	93.396	Kaiser Foundation Research Institute	3R01CA251589-04S1	(9,163)	-
Cancer Biology Research	93.396	Kaiser Permanente Division of Research	3R01CA251589-04S1	7,237	-
Cancer Biology Research	93.396	Kaiser Permanente Division of Research	R01CA251589	(12,219)	-
Cancer Biology Research	93.396	Massachusetts Institute of Technology	1UG3CA275687-02	762	-
Cancer Biology Research	93.396	Massachusetts Institute of Technology	1UH3CA275687-03	665,183	-
Cancer Biology Research	93.396	Massachusetts Institute of Technology	7R01CA248280-03	6,284	-
Cancer Biology Research	93.396	MD Anderson Cancer Center	5P01CA117969-20	332,174	-
Cancer Biology Research	93.396	Memorial Sloan-Kettering Institute Cancer Center	5U01CA228963-05	267,563	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	1R01CA279054-01A1	48,694	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	1U01CA284207-01	28,034	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R01CA240924-05	(14,120)	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R01CA273461-03	27,528	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R01CA276866-03	56,471	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R35CA220523-07	42,044	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5U01CA267827-04	18,192	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	7R01CA269281-03	49,831	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	7R01CA279550-02	68,347	-
Cancer Biology Research	93.396	Research Foundation of the City University of New York	1U24CA289073-01	212,903	-
Cancer Biology Research	93.396	The Broad Institute, Inc.	1R35CA263817-01A1	2,553	-
Cancer Biology Research	93.396	The Broad Institute, Inc.	1R61CA281807	9,485	-
Cancer Biology Research	93.396	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01CA256068-05	12,339	-
Cancer Biology Research	93.396	University of Texas Southwestern Medical Center	5UM1CA221940-06	34,095	-
Cancer Biology Research	93.396	Wistar Institute of Anatomy and Biology	5P01CA269043-03	242,883	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Cause and Prevention Research	93.393	Albert Einstein College of Medicine	5R01CA275521-03	72,915	-
Cancer Cause and Prevention Research	93.393	Baylor College of Medicine	5P01CA263025-03	295,914	-
Cancer Cause and Prevention Research	93.393	Baylor College of Medicine	5P01CA263025-04	83,825	-
Cancer Cause and Prevention Research	93.393	BC Cancer, a part of the Provincial Health Services Authority	5U01CA253858-05	173,873	-
Cancer Cause and Prevention Research	93.393	Beth Israel Deaconess Medical Center	5R01CA242747-04	125	-
Cancer Cause and Prevention Research	93.393	Children's Hospital of Philadelphia (The)	5R37CA282153-03	41,974	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA256877-03	28,489	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA258924-05	81,257	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA279044-02	27,783	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA279414-02	25,427	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA281861-02	17,752	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA283395-02	330,790	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R37CA289639-02	38,054	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	R01CA248857	9,740	-
Cancer Cause and Prevention Research	93.393	Direct		20,475,063	6,287,610
Cancer Cause and Prevention Research	93.393	Duke University	1U54CA231630-01A1	(7,088)	-
Cancer Cause and Prevention Research	93.393	Duke University	5R01CA235677-05	(514)	-
Cancer Cause and Prevention Research	93.393	ECOG-ACRIN Medical Research Foundation, Inc.	5U01CA274996-03	267,509	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Center	5R01CA248857-07	169,294	-
Cancer Cause and Prevention Research	93.393	HealthPartners Institute	5R01CA263542-03	13,738	-
Cancer Cause and Prevention Research	93.393	Icahn School of Medicine at Mount Sinai	5R01CA260889-04	67,825	-
Cancer Cause and Prevention Research	93.393	Icahn School of Medicine at Mount Sinai	5R01CA283469-02	37,194	-
Cancer Cause and Prevention Research	93.393	International Agency for Research on Cancer	2U19CA203654-07	13,371	-
Cancer Cause and Prevention Research	93.393	Joan & Sanford I. Weill Medical College of Cornell University	5U01CA260352-05	44,603	-
Cancer Cause and Prevention Research	93.393	Mary Hitchcock Memorial Hospital	5UG3CA286852-02	123,648	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	1R01CA299969-01	4,357	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	1R37CA275914-01A1	205	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	5R01CA288530-02	272,895	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5R01CA248288-05	37,629	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	1R21CA263489-01A1	3,292	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5R01CA244185-05	40,176	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5R37CA276322-02	42,136	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5U01CA253913-05	93,850	-
Cancer Cause and Prevention Research	93.393	Northeastern University	5R01CA252966-05	6,500	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5R01CA266402-04	145,210	-
Cancer Cause and Prevention Research	93.393	Oregon Health & Science University (OHSU)	5R01CA276224-03	164,277	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	1P01CA281850-01A1	31,673	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	1R01CA285851-01A1	222,556	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	1U19CA291431-01	92,583	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA167552-13	1,552	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA209414-08	33,895	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5P01CA228696-04	(463)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R01CA240299-04	(3,278)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R37CA225655-08	2,494	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA167552-13	46,817	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA176726-12	1,220,697	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA209414-08	123,148	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA209414-09	55,933	9,878
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA253912-05	132,625	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA261961-03	141,807	-
Cancer Cause and Prevention Research	93.393	Regents of the University of California, Irvine	5R37CA252081-04	19,859	-
Cancer Cause and Prevention Research	93.393	Regents of the University of California, San Francisco	1P01CA281826-01A1	31,898	-
Cancer Cause and Prevention Research	93.393	Regents of the University of Michigan	5R01CA269367-03	34,593	-
Cancer Cause and Prevention Research	93.393	Regents of the University of Michigan	5R01CA279746-02	194,810	-
Cancer Cause and Prevention Research	93.393	Regents of the University of Michigan	7R01CA275993-04	3,938	-
Cancer Cause and Prevention Research	93.393	Research Foundation of the City University of New York	5U24CA180996-11	673	-
Cancer Cause and Prevention Research	93.393	Seattle Institute for Biomedical and Clinical Research	5R01CA239208-06	424,245	24,442
Cancer Cause and Prevention Research	93.393	Strategen Bio	1R43CA281444-01	4,801	-
Cancer Cause and Prevention Research	93.393	Trustees of Boston University	1R21CA279942-01A1	42,130	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Cause and Prevention Research	93.393	Trustees of Boston University	5R01CA286064-02	22,003	-
Cancer Cause and Prevention Research	93.393	Trustees of Columbia University in the City of New York (The)	5R01CA240080-06	69,883	-
Cancer Cause and Prevention Research	93.393	Trustees of Columbia University in the City of New York (The)	5U01CA265739-04	15,828	-
Cancer Cause and Prevention Research	93.393	Trustees of Indiana University	R01CA157823	17,109	-
Cancer Cause and Prevention Research	93.393	University of Alabama, Birmingham	5R01CA229197-07	37,109	-
Cancer Cause and Prevention Research	93.393	University of Colorado at Denver	3U01CA261614-04S1	(6,226)	-
Cancer Cause and Prevention Research	93.393	University of Colorado at Denver	5U01CA261614-05	115,668	-
Cancer Cause and Prevention Research	93.393	University of Hawaii	1UG3CA290375-01	101,326	-
Cancer Cause and Prevention Research	93.393	University of Miami	1R01CA296889-01	131,290	-
Cancer Cause and Prevention Research	93.393	University of Nebraska Medical Center	1R34CA287719-01A1	55,446	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Chapel Hill, The	1R01CA282682-01A1	21,001	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Chapel Hill, The	1R01CA298002-01	26,170	-
Cancer Cause and Prevention Research	93.393	University of Southern California	5R01CA276826-02	135,908	-
Cancer Cause and Prevention Research	93.393	University of Utah	5R01CA276825-02	94,916	-
Cancer Cause and Prevention Research	93.393	University of Washington	5R01CA258590-04	53,897	-
Cancer Cause and Prevention Research	93.393	University of Washington - Seattle	5U01CA194393-08	22,026	-
Cancer Cause and Prevention Research	93.393	Vizlitics Inc.	1R43CA281547-01A1	(3,075)	-
Cancer Cause and Prevention Research	93.393	Wake Forest University Health Sciences	1R01CA282653-01A1	36,087	-
Cancer Cause and Prevention Research	93.393	Washington University, The	5R37CA246175-05	42,396	-
Cancer Cause and Prevention Research	93.393	Yale University	7R37CA262299-04	71,140	-
Cancer Cause and Prevention Research	93.393	Yale University	7U01CA259208-03	48,775	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	2P50CA101942-19	369,947	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	5P50CA101942-20	298,069	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	2P50CA165962-08	(4,078)	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	2P50CA165962-11	331,626	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	5P50CA165962-10	(8,579)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA272390-01	32,318	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA272390-02	181,414	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1U54CA274516-01A1	168,535	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1U54CA274516-2	22,924	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P50CA165962-11	40,377	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	3P30CA006516-59S1	229,705	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	3P30CA006516-59S2	-	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P30CA006516-58	(66,490)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P30CA006516-59	792,543	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P30CA006516-60	819,168	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA127003-15	(4,047)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA168504-10	(5,037)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA240243-04	70,511	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA240243-05	507,040	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA265826-02	(429)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA265826-03	1,206,209	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA272390-02	336,540	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5U54CA156732-14	159,532	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5U54CA274516-02	180,571	-
Cancer Centers Support Grants	93.397	Direct		2,760,817	1,815,665
Cancer Centers Support Grants	93.397	Massachusetts Institute of Technology	1U54CA283114-01	8,073	-
Cancer Centers Support Grants	93.397	Massachusetts Institute of Technology	3U54CA283114-02S1	403,422	-
Cancer Centers Support Grants	93.397	Regents of the University of California, San Francisco	5U54CA254571-05	43,329	-
Cancer Centers Support Grants	93.397	Regents of the University of Michigan	1P50CA272170-01	12,090	-
Cancer Centers Support Grants	93.397	Regents of the University of Michigan	1P50CA272170-03	603,105	-
Cancer Centers Support Grants	93.397	Regents of the University of Michigan	5P50CA272170-03	42,675	-
Cancer Centers Support Grants	93.397	The Broad Institute, Inc.	2P50CA127003-11A1	(604)	-
Cancer Centers Support Grants	93.397	Washington University, The	2P50CA171963-11A1	178,411	-
Cancer Centers Support Grants	93.397	Washington University, The	3P50CA171963-10S1	(7,354)	-
Cancer Control	93.399	Alliance NCTN Foundation	5UG1CA189823-10	5,366	-
Cancer Control	93.399	Dana-Farber Cancer Institute, Inc.	5UG1CA233180-06	29,280	-
Cancer Control	93.399	Direct		248,824	140,377
Cancer Control	93.399	ECOG-ACRIN Medical Research Foundation, Inc.	5UG1CA189828-09	15,244	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Control	93.399	ECOG-ACRIN Medical Research Foundation, Inc.	5UG1CA189828-11	6,072	-
Cancer Control	93.399	The Broad Institute, Inc.	U54CA272688	3,350	-
Cancer Detection and Diagnosis Research	93.394	AIQ Solutions, Inc.	2R44CA257253-02	98,265	-
Cancer Detection and Diagnosis Research	93.394	Baylor College of Medicine	5U01CA230997-07	91,218	-
Cancer Detection and Diagnosis Research	93.394	Brigham and Women's Hospital, Inc.	5R01CA235589-05	35,826	-
Cancer Detection and Diagnosis Research	93.394	Cedar-Sinai Medical Center	5R01CA201709-06	24,290	-
Cancer Detection and Diagnosis Research	93.394	Cedars-Sinai Health System	5R01CA260955-04	19,002	-
Cancer Detection and Diagnosis Research	93.394	Cedars-Sinai Medical Center	1R01CA287075-01A1	249,622	-
Cancer Detection and Diagnosis Research	93.394	Children's Hospital of Philadelphia (The)	5R01CA258524-05	50,624	-
Cancer Detection and Diagnosis Research	93.394	Collagen Medical, LLC	1R44CA250771-01	378,290	-
Cancer Detection and Diagnosis Research	93.394	Collagen Medical, LLC	1R44CA275590-01A1	(4,698)	-
Cancer Detection and Diagnosis Research	93.394	Collagen Medical, LLC	4R44CA275590-02	103,294	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	2U01CA210171-06	32,571	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA188446-10	36,214	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA214385-06	22,023	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA240592-05	7,238	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA255184-03	23,952	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA260202-03	23,621	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA266424-04	189,625	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	R01CA240582-05	45,433	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	U01CA210171	8,660	-
Cancer Detection and Diagnosis Research	93.394	Direct		18,922,806	2,904,303
Cancer Detection and Diagnosis Research	93.394	Duke University	2R01CA182076-06A1	77,126	-
Cancer Detection and Diagnosis Research	93.394	ECOG-ACRIN Medical Research Foundation, Inc.	5U24CA196172-11	11,670	-
Cancer Detection and Diagnosis Research	93.394	Emory University	5R21CA256280-02	13,392	-
Cancer Detection and Diagnosis Research	93.394	Fred Hutchinson Cancer Center	5U24CA086368-24	151,936	-
Cancer Detection and Diagnosis Research	93.394	Johns Hopkins University	5R01CA285379-02	215,226	-
Cancer Detection and Diagnosis Research	93.394	Johns Hopkins University	5U01CA230691-07	212,386	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA257623-05	34,576	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA265742-05	192,926	-
Cancer Detection and Diagnosis Research	93.394	Memorial Sloan Kettering Institute	5R37CA262662-04	38,641	-
Cancer Detection and Diagnosis Research	93.394	Ohio State University	5R01CA237133-05	40,208	-
Cancer Detection and Diagnosis Research	93.394	Reveal Pharmaceuticals	R44CA239935	(5,585)	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	5U24CA264024	59,601	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	5U24CA264024-04	117,427	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U01CA271492	2,352	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U24CA210979	(278)	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U24CA264029	2,804	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U24CA270823	54,646	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U24CA271075	79,100	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	WU-23-0056	41,335	(15,947)
Cancer Detection and Diagnosis Research	93.394	Trustees of Boston University	5R01CA232056-05	58,260	-
Cancer Detection and Diagnosis Research	93.394	University of California at Davis	5U01CA269191-02	15,484	-
Cancer Detection and Diagnosis Research	93.394	University of Florida Board of Trustees	5R01CA277817-02	228,988	-
Cancer Detection and Diagnosis Research	93.394	University of Kentucky	5R21CA267152-02	38,796	-
Cancer Detection and Diagnosis Research	93.394	University of Texas - Southwestern Medical Center	5U01CA288375-02	100,578	-
Cancer Detection and Diagnosis Research	93.394	University of Texas Southwestern Medical Center	5U24CA086368-24	133,485	-
Cancer Detection and Diagnosis Research	93.394	University of Texas, MD Anderson Cancer Center	5R01CA276178-03	27,014	-
Cancer Detection and Diagnosis Research	93.394	University of Texas, MD Anderson Cancer Center	5U01CA200462-08	69,969	-
Cancer Detection and Diagnosis Research	93.394	University of Washington	5R01CA251803-04	26,103	-
Cancer Detection and Diagnosis Research	93.394	University of Washington	5U24CA264044-04	28,035	-
Cancer Detection and Diagnosis Research	93.394	Washington University, The	5U24CA196171-11	107,387	-
Cancer Detection and Diagnosis Research	93.394	Yale University	5R01CA275188-03	94,266	-
Cancer Detection and Diagnosis Research	93.394	Yale University	5R01CA290745-02	16,436	-
Cancer Detection and Diagnosis Research	93.394	Yale University	5U01CA233364-05	96,088	-
Cancer Research Manpower	93.398	Beth Israel Deaconess Medical Center	5R25CA168544-13	21,884	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5K08CA283279-02	307,406	-
Cancer Research Manpower	93.398	Direct		646,501	-
Cancer Research Manpower	93.398	Rutgers, the State University of New Jersey	5R00CA267557-04	57,518	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Treatment Research	93.395	Beckman Research Institute of the City of Hope	R01CA266783-02	180,900	-
Cancer Treatment Research	93.395	Beth Israel Deaconess Medical Center	2U01CA236489-05A1	207,486	-
Cancer Treatment Research	93.395	Beth Israel Deaconess Medical Center	5R01CA276107-02	298,543	-
Cancer Treatment Research	93.395	Beth Israel Deaconess Medical Center	5U01CA236489-04	1,104	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	2P01CA163205-11	27,562	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5P01CA236749-05	123,954	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5R01CA272637-04	363,794	-
Cancer Treatment Research	93.395	Children's Hospital Corporation dba Boston Children's Hospital	1R01CA286036-01A1	95,701	-
Cancer Treatment Research	93.395	Curer, Inc	1R42CA268629-01A1	(7,726)	-
Cancer Treatment Research	93.395	Curer, Inc	R42CA268629-02	377,461	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1P01CA269021-01A1	128,341	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R01CA284565-01A1	79,931	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA277316-02	10,406	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA286345-01	2,975	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA288234-01	43,333	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA296230-01	8,454	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R37CA279737-02	28,576	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	2P01CA163222-11	35,332	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	2R01CA205406	23,091	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5P01CA155258-12	103,137	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA240804-05	41,022	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA258688-04	71,656	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA267726-03R1	11,539	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA272982-03	12,166	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA279391-02	4,307	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA284565-02	86,995	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R21CA288234-02	10,657	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R37CA269990-03	18,749	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R44CA174129-05	10,438	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5U01CA269505-03	1,683	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5U10CA180886-11	2,099	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5UG1CA242609-06	2,632	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5UM1CA186709-09	206,137	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	R01CA244936	1,849	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	R01CA272657	57,149	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	U01CA260369	6,938	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	U10CA180886-11	(944)	-
Cancer Treatment Research	93.395	Direct		43,143,683	14,622,968
Cancer Treatment Research	93.395	Duo Oncology	1R41CA285174-01	(19,344)	-
Cancer Treatment Research	93.395	East Tennessee State University	5R01CA272760-02	3,731	-
Cancer Treatment Research	93.395	ECOG-ACRIN Medical Research Foundation, Inc.	3U10CA180820-11S2	42,465	-
Cancer Treatment Research	93.395	ECOG-ACRIN Medical Research Foundation, Inc.	5U10CA180820-11	217,231	-
Cancer Treatment Research	93.395	Fox Chase Cancer Center	1R01CA285671-01A1	21,712	-
Cancer Treatment Research	93.395	Fred Hutchinson Cancer Center	5R01CA276040-02	17,336	-
Cancer Treatment Research	93.395	H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc.	5R01CA266803-03	322,074	-
Cancer Treatment Research	93.395	Health Research, Inc. -Roswell Park Cancer Institute Division	5R01CA267690-03	32,679	-
Cancer Treatment Research	93.395	Joan & Sanford I. Weill Medical College of Cornell University	1R01CA270245-03	49,305	-
Cancer Treatment Research	93.395	Johns Hopkins University	1R01CA297470-01	57,561	-
Cancer Treatment Research	93.395	Massachusetts Institute of Technology	5R01CA247632-02	2,719	-
Cancer Treatment Research	93.395	Mayo Clinic	5R37CA276851-03	78,775	-
Cancer Treatment Research	93.395	Mayo Clinic	5U19CA264362-04	61,429	-
Cancer Treatment Research	93.395	Northeastern University	R01CA226855	93,609	-
Cancer Treatment Research	93.395	NRG Oncology	5U10CA180868-11	26,837	-
Cancer Treatment Research	93.395	NRG Oncology	5UG1CA189867-11	1,482	-
Cancer Treatment Research	93.395	Oregon Health & Science University (OHSU)	5U10CA180888-11	8,905	-
Cancer Treatment Research	93.395	President and Fellows of Harvard College	5R01CA263776-03	195,567	-
Cancer Treatment Research	93.395	Public Health Institute	5U10CA180886-11	4,880	-
Cancer Treatment Research	93.395	Public Health Institute	U10CA180886	(8,133)	-
Cancer Treatment Research	93.395	Stanford University Medical Center	5R01CA177684-10	88,435	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Treatment Research	93.395	Strategen Bio	1R43CA261401-1A1	(10)	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	P01CA206978	44,110	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	R01CA155010	5,930	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	R21CA267607	(345)	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	UG1CA189955	421	-
Cancer Treatment Research	93.395	Trustees of Boston University	1R01CA2961810-01	98,893	-
Cancer Treatment Research	93.395	Trustees of Boston University	5R01CA232708-05	42,041	-
Cancer Treatment Research	93.395	Trustees of Boston University	5U01CA265713-03	259,676	-
Cancer Treatment Research	93.395	Trustees of Columbia University in the City of New York (The)	1R01CA294689-01	269,248	-
Cancer Treatment Research	93.395	Trustees of the University of Pennsylvania	5R01CA278882-02	25,028	-
Cancer Treatment Research	93.395	University of Arizona	5UG1CA242596-05	134,447	-
Cancer Treatment Research	93.395	University of Maryland, Baltimore	5R01CA260340-04	367,498	-
Cancer Treatment Research	93.395	University of North Carolina at Chapel Hill, The	7R01CA274254-02	41,453	-
Cancer Treatment Research	93.395	University of Texas, MD Anderson Cancer Center	5R01CA260872-05	223,224	-
Cancer Treatment Research	93.395	Yale University	5R01CA278212-02	560,911	-
Cancer Treatment Research	93.395	Yale University	5R37CA279822-02	73,788	-
Cancer Treatment Research	93.395	Yale University	7P01CA240239-05	(964)	-
Cardiovascular Diseases Research	93.837	Africa Health Research Institute (AHRI)	5R01HL144848-05	154,903	-
Cardiovascular Diseases Research	93.837	Albany Medical College	5R01HL153019-04	(25)	-
Cardiovascular Diseases Research	93.837	Augusta University	5R01HL157665-04	92,763	-
Cardiovascular Diseases Research	93.837	Baylor College of Medicine	5R01HL148050-05	(6,440)	2
Cardiovascular Diseases Research	93.837	Beckman Research Institute of the City of Hope	5R01HL150069-05	5,606	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL129185-08	18,988	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL133870-7	40,181	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL157991-04	11,251	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL157991-05	5,907	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL158077-04	59,801	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL161697-03	16,243	-
Cardiovascular Diseases Research	93.837	Board of Regents of the University of Oklahoma Health Sciences Center	5R01HL161008-04	267,695	-
Cardiovascular Diseases Research	93.837	Board of Regents of the University of Wisconsin System, The	1R01HL163987-01	46,713	-
Cardiovascular Diseases Research	93.837	Boston University School of Medicine	5R01HL127564-08	134,072	-
Cardiovascular Diseases Research	93.837	Boston VA Research Institute Inc	7R01HL126896-07	59,486	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R01HL164409-04	328,507	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	5R01HL157457-03	46,814	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	5R01HL166487-02	20,069	-
Cardiovascular Diseases Research	93.837	Cedar-Sinai Medical Center	5R01HL151828-04	18,071	-
Cardiovascular Diseases Research	93.837	Cedars-Sinai Health System	5R01HL165840-03	455,491	-
Cardiovascular Diseases Research	93.837	Cedars-Sinai Health System	5R35HL161195-04	(52,044)	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	1R01HL174928-01	47,876	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL156362-04	61,788	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL158097-04	20,876	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL162367-04	200,716	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL167925-02	17,248	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5U01HL098147-16	167,273	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	OT3HL147741-01	(2,758)	-
Cardiovascular Diseases Research	93.837	Columbia University Irving Medical Center (CUIMC)	1R35HL177389-01	12,317	-
Cardiovascular Diseases Research	93.837	Columbia University Irving Medical Center (CUIMC)	5R01HL139759-06	38,475	-
Cardiovascular Diseases Research	93.837	Columbia University Irving Medical Center (CUIMC)	5R01HL157216-05	77,111	-
Cardiovascular Diseases Research	93.837	Direct		61,052,168	13,741,363
Cardiovascular Diseases Research	93.837	Duke University	1R21HL157856-02	(7,953)	-
Cardiovascular Diseases Research	93.837	Emory University	5R01HL168894-02	259,460	-
Cardiovascular Diseases Research	93.837	George Washington University	5R01HL140977-04	505	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	3U01HL088942-16S1	137,581	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5P01HL131478-08	647,878	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5U01HL088942-17	40,135	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5U01HL088942-18	90,936	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5R01HL159987-04	226,807	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	7R01HL149998-04	483,011	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	7R01HL150401-05	334,700	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL161858-04	278,596	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL161864-04	137,460	-
Cardiovascular Diseases Research	93.837	LiquiGlide Inc.	1R43HL162196-01A1	(120,501)	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R01HL181150-01	3,411	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R56HL171144-01A1	289,016	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL149516-05	2,348	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL149647-04	20,732	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151293-03	50,327	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151293-05	11,151	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151643-05	99,980	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL163234-03	53,303	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL160278-04	95,402	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U24HL164284-02	12,808	-
Cardiovascular Diseases Research	93.837	Massachusetts Institute of Technology	5R01HL153857-05	251,468	-
Cardiovascular Diseases Research	93.837	Massachusetts Institute of Technology	5R01HL161069-04	206,349	-
Cardiovascular Diseases Research	93.837	Massachusetts Institute of Technology	5R01HL167947-02	2,526	-
Cardiovascular Diseases Research	93.837	Mayo Clinic Arizona	5R01HL165176-03	282,326	-
Cardiovascular Diseases Research	93.837	Mayo Clinic Jacksonville	5R01HL140411-06	124,729	-
Cardiovascular Diseases Research	93.837	MedStar Health Research Institute (MHRI)	5U01HL117006-05	3,366	-
Cardiovascular Diseases Research	93.837	Mount Sinai School of Medicine	5U01HL088942-18	168,027	-
Cardiovascular Diseases Research	93.837	New York Genome Center	5R01HL168247-02	153,939	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL157220-04	4,702	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL161090-02	(148,087)	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL165208-03	31,504	-
Cardiovascular Diseases Research	93.837	Northwestern University	4UH3HL165065-04	1,760	-
Cardiovascular Diseases Research	93.837	Northwestern University	5U54HL160273-04	45,381	-
Cardiovascular Diseases Research	93.837	Northwestern University	5U54HL160273-05	114,935	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL168892-03	386,418	-
Cardiovascular Diseases Research	93.837	Oklahoma Medical Research Foundation	5R01HL167656-03	19,544	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5R01HL035464-33	118,346	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5U01HL145386-06	343,309	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, Los Angeles, The	7R01HL164337-03	49,659	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	5R01HL164337-02	(13,367)	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R01HL146619-04	(4,197)	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R01HL155834-05	101,029	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R35HL155318-06	171,679	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5UH3HL159134-04	109	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	R01HL175879-02	63,039	-
Cardiovascular Diseases Research	93.837	Research Triangle Institute International	5R01HL149352-04	(954)	-
Cardiovascular Diseases Research	93.837	Rutgers, the State University of New Jersey	5R01HL160326-05	9,242	-
Cardiovascular Diseases Research	93.837	St. Jude Children's Research Hospital	5R01HL173881-02	31,838	-
Cardiovascular Diseases Research	93.837	Stanford University	5R01HL166509-02	32,108	-
Cardiovascular Diseases Research	93.837	The Administrators of the Tulane Educational Fund d/b/a Tulane University	2R01HL034594-36A1	286,618	-
Cardiovascular Diseases Research	93.837	The Administrators of the Tulane Educational Fund d/b/a Tulane University	5R21HL161718-02	(3,745)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1OT3HL147154-13	27,575	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL157717-01A1	(703)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL164811-01	29,853	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL170600-01	(2,775)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	237407	(650)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	240336	5,862	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	4500004030	9,056	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL143295-04	117,915	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL151152	(7)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL156991-03	20,948	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL156991-04	4,544	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL157717-03	60,658	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	R01HL142711	13,602	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	R01HL143295	(18,728)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	R01HL157717	83,167	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	R01HL170600	14,943	-
Cardiovascular Diseases Research	93.837	The Curators of the University of Missouri	1R01HL166836-01A1	8,706	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL098028-12	107,759	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL131029-07	50,450	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL156975-04	48,385	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL159620-03	(11,080)	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL166407-02	127,138	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5T32HL125232-09	65,861	-
Cardiovascular Diseases Research	93.837	Trustees of Columbia University in the City of New York (The)	5P01HL172741-02	29,318	-
Cardiovascular Diseases Research	93.837	Trustees of Columbia University in the City of New York (The)	5P01HL172741-05	24,339	-
Cardiovascular Diseases Research	93.837	Trustees of Columbia University in the City of New York (The)	5R01HL168382-03	42,351	-
Cardiovascular Diseases Research	93.837	Trustees of the University of Pennsylvania	5R01HL148272-05	(25,793)	-
Cardiovascular Diseases Research	93.837	Trustees of the University of Pennsylvania	5R01HL168841-02	10,760	-
Cardiovascular Diseases Research	93.837	Tufts Medical Center, Inc.	1R01HL166810-01A1	781,821	-
Cardiovascular Diseases Research	93.837	Tufts Medical Center, Inc.	5R01HL166810-02	46,622	-
Cardiovascular Diseases Research	93.837	Tufts Medical Center, Inc.	R01HL149999	9,257	-
Cardiovascular Diseases Research	93.837	University of California at Davis	1R01HL157712-04	163,549	-
Cardiovascular Diseases Research	93.837	University of California at Davis	7R01HL150119-05	164,359	-
Cardiovascular Diseases Research	93.837	University of Georgia Research Foundation, Inc. (UGARF)	1R21HL168507-01A1	63,119	-
Cardiovascular Diseases Research	93.837	University of Michigan Medical School	5R01HL146619-05	(22,493)	-
Cardiovascular Diseases Research	93.837	University of North Carolina at Chapel Hill, The	5R01HL163262-03	35,798	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	2R01HL133040-06A1	149,636	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5UH3HL153847-05	872	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	7R01HL171098-02	141,386	-
Cardiovascular Diseases Research	93.837	University of Rochester	5R01HL153390-04	33,952	-
Cardiovascular Diseases Research	93.837	University of Rochester	5R01HL160795-04	53,470	-
Cardiovascular Diseases Research	93.837	University of Texas - Southwestern Medical Center	1R01HL172495-01A1	58,605	-
Cardiovascular Diseases Research	93.837	University of Texas Southwestern Medical Center	5R01HL135008-07	110,708	-
Cardiovascular Diseases Research	93.837	University of Texas Southwestern Medical Center	7R01HL148218-04	157,209	-
Cardiovascular Diseases Research	93.837	University of Utah	1R01HL164715-02	13,705	-
Cardiovascular Diseases Research	93.837	University of Washington	5R01HL167645-02	171,603	-
Cardiovascular Diseases Research	93.837	University of Washington - Seattle	5R01HL158765-04	302,124	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL159487-04	32,418	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL161516-04	25,909	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL164526-02	1,910	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL164675-04	254,356	-
Cardiovascular Diseases Research	93.837	Washington University, The	4UH3HL162970-03	63,601	-
Cardiovascular Diseases Research	93.837	Washington University, The	5R01HL156991-04	44,110	-
Cardiovascular Diseases Research	93.837	Washington University, The	5R21HL167126-02	995	-
Cardiovascular Diseases Research	93.837	Washington University, The	5UG3HL162970-02	(13,291)	-
Cardiovascular Diseases Research	93.837	Yale University	5R01HL125918-02	6,238	-
Child Health and Human Development Extramural Research	93.865	Avera McKennan	5U54HD113179-02	231,298	-
Child Health and Human Development Extramural Research	93.865	Barrett Technology	1R44HD109106-01A1	65,314	-
Child Health and Human Development Extramural Research	93.865	Beth Israel Deaconess Medical Center	5R01HD108047-03	26,906	-
Child Health and Human Development Extramural Research	93.865	Bionic Skins LLC	1R44HD110327-01	462,300	-
Child Health and Human Development Extramural Research	93.865	BioSensics LLC	2R44HD084035-04	523,096	-
Child Health and Human Development Extramural Research	93.865	Boston College	5R01HD098421-05	(2,422)	-
Child Health and Human Development Extramural Research	93.865	Boston University School of Medicine	5R01HD086742-09	18,207	-
Child Health and Human Development Extramural Research	93.865	Brandeis University	1R01HD116322-01	134,681	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	1R21HD117308-01	24,290	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	5R01HD093724-05	(4,173)	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	5R01HD107772-04	43,358	-
Child Health and Human Development Extramural Research	93.865	Brown University	5P2CHD101895-03	6,745	-
Child Health and Human Development Extramural Research	93.865	Charles River Analytics, Inc.	1R43HD116639-01A1	498	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children’s Hospital	1R03HD104891-02	(3,548)	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children’s Hospital	5R21HD106553-02	6,002	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Los Angeles	5R33HD107983-04	16,467	-
Child Health and Human Development Extramural Research	93.865	Direct		39,461,715	10,911,903
Child Health and Human Development Extramural Research	93.865	Emma Pendleton Bradley Hospital	5R01HD103665-04	23,373	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Child Health and Human Development Extramural Research	93.865	Emory University	5R01HD110480-03	29,566	-
Child Health and Human Development Extramural Research	93.865	Eunice Kennedy Shriver National Institute of Child		591,427	-
Child Health and Human Development Extramural Research	93.865	Florida State University	5P50HD052120-18	287,266	-
Child Health and Human Development Extramural Research	93.865	Florida State University	5UM2HD111102-03	257,663	-
Child Health and Human Development Extramural Research	93.865	Fred Hutchinson Cancer Center	5R01HD113709-02	148,682	-
Child Health and Human Development Extramural Research	93.865	Fred Hutchinson Cancer Center	5R21HD107577-02	(191)	-
Child Health and Human Development Extramural Research	93.865	George Washington University	5U24HD036801-28	267,638	-
Child Health and Human Development Extramural Research	93.865	Harvard Pilgrim Health Care	5R01HD114807-02	345,186	-
Child Health and Human Development Extramural Research	93.865	Jackson Laboratory, The	1R01HD115718-01	201,923	-
Child Health and Human Development Extramural Research	93.865	Lawrence Berkeley National Laboratory		253,755	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD105266-04	144,940	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD107064-04	358,668	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	R33HD103099-05	2,200	-
Child Health and Human Development Extramural Research	93.865	Mayo Clinic Jacksonville	5R01HD106096-05	391,839	-
Child Health and Human Development Extramural Research	93.865	Mbarara University of Science and Technology	1R01HD111692-01	37,553	-
Child Health and Human Development Extramural Research	93.865	Mbarara University of Science and Technology	4R33HD107985-04	20,494	-
Child Health and Human Development Extramural Research	93.865	Merrimack College	7R21HD107515-03	162,651	-
Child Health and Human Development Extramural Research	93.865	MGH Institute of Health Professions	5R01HD106122-04	47,437	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD094842-05	258,706	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD096033-05	63,601	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD107019-03	68,568	-
Child Health and Human Development Extramural Research	93.865	Northeastern University	5R37HD087089-09	178,605	-
Child Health and Human Development Extramural Research	93.865	Northwestern University	5UG1HD113160-02	55,293	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University (OHSU)	5U54HD100982-04	(14,586)	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1R01HD095766	(49)	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1R01HD112403-01A1	37,802	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	3P01HD103133-04	(3,961)	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD103133-05	89,103	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD107670	18,472	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD107670-04	161,304	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD041702-18	12,959	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD093761-05	1,971	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD094725-05	157,819	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD098232-04	(5,881)	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD101351-04	50,961	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD102342-05	63,484	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD115272-02	8,131	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R33HD103052-04	41,416	-
Child Health and Human Development Extramural Research	93.865	Regents of the University of California, San Francisco	R01HD098978	134,202	-
Child Health and Human Development Extramural Research	93.865	Regents of the University of Michigan	1R01HD111242-03	427,773	-
Child Health and Human Development Extramural Research	93.865	Rush University Medical Center	5R01HD107348-04	27,132	-
Child Health and Human Development Extramural Research	93.865	St. Louis College of Pharmacy	5R33HD099748-05	2,653	-
Child Health and Human Development Extramural Research	93.865	Stellenbosch University	5R33HD103093-04	18,559	-
Child Health and Human Development Extramural Research	93.865	The Broad Institute, Inc.	239748	2,468	-
Child Health and Human Development Extramural Research	93.865	The Broad Institute, Inc.	2R01HD094862-06	11,473	-
Child Health and Human Development Extramural Research	93.865	The Broad Institute, Inc.	5R01HD094862-05	(4,589)	-
Child Health and Human Development Extramural Research	93.865	The Broad Institute, Inc.	6(GG014633-04)	(492)	-
Child Health and Human Development Extramural Research	93.865	Trustees of Columbia University in the City of New York (The)	5R01HD094793-05	46,440	-
Child Health and Human Development Extramural Research	93.865	Trustees of Indiana University	5R01HD110994-02	(2,462)	-
Child Health and Human Development Extramural Research	93.865	Tufts Medical Center, Inc.	R01HD109206	27,683	-
Child Health and Human Development Extramural Research	93.865	University of Arizona	5R01HD110994-04	16,010	-
Child Health and Human Development Extramural Research	93.865	University of Cape Town	5R21HD110305-02	12,382	-
Child Health and Human Development Extramural Research	93.865	University of Cincinnati	5R01HD105818-04	155,926	-
Child Health and Human Development Extramural Research	93.865	University of Colorado at Denver	5R01HD108133-04	175,849	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts at Lowell	5R00HD093814-05	5,392	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	5P2CHD101895-05	3,975	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	U24HD036801-26	(406)	-
Child Health and Human Development Extramural Research	93.865	University of Utah	2R01HD092431-06	60,810	-
Child Health and Human Development Extramural Research	93.865	Virginia Commonwealth University	5R01HD113711-02	185,382	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Child Health and Human Development Extramural Research	93.865	Washington State University	1R01HD111948-01A1	10,581	-
Child Health and Human Development Extramural Research	93.865	Worcester Polytechnic Institute	1R15HD104169-01A1	(9,442)	-
COVID-19 Aging Research	93.866	COVID-19 Direct		2,216,148	406,711
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	3P01AG032952-12S3	(3)	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	5R01AG075507-03	13,431	-
COVID-19 Aging Research	93.866	COVID-19 University of Texas Health Science Center at San Antonio	1R56AG074467-01	(506)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Benaroya Research Institute at Virginia Mason	3UM1AI109565-10S1	(1,288)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Brigham and Women's Hospital, Inc.	1P01AI165072-01	(281,447)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Brigham and Women's Hospital, Inc.	3P01AI165072-01S1	2,703,489	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Brigham and Women's Hospital, Inc.	5R01AI176287-02	636,880	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Children's Hospital Corporation dba Boston Children's Hospital	R01AI174938-02	193,261	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Direct		13,405,474	7,400,523
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Emory University	3U19AI110483-08S4	(405,401)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Center	3UM1AI068614-17S5	(2,754)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Massachusetts Institute of Technology	5U19AI167899-04	1,201,379	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Regents of the University of California, Los Angeles, The	UM1AI068636	529,171	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Scripps Research Institute	5U19AI135995-07	(9,447)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 The Broad Institute, Inc.	3U19AI110818-09S1	(5,550)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 The Broad Institute, Inc.	3U19AI110818-10	(561)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Washington University in St. Louis	1U19AI181103-01	190,939	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Washington University, The	1P01AI168347-01	253,734	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Brigham and Women's Hospital, Inc.	5R01AR080659-02	209,445	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Direct		647,126	126,509
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Northwestern University	5R01AR080089-03	223,412	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 University of Alabama, Birmingham	5R01MD019235-02	117,259	-
COVID-19 Biomedical Research and Research Training	93.859	COVID-19 Direct		147,572	-
COVID-19 Blood Diseases and Resources Research	93.839	COVID-19 Direct		939,740	444,088
COVID-19 Cancer Detection and Diagnosis Research	93.394	COVID-19 Beth Israel Deaconess Medical Center	3U01CA260476-02S1	(21,875)	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Beth Israel Deaconess Medical Center	5R01HL160003-04	122,239	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Direct		252	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Duke University	10T2HL156812-01	301,871	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Icahn School of Medicine at Mount Sinai	5R01HL159433-03	154,905	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Direct		116,660	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Michigan State University	3R01HD094842-04S1	(9,192)	-
COVID-19 Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	COVID-19 Direct		5,214,748	590,000
COVID-19 Drug Abuse and Addiction Research Programs	93.279	COVID-19 Direct		160,149	3,915
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Direct		774,466	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Regents of the University of California, San Francisco	1R01NS136197-01	7,643	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Regents of the University of Minnesota	3R01NS124065-02S1	34,448	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Regents of the University of Minnesota	5R01NS124065-05	53,842	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Beth Israel Deaconess Medical Center	1OT2HL156812-01	152,117	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Brigham and Women's Hospital, Inc.	OT2HL161847	1,343,369	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Direct		31,556,462	18,913,560
COVID-19 Lung Diseases Research	93.838	COVID-19 Duke University	1OT2HL156812-01	600,609	-
COVID-19 Lung Diseases Research	93.838	COVID-19 MaineHealth	OT2HL161847	16,822	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	1OT2HL161841-01	1,777,815	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	1OT2HL161847-01	157,129	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	5R01HL162373-03	35,929	-
COVID-19 Lung Diseases Research	93.838	COVID-19 National Jewish Health	2HL156812-03	(12,244)	-
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	1OT2HL161847-01	1,008,760	166,040
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	OT2HL161847	5,552,827	3,602,405
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	OT2HL161847-01	220,199	24,404
COVID-19 Lung Diseases Research	93.838	COVID-19 Regents of the University of California, San Francisco	1OT2HL156812-01	17,688	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Research Triangle Institute International	1OT2HL156812-01	70,473	-
COVID-19 Lung Diseases Research	93.838	COVID-19 The Administrators of the Tulane Educational Fund d/b/a Tulane University	3R01HL165265-01S1	24,290	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Trustees of Columbia University in the City of New York (The)	RTI22-312-0217571-66178	102	-
COVID-19 Lung Diseases Research	93.838	COVID-19 University of Pittsburgh Of the Commonwealth System of Higher Education	1OT2HL156812-01	131,819	123,988
COVID-19 Lung Diseases Research	93.838	COVID-19 Vanderbilt University Medical Center	1OT2HL156812-01	(461,513)	-
COVID-19 Mental Health Research Grants	93.242	COVID-19 Direct		3,110,337	575,787

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
COVID-19 Minority Health and Health Disparities Research	93.307	COVID-19 Direct		822,652	155,966
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 Direct		(44)	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Johns Hopkins University	75N93021C00045	(8,315)	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Leidos Biomedical Research Inc	23PPA-DM0019	4,062	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Leidos Biomedical Research Inc	75N91019D00024	(21,518)	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 New York University Grossman School of Medicine	OA00001212	54,481	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 University of Chicago	75N92020D00021	52,422	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 University of Georgia Research Foundation, Inc. (UGARF)	75N93021C00018	123,617	-
COVID-19 Nursing Research	93.361	COVID-19 Washington University, The	5U01NR020555-03	25,360	-
COVID-19 Oral Diseases and Disorders Research	93.121	COVID-19 The Administrators of the Tulane Educational Fund d/b/a Tulane University	5R01DE031928-05	1,489	-
COVID-19 Research Related to Deafness and Communication Disorders	93.173	COVID-19 Direct		698,645	71,416
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Direct		2,978,940	167,916
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Mbarara University of Science and Technology	5U54TW012043-04	171,733	-
COVID-19 Vision Research	93.867	COVID-19 Rector and Visitors of the University of Virginia, The	5R01EY026171-07	19,699	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Ann & Robert H. Lurie Children's Hospital of Chicago	7UM1DK072493-17	(15,863)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5R01DK121003-05	(30,337)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5R01DK133520-03	83,739	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK128851-03	79,370	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beth Israel Deaconess Medical Center	5R01DK124502-04	(23,354)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Board of Trustees of the University of Illinois, The	5R01DK118736-04	357	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Board of Trustees of the University of Illinois, The	5R01DK125782-06	77,228	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	1R01DK137856-01	294,276	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	5R01DK125786-05	551	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	5R01DK126685-03	160,483	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	5U2CDK140927-02	156,783	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brown University	5R01DK127585-04	15,029	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK094157-15	328,501	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars-Sinai Medical Center	1R01DK141162-02	59,466	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2P30DK034854-36	45,703	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2P30DK034854-38	26,898	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2R01DK048106-31	9,052	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5K23DK134881-02	11,083	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5P30DK034854-38	770	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5P30DK034854-39	256,991	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5P30DK034854-40	39,926	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK097112-09	12,723	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK126448-05	163,660	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK135884-03	28,221	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5RC2DK131963-04	417,922	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Dana-Farber Cancer Institute, Inc.	5R01DK124384-05	24,901	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Direct		60,016,202	13,282,992
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK094176-10	(954)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK098246-10	36,348	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Georgia Institute of Technology	5R01DK133702-02	(1,098)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine at Mount Sinai	5U54DK083909-15	28,572	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Johns Hopkins University	5R01DK124782-04	14,226	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5P30DK036836-39	19,813	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK106193-08	145,734	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK134996-03	63,957	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK135095-0	280,170	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK142331-02	60,346	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	R01DK122808	7,286	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1R01DK133364-01A1	(80)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1R21DK137432-01	44,062	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	2P30DK040561-26	(21,585)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	2R01DK124145-06	17,310	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	3P30DK040561-27S1	738	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5P30DK135043-02	49,249	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK101495-08	(3,089)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124223-05	21,782	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124710-05	183,378	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	7R01DK124280-04	70,725	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	MelliCell, Inc.	1R43DK137676-01A1	48,240	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Mgh	1UM1NS132358-03	145,841	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	MONTREAL HEART INSTITUTE	5U01DK062432-24	188,479	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York University	5R01DK133871-02	190,374	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York University Grossman School of Medicine	1R01DK137473-01A1	225,724	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York University Grossman School of Medicine	5R01DK108803-09	210,568	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	North Carolina Agricultural and Technical State University	5R01DK131753-02	177,240	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute for Research and Education	R01DK120387	12,229	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5U01DK123759-05	109,314	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5U01DK134321-02	105	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	1U2CDK129670	17,918	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120560-04	45,971	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK126698-03	19,399	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5U2CDK129670-04	(2,580)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5UC2DK126023-05	137,573	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	7U24DK114886-08	4,292	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	1U01HLDK142338-01	376,968	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK128803-05	49,538	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK135868-03	128,200	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of Michigan	5R01DK106618-09	61,157	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of Michigan	5U01DK133090-03	91,988	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Reveal Pharmaceuticals	4R44DK134295-02	311,599	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Spaulding Rehabilitation Hospital	5R01DK136243-02	119,521	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Sylvatica Biotech, Inc	4R44DK124053-02	114,618	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1R01DK131482-01A1	(11,029)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1R01DK137993-01A1	47,770	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1R01GM137606-01A1	22,054	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1RC2DK135492	85,756	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1RC2DK135492-01	(107)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1U01DK137242	44,142	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1U01DK140757-01	25,044	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5125107	(537)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5125107/5400001977	40,763	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5400002072	(5,679)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5P30DK043351-34	7,331	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK129364-03	10,366	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK129464-03	29,041	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK132299-03	5,563	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK132900-02	209,566	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5RC2DK135492-02	510,884	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	FP068366-01A/5400001805	(2,939)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	R01DK099465	11,987	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	R01DK131482	2,952	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	R01DK132900	16,512	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	U01DK114907	2,506	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	UM1DK105554	5,790	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Columbia University in the City of New York (The)	5R01DK135671-02	38,750	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Dartmouth College	5P30DK117469-07	83,949	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK103225-07	(18,007)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK126654-04	(52,957)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK126654-05	3,794	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	2U54DK118612-06	156,158	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5U54DK118612-05	(27,222)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Cincinnati	5R01DK123330-05	(22,773)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Massachusetts, Worcester	1R01DK127180-04	60,014	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Massachusetts, Worcester	1R01DK127207-03	2,856	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	1R01DK139598-01	12,524	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	5R01DK125831-05	76,388	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	5R01DK127365-05	127,819	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01DK137913-01A1	39,208	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Texas Medical Branch at Galveston	7R01DK133364-03	17,888	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	1R01DK138948-01	138,368	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	5U24DK114886-07	(57)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5R01DK127912-04	54,567	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5R01DK131129-04	157,013	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5U01DK112271-05	6,946	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Yale University	5R01DK135650-03	19,766	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Yale University	5R01DK140717-02	199,119	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Barrett Technology	2R44EB027525-02	12,382	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Board of Trustees of the Leland Stanford Junior University, The	1R01EB033206-01	163,560	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	5R01EB032378-04	117,626	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	5R01EB033866-03	47,797	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cedars-Sinai Health System	5R01EB034586-04	90,712	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Children's Hospital Corporation dba Boston Children's Hospital	5R01EB032708-04	15,654	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Children's Hospital Corporation dba Boston Children's Hospital	5R01EB034757-02	133,260	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	1U54EB034654-01	91,342	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Dana-Farber Cancer Institute, Inc.	1R21EB035247-01A1	21,148	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Direct		36,988,720	9,312,102
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Duke University	5R01EB028143-04	(208)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Georgia Institute of Technology	5R01EB034359-02	132,249	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts Eye and Ear Infirmary	1R01EB036978-01	6,972	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	1U01EB034228-03	22,521	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	2R01EB031008-05	36,175	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	5R01EB031008-04	(13,986)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	5R01EB033321-03	47,692	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	5U54EB033650-04	77,724	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts Institute of Technology	1R01EB031813-04	336,591	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Pennsylvania State University	3R01EB030130-03S1	9,378	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Pennsylvania State University	7R21EB030257-02	(15,765)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Regents of the University of California, Santa Barbara	7R56EB029259-06	26,233	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Rensselaer Polytechnic Institute	R01EB031102	219,732	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	1R01EB035574-01A1	9,927	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	1R21EB029154-01	(4,032)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	5R21EB030197-03	(140)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	5UG3EB034710-03	130,809	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Florida Board of Trustees	5R01EB034692-02	23,074	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Maryland	1R21EB034835-01	142,546	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Massachusetts Amherst	5R01EB027777-05	84,091	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Texas at Dallas	1R01EB034360	96,455	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Yale University	5R01EB031114-04	327,232	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Yale University	5R01EB033582-04	11,761	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Yale University	5R21EB034911-02	28,099	-
Drug Abuse and Addiction Research Programs	93.279	Avera McKennan	5R01DA050696-04	10,652	-
Drug Abuse and Addiction Research Programs	93.279	Beth Israel Deaconess Medical Center	1UG3NS130592-01A1	45,654	-
Drug Abuse and Addiction Research Programs	93.279	Board of Regents of the University of Nebraska for the University of Nebras	5R01DA046852-05	(30,722)	-
Drug Abuse and Addiction Research Programs	93.279	Board of Regents of the University of Nebraska for the University of Nebras	5R21DA058588-02	42,390	-
Drug Abuse and Addiction Research Programs	93.279	Board of Trustees of the Leland Stanford Junior University, The	5R01DA056593-05	565,616	-
Drug Abuse and Addiction Research Programs	93.279	Board of Trustees of the Leland Stanford Junior University, The	5R01DA058694-02	201,227	-
Drug Abuse and Addiction Research Programs	93.279	Board of Trustees of the University of Alabama for the University of Alabam	5R01DA044112-05	54,229	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	5R01DA058367-02	112,243	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	5UM1DA049412-04	57,840	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	7R61DA060588-02	13,285	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	1U19NS130617-03	296,902	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5R01DA044167-05	(883)	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5R21DA056799-02	(1,144)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5U19NS130617-03	150,312	-
Drug Abuse and Addiction Research Programs	93.279	Brown University	1R34DA052836-02	21,594	-
Drug Abuse and Addiction Research Programs	93.279	Brown University	5R01DA047975-05	7,735	-
Drug Abuse and Addiction Research Programs	93.279	Charles River Analytics, Inc.	1R44DA059018-01	(6,744)	-
Drug Abuse and Addiction Research Programs	93.279	Charles River Analytics, Inc.	4R44DA059018-02	54,336	-
Drug Abuse and Addiction Research Programs	93.279	Children's Hospital Corporation dba Boston Children's Hospital	5R21DA058072-02	39,961	-
Drug Abuse and Addiction Research Programs	93.279	Children's Hospital Corporation dba Boston Children's Hospital	5U01DA055353-04	176,454	-
Drug Abuse and Addiction Research Programs	93.279	Dimagi, Inc	5R44DA050218-03	284,306	-
Drug Abuse and Addiction Research Programs	93.279	Direct		26,487,640	6,483,148
Drug Abuse and Addiction Research Programs	93.279	ExQor Technologies Inc	2R44DA044050-02A1	6,546	-
Drug Abuse and Addiction Research Programs	93.279	Fenway Community Health Center	1DP2DA056107-01	4,609	-
Drug Abuse and Addiction Research Programs	93.279	General Biophysics LLC	1R41DA061962-01	30,949	-
Drug Abuse and Addiction Research Programs	93.279	George Mason University	2U2CDA050097-06	531	-
Drug Abuse and Addiction Research Programs	93.279	George Mason University	5U2CDA050097-04	13,519	12,058
Drug Abuse and Addiction Research Programs	93.279	Harvard Pilgrim Health Care	5U01DA059472-02	326,041	-
Drug Abuse and Addiction Research Programs	93.279	Hennepin Healthcare Research Institute	2UG1DA040316-11	465,627	-
Drug Abuse and Addiction Research Programs	93.279	Joan & Sanford I. Weill Medical College of Cornell University	5P30DA040500-09	(1,304)	-
Drug Abuse and Addiction Research Programs	93.279	Massachusetts General Hospital	5R33DA047034-05	146,656	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R01DA045632-04	90	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R01DA058315-03	122,268	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R21DA056864-02	18,153	-
Drug Abuse and Addiction Research Programs	93.279	MindLight, LLC	2R44DA050358-02A1	333,302	-
Drug Abuse and Addiction Research Programs	93.279	New York University Grossman School of Medicine	3UH3CA261067-05S1	2,877	-
Drug Abuse and Addiction Research Programs	93.279	New York University Grossman School of Medicine	5UG3CA261067-05	108,441	-
Drug Abuse and Addiction Research Programs	93.279	Northeastern University	5R01DA047130-05	(209)	-
Drug Abuse and Addiction Research Programs	93.279	Partnership to End Addiction	R24DA051946	109,295	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	1R01DA054601-01A1	23,267	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	2R01DA048533-05	10,578	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5P30 DA035772-08	18,179	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5P30DA035772-08	29,218	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5R01AA030539-02	34,410	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5R01DA048533-04	(1,504)	-
Drug Abuse and Addiction Research Programs	93.279	Regents of the University of Michigan	5R01DA031160-11	23,122	-
Drug Abuse and Addiction Research Programs	93.279	Regents of the University of Minnesota	5R01DA047287-05	17,433	-
Drug Abuse and Addiction Research Programs	93.279	Research Triangle Institute International	4UM1DA049394-02	3,711	-
Drug Abuse and Addiction Research Programs	93.279	Rutgers, the State University of New Jersey	5R01DA050721-05	58,373	-
Drug Abuse and Addiction Research Programs	93.279	The Broad Institute, Inc.	1U01DA053631-01	(14,347)	-
Drug Abuse and Addiction Research Programs	93.279	Trustees of Boston University	5R01NS121419-03	(19,490)	-
Drug Abuse and Addiction Research Programs	93.279	Trustees of Boston University	5R33DA045148-05	75,284	-
Drug Abuse and Addiction Research Programs	93.279	Tufts Medical Center, Inc.	R61DA060588	4,325	-
Drug Abuse and Addiction Research Programs	93.279	University of Cincinnati	2UG1DA013732-26	108,661	-
Drug Abuse and Addiction Research Programs	93.279	University of Colorado at Denver	7DP2DA051864-02	30,019	-
Drug Abuse and Addiction Research Programs	93.279	University of Delaware	5R01DA059557-02	71,928	-
Drug Abuse and Addiction Research Programs	93.279	University of Florida Board of Trustees	5R01DA055568-03	220,048	-
Drug Abuse and Addiction Research Programs	93.279	University of New South Wales	1R01DA059822-01A1	24,668	-
Drug Abuse and Addiction Research Programs	93.279	University of Pittsburgh Of the Commonwealth System of Higher Education	1UG3DA060431-01	10,616	-
Drug Abuse and Addiction Research Programs	93.279	University of Texas Medical Branch at Galveston	5R01DA040621-10	7,617	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	2UG1DA015831-24	104,534	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	3UG1DA015831-24S1	89,678	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	4R33DA059169-02	24,392	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA015831-22	343,559	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA015831-23	692,547	-
Environmental Health	93.113	Arizona State University	5R01ES033999-03	29,859	-
Environmental Health	93.113	Brown University	R01ES034014-02	130,758	-
Environmental Health	93.113	Dartmouth-Hitchcock Clinic	5R01ES034133-03	47,072	-
Environmental Health	93.113	Direct		5,509,192	2,385,977
Environmental Health	93.113	Drexel University	5R01ES032469-04	174,689	-
Environmental Health	93.113	Icahn School of Medicine at Mount Sinai	1R01ES035791-01A1	128,224	-
Environmental Health	93.113	President and Fellows of Harvard College	1R01ES034021-01A1	14,590	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Environmental Health	93.113	President and Fellows of Harvard College	1R01ES035736-01A1	428,538	-
Environmental Health	93.113	President and Fellows of Harvard College	1U24ES035309-01	33,116	-
Environmental Health	93.113	President and Fellows of Harvard College	5P30ES000002-60	47,508	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES022981-09	1,378	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031657-04	(138)	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031657-05	155,965	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031943-05	6,752	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES032470-04	22,409	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES033185-04	3,117	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES035106-03	364,766	-
Environmental Health	93.113	Regents of the University of California, Irvine	5R01ES023316-12	183,193	-
Environmental Health	93.113	Regents of the University of Michigan	5R01ES031591-05	75,380	-
Environmental Health	93.113	Rutgers, the State University of New Jersey	5R01ES034038-04	164,772	-
Environmental Health	93.113	Trustees of Columbia University in the City of New York (The)	5R01ES026991-08	149,595	-
Environmental Health	93.113	University of California at Irvine	3R01ES031139-04S1	20,308	-
Environmental Health	93.113	University of Florida Board of Trustees	1R24ES036131-01	63,314	-
Environmental Health	93.113	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01ES033519-05	39,893	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Aalto-korkeakoulusaatio sr	5R01NS104585-07	78,119	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Baylor College of Medicine	1UH3NS136631-01	25,070	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	1R21NS128815-01	(1,618)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01HL161253-04	221,424	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS105844-05	(48)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS120947-04	43,801	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS126282-03	102,685	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS128045-02	93,558	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS129156-03	87,888	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5U01NS102289-05	173,382	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	BioSensics LLC	1R44NS122672-01A1	(1,333)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Board of Regents of the University of Wisconsin System, The	1R01NS138422-01	64,278	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Board of Trustees of the Leland Stanford Junior University, The	5U01NS123101-04	302,613	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	1R01NS136297-01A1	11,665	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	1RF1NS139183-01	197,411	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	5R01NS115951-05	52,243	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	5R01NS123557-04	39,091	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brown University	5R01NS113141-07	24,429	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brown University	5U24NS129945-03	39,132	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Celdara Medical LLC	R43NS127620	(7)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	1R61NS130215-01A1	163,620	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	2R37NS035129-26	241,418	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R01NS128281-02	13,935	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R21NS121735-02	(10,242)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R61NS126792-03	18,225	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	3U54NS115052-05S4	79,195	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U54NS115052-05	(72,028)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cook Children's Health Care System	5R01NS104116-05	(24,038)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Dignity Health	1OT2NS136939-01	1,316,967	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Direct		151,216,107	31,140,686
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	1DP2NS127291-01	(953)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	4DP2NS127291-02	30,681	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5R01NS113541-05	88,027	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Highland Instruments	5R44NS110237-03	(19)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1RF1NS115268-01	(2,648)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1RF1NS128961-01	485,983	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	5R01NS115957-06	140,247	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	5U01NS107016-05	9,430	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	2RF1NS095969-06	22,123	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute Inc	5R61NS131928-02	40,846	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1R01NS130119-01A1	218,145	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1R01NS142153-01	16,497	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1RM1NS128741-01	116,621	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1RM1NS132996-01	632,011	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	2R01NS093870-08	342,779	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	2R01NS095640-08A1	38,581	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	2U24NS107243-07	2,688	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	3U01NS077179-14S1	7,893	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS093870-08	54,807	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS102574-05	424	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS103924-05	(5,863)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U19NS115388-06	135,092	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS107243-07	7,225	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS113850-05	117,794	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS120901	5,066	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5R01NS121073-04	115,898	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5R01NS121078-05	115,902	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5U01NS121471-05	240,956	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5U19NS128613-03	89,399	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5R01NS076491-13	(15,154)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5UH3NS103870-05	(18,612)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5P01NS084974-10	115,128	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5U01NS080168-11	(69,969)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5U01NS119169-04	2,001	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	McLean Hospital Corporation	5U01NS109463-05	269,632	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Merlin Therapeutics Inc.	1R41NS135883-01	100,887	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	MGH INTERNAL SUPPORT	1U01NS136020-01	156,816	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	MGH INTERNAL SUPPORT	1U01NS136021-01	281,846	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Michigan State University	1RF1NS128611-01	286,348	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuro42	1U44NS136026-01A1	(2,029)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuropace, Inc.	1UH3NS109557-01A1	100,105	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuropace, Inc.	5UH3NS109557-02	61,608	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northeastern University	5R01NS131467-03	382,878	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5R01NS085770-10	82,821	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	5UG3NS117844-05	198,195	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	PathMaker Neurosystems Inc.	1U44NS104138-01	(378,499)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	1R01NS124017-01	345	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	4R01NS124017-02	48,017	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS126248-04	84,139	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS126260-04	126,936	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rector and Visitors of the University of Virginia, The	1UG3NS131532-01A1	77,800	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Diego	5R01NS112503-06	362,362	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Diego	5UG3NS123723-03	51,283	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	1RF1NS128217-01A1	345,091	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	5R01NS111166-04	(45,426)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	5R01NS124051-04	12,790	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Michigan	1U01NS099046-01A1	60	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Michigan	7R01NS125742-05	311,215	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Minnesota	1RF1NS135615-01	114,647	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	RevBio, Inc.	1R44NS135736-01A1	49,128	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	State University of New York at Buffalo, The	7R01NS058949-14	163,486	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Temple University - Of the Commonwealth System of Higher Education	5R01NS070267-15	7,117	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	1U2NS132940	176,601	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	1UG3NS132135	14,756	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	231500	(470)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	5R01NS102371-05	1,229	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	U01NS136398	46,445	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	1RF1NS143015-01	2,355	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS121419-04	70,964	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS125307-04	285,266	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS139383-02	55,240	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R21NS136960-02	40,160	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5U19NS123717-05	573,192	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	1U54NS137199-01	2,201	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5R01NS131606-02	130,596	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5U54NS078059-13	18,567	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of the University of Pennsylvania	5U01NS114140-04	224	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Buffalo	5R01NS058949-14	49,466	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	1R21NS137117-01	71,660	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	5R01NS116262-05	59,690	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS102289-01A1	3,612	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS110772-01	13,745	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS120910-01	2,251	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1UG3NS119199-01A1	1,154	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1UG3NS125023-01A1	5,863	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	3OT2NS129366-01S1	5,154	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS069763-10	267,200	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS099043-02	1,491	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS106513-02	13,013	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS110728-02	970	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	U01NS117450	4,698	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Florida Board of Trustees	5U01NS119562-05	23,223	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Florida Board of Trustees	5U01NS124613-02	623,175	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Maryland	5R01NS122980-04	99,611	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts, Worcester	5R01NS108769-05	7,336	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts, Worcester	5U01NS114098-05	26,107	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Miami	5U54NS092091-10	1,580	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh Of the Commonwealth System of Higher Education	1U44NS121557-01A1	(8,173)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh Of the Commonwealth System of Higher Education	2R01NS098023-08	114,681	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Rochester	5R01NS126933-03	36,902	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas at Austin	1U24NS140384-01	76,997	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Medical Branch at Galveston	1UG3NS128397-01A1	2,685	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	5U01NS120901-03	2,515,305	437,430
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	1U01NS137484-01	364,856	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University Medical Center	5R01NS123281-04	23,137	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Washington University in St. Louis	1R01NS131610-01A1	107,252	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1R21NS138995-01	104,570	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1U01NS099046-01A1	6,469	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS117904-05	219,781	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS130189-03	84,887	-
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	Direct		(25)	-
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	University of Southern California	5R01CA260459-03	17,694	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	2U01HG008685-09	88,893	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	5R01HG012810-03	123,351	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	9U01NS134357-09	91,931	-
Human Genome Research	93.172	Children's Hospital Corporation dba Boston Children's Hospital	1R01HG013618-01	421,402	-
Human Genome Research	93.172	Children's Hospital Medical Center	5R01HG010730-03	(25)	-
Human Genome Research	93.172	Dana-Farber Cancer Institute, Inc.	1R56HG013083-01	(12,921)	-
Human Genome Research	93.172	Dana-Farber Cancer Institute, Inc.	5R01HG013083-02	223,578	-
Human Genome Research	93.172	Dana-Farber Cancer Institute, Inc.	5U24HG004059-21	256,552	-
Human Genome Research	93.172	Direct		8,846,438	2,565,771
Human Genome Research	93.172	Jackson Laboratory, The	2U24HG007497-09	151,561	-
Human Genome Research	93.172	Johns Hopkins University	5U24HG010263-05	(3,740)	-
Human Genome Research	93.172	Johns Hopkins University	5U24HG010263-08	190,943	-
Human Genome Research	93.172	Massachusetts General Hospital	5UM1HG012010-04	572,876	-
Human Genome Research	93.172	New York University Grossman School of Medicine	2RM1HG009491-07	25,863	-
Human Genome Research	93.172	Northwell Health, Inc	5R01HG011711-04	268,580	-
Human Genome Research	93.172	President and Fellows of Harvard College	1R56HG013314-01A1	7,063	-
Human Genome Research	93.172	President and Fellows of Harvard College	5R01HG012926-03	13,799	-
Human Genome Research	93.172	The Broad Institute, Inc.	1U01HG011723	8,761	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Human Genome Research	93.172	The Broad Institute, Inc.	1U01HG011755	198,627	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011723-03	(242)	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011723-04	185,296	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011755-05	464,383	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U24HG006834	16,373	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U24HG011025	14,952	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U24HG011735-04	3,689	-
Human Genome Research	93.172	The Broad Institute, Inc.	R01HG010647	51,363	-
Human Genome Research	93.172	The Broad Institute, Inc.	R01HG012781	120,292	-
Human Genome Research	93.172	The Broad Institute, Inc.	U01HG011723	4,515	-
Human Genome Research	93.172	The Broad Institute, Inc.	U01HG011723/5400001939	48,399	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG006834-08/5400001914	80,334	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG011450	230,341	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG012090	11,922	-
Human Genome Research	93.172	University of North Carolina at Chapel Hill, The	1R21HG012365-02	43,706	-
Human Genome Research	93.172	University of North Carolina at Chapel Hill, The	5U24HG009650-08	80,748	-
Human Genome Research	93.172	Vanderbilt University Medical Center	1U24HG013233-02	302,822	-
Human Genome Research	93.172	Vanderbilt University Medical Center	5U24HG013233-02	315,094	-
International Research and Research Training	93.989	Les Centres GHESKIO	1R21TW012644-02	4,590	-
International Research and Research Training	93.989	Mbarara University of Science and Technology	1R21TW012563-01A1	16,010	-
International Research and Research Training	93.989	President and Fellows of Harvard College	1P20TW013028-01	17,064	-
International Research and Research Training	93.989	President and Fellows of Harvard College	2D43TW009610-12	4,908	-
Lung Diseases Research	93.838	Baylor College of Medicine	5R01HL149744-05	1,605	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	1U24HL166784-02	224,907	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	1UG3HL166785-01A1	3,604	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	5R01HL149422-04	47,791	-
Lung Diseases Research	93.838	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL118455-08	117,638	-
Lung Diseases Research	93.838	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL163513-03	569,882	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL148856-05	(109)	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5R61HL165366-02	(2,582)	-
Lung Diseases Research	93.838	Columbia University Irving Medical Center (CUIMC)	5R01HL159675-04	44,048	-
Lung Diseases Research	93.838	Dartmouth-Hitchcock Clinic	5R01HL174700-02	6,228	-
Lung Diseases Research	93.838	Direct		42,085,813	8,768,381
Lung Diseases Research	93.838	Duke University	1OT2HL156812-01	207,739	-
Lung Diseases Research	93.838	Duke University	5U24HL163122-03	3,840	-
Lung Diseases Research	93.838	Emory University	5R01HL169373-02	50,901	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	5UH3HL147011-05	(746)	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	4R33HL153011-03	19,070	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	4R33HL158540-02	445	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5P01HL114501-08	(1,199)	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5P01HL114501-09	655,776	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5R33HL153011-03	164,211	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5UH3HL154944-04	23,891	-
Lung Diseases Research	93.838	Johns Hopkins University	1R01HL168663-01A1	244,042	-
Lung Diseases Research	93.838	Johns Hopkins University	5R01HL160008-04	84,712	-
Lung Diseases Research	93.838	Massachusetts General Hospital	1OT2HL161841-01	2,033,287	-
Lung Diseases Research	93.838	Massachusetts General Hospital	1R01HL169225-01A1	55,737	-
Lung Diseases Research	93.838	National Jewish Health	5R01HL109557-13	151,180	-
Lung Diseases Research	93.838	Northwestern University	5R01HL122477-09	389,015	-
Lung Diseases Research	93.838	Northwestern University	5R01HL159250-04	252,420	-
Lung Diseases Research	93.838	Northwestern University	5U01HL146408-06	395,727	-
Lung Diseases Research	93.838	President and Fellows of Harvard College	5R01HL150520-04	(2,127)	-
Lung Diseases Research	93.838	Rector and Visitors of the University of Virginia, The	5R01HL153248-04	211,649	-
Lung Diseases Research	93.838	Rector and Visitors of the University of Virginia, The	5R01HL167202-03	13,742	-
Lung Diseases Research	93.838	Regents of the University of California, San Diego	5R01HL161362-03	306,793	-
Lung Diseases Research	93.838	Regents of the University of California, San Diego	5R01HL162570-07	23,719	-
Lung Diseases Research	93.838	Regents of the University of Michigan	5U24HL145265-06	8,367	-
Lung Diseases Research	93.838	RTI International	1OT2HL156812-01	89,698	-
Lung Diseases Research	93.838	The University of Texas Health Science Center at Houston	5R01HL145025-05	(100,127)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Lung Diseases Research	93.838	Trustees of Boston University	5P01HL170952-02	95,563	-
Lung Diseases Research	93.838	Trustees of Boston University	5R01HL159644-03	364,241	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	5R01HL137234-04	6,971	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	5UH3HL140177-05	(223,641)	-
Lung Diseases Research	93.838	Trustees of Tufts College	5R01HL171728-02	198,664	-
Lung Diseases Research	93.838	University Health Network	5U01HL163298-03	55,438	-
Lung Diseases Research	93.838	University of Florida Board of Trustees	1R01HL178032-01	156,903	-
Lung Diseases Research	93.838	University of Florida Board of Trustees	5R01HL157879-04	344,210	-
Lung Diseases Research	93.838	University of Maryland, Baltimore	R01HL139613	40,034	-
Lung Diseases Research	93.838	University of Maryland, Baltimore	R01HL155096	37,056	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill, The	5R01HL111527-11	67,586	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill, The	5U24HL138998-06	(910,729)	-
Lung Diseases Research	93.838	University of Pittsburgh Of the Commonwealth System of Higher Education	R01HL161164-03	297	-
Lung Diseases Research	93.838	University of South Florida	1R21HL172124-01A1	82,096	-
Lung Diseases Research	93.838	University of Texas Southwestern Medical Center	7R01HL160025-03	19,961	-
Lung Diseases Research	93.838	University of Vermont and State Agricultural College	5R01HL161220-03	46,956	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	1OT2HL156812-01	235,187	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL158906-04	50,490	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL163960-04	35,814	-
Lung Diseases Research	93.838	Verra Therapeutics LLC	3R44HL149580-03	8,540	-
Medical Library Assistance	93.879	Dana-Farber Cancer Institute, Inc.	5R01LM013352-04	28,192	-
Medical Library Assistance	93.879	Direct		1,363,996	492,953
Medical Library Assistance	93.879	Northeastern University	5R01LM013772-03	303,296	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5R01LM013614-04	48,688	-
Mental Health Research Grants	93.242	Allen Institute	5UM1MH130981-03	714,170	-
Mental Health Research Grants	93.242	Baylor College of Medicine	5R01MH128676-04	98,648	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH111448-07	63,536	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH116170-07	622,238	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH127174-03	20,787	-
Mental Health Research Grants	93.242	Board of Trustees of the Leland Stanford Junior University, The	2R01MH116173-06	238,700	-
Mental Health Research Grants	93.242	Board of Trustees of the Leland Stanford Junior University, The	5R01MH116173-05	(671)	-
Mental Health Research Grants	93.242	Board of Trustees of the Leland Stanford Junior University, The	5R01MH132074-03	244,472	-
Mental Health Research Grants	93.242	Board of Trustees of the University of Alabama for the University of Alabam	R34RMH118044A	122	-
Mental Health Research Grants	93.242	Board of Trustees of the University of Illinois, The	1R34MH132432-01A1	8,977	-
Mental Health Research Grants	93.242	Boston Medical Center	1R34MH137223-01	23,123	-
Mental Health Research Grants	93.242	Boston University School of Medicine	5R01MH128377-04	268,934	-
Mental Health Research Grants	93.242	Boston VA Research Institute Inc	5R61MH129479	276,843	-
Mental Health Research Grants	93.242	Boston VA Research Institute Inc	5R61MH129479-02	258,280	-
Mental Health Research Grants	93.242	Boston VA Research Institute Inc	7R33MH113751	285,793	-
Mental Health Research Grants	93.242	Boston VA Research Institute Inc	7R33MH113751-05	104,598	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	1R01MH136160-01A1	10,213	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	1U24MH137171-01	310,756	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH113929-09	176,392	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH125860-05	136,370	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH130666-04	32,945	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH132610-03	164,213	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5U24MH124629-05	1,377,712	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5U24MH137171-02	91,006	-
Mental Health Research Grants	93.242	Cambridge Health Alliance	5P50MH126283-04	46,613	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	5R01MH126977-04	228,049	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	5U01MH136558-03	15,871	-
Mental Health Research Grants	93.242	Children's Hospital of Philadelphia (The)	5R01MH134886-02	16,819	-
Mental Health Research Grants	93.242	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University	5R01MH125214-03	146,408	-
Mental Health Research Grants	93.242	Dartmouth Hitchcock Medical Center	1R01MH133610-01A1	71,585	-
Mental Health Research Grants	93.242	Direct		70,672,070	16,807,731
Mental Health Research Grants	93.242	Emory University	5R01MH131434-02	42,839	-
Mental Health Research Grants	93.242	Huntington Medical Research Institute	5R01MH110438-09	(177,060)	-
Mental Health Research Grants	93.242	Icahn School of Medicine at Mount Sinai	5R01MH131537-03	141,652	-
Mental Health Research Grants	93.242	Icahn School of Medicine at Mount Sinai	5U01MH136535-02	293,134	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Mental Health Research Grants	93.242	King's College London	5R01MH114708-05	63,155	-
Mental Health Research Grants	93.242	London School of Hygiene & Tropical Medicine	5R01MH115504-04	51,262	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	1R01MH128246-03	194,714	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	1R61MH129331-02	160,078	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH113930-08	(3,003)	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH116205-05	75,982	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH134823-03	36,589	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5U54MH118919-05	34,354	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	2P50MH115846-05	204,741	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH115846-06	160,507	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH119467-05	481,481	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH117012-05	38,280	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH120991-05	(1,019)	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH134074-02	211,375	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH135093-02	85,507	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R37MH068376-19	3,046	-
Mental Health Research Grants	93.242	MindTrace Technologies, Inc.	1R44MH135726-01	18,055	-
Mental Health Research Grants	93.242	Nalu Scientific, LLC	9R44MH140338-02A1	84,441	-
Mental Health Research Grants	93.242	New York University School of Medicine	5R01MH126981-05	56,290	-
Mental Health Research Grants	93.242	New York University School of Medicine	5R33MH122647-05	481,524	-
Mental Health Research Grants	93.242	Northeastern University	5R01MH113234-05	(180)	-
Mental Health Research Grants	93.242	Ocean State Research Institute, Inc.	1U01MH123427-04	(68,534)	-
Mental Health Research Grants	93.242	Oregon Health & Science University (OHSU)	5U01MH135970-02	223,457	-
Mental Health Research Grants	93.242	Paradromics, Inc.	1R44MH125700-01A1	(10,971)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1P50MH129699	44,062	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1R01MH133657-01	(2,711)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1RF1MH128861-01	(15,419)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5P50MH129699-02	25,059	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101244-13	266,441	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101269-08	(50)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH112829-08	16,494	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH121191-05	6,672	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH121632-03	85,510	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH131414-03	20,531	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH133230-02	44,332	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH137201-02	536,210	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	R01MH121191-05	10,868	-
Mental Health Research Grants	93.242	RAND Corporation	5R01MH117760-05	(21,770)	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	1R21MH132406-01A1	18,956	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	5R01MH106595-06	59,151	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	5R01MH106595-08	(72)	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	5R01MH106595-10	124,260	-
Mental Health Research Grants	93.242	Regents of the University of Minnesota	7R01MH134144-02	148,004	-
Mental Health Research Grants	93.242	Rhode Island Hospital	5P50MH106435-08	7,744	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	1R01MH137793-01	24,148	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	1R21MH135493-01A1	20,927	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	2R01MH120080-07A1	70,623	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	3R34MH113757-03S1	(409)	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	5R01MH124899-03	98,685	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	7R01MH120080-06	78,393	-
Mental Health Research Grants	93.242	State University of New York Downstate Health Sciences University, The	5R01MH125938-04	30,809	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1R01MH134468	31,787	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1R01MH134468-01	13,414	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1RF1MH130468-01A1	43,966	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1U01MH137298-01	10,335	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	3U01MH125047-04S1	(6,479)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	3U24MH124629-04S1	23,076	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH104964-11	49,476	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH106595-08	(2,696)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH106595-10	3,489	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH115957-07	563,482	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH116037-05	1,797	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH123451-04	26,487	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH128813-03	8,076	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH129722-04	45,474	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH130675-03	64,231	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH134468-02	23,076	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R37MH107649-10	320,300	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5U01MH125047-05	185,666	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	7R01MH112904-06	1,925	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	GR1162-80003672	4,947	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	MH115957	29,064	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	U01MH119689	45,251	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	U01MH124602	(2,920)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	UM1MH130966	150,705	-
Mental Health Research Grants	93.242	Trustees of Boston University	1R01MH128280-02	37,908	-
Mental Health Research Grants	93.242	Trustees of Boston University	5R01MH125703-05	63,349	-
Mental Health Research Grants	93.242	Trustees of the University of Pennsylvania	5R01MH132962-02	95,281	-
Mental Health Research Grants	93.242	Trustees of Tufts College	5R01MH136641-02	79,872	-
Mental Health Research Grants	93.242	Turing Medical Technologies Inc.	R44MH124567-04	57,839	-
Mental Health Research Grants	93.242	University of Delaware	1R01MH126196-01A1	69,903	-
Mental Health Research Grants	93.242	University of Florida Board of Trustees	R01MH117114	(989)	-
Mental Health Research Grants	93.242	University of Massachusetts Amherst	5R01MH122371-04	11,278	-
Mental Health Research Grants	93.242	University of Massachusetts Chan Medical School	5R01MH128275-03	162,371	-
Mental Health Research Grants	93.242	University of Massachusetts, Worcester	5R01MH128904-04	116,909	-
Mental Health Research Grants	93.242	University of Miami	1R01MH136972-01	97,265	-
Mental Health Research Grants	93.242	University of Miami	R01MH118043	5,276	-
Mental Health Research Grants	93.242	University of Mississippi Medical Center	5R01MH125833-04	34,389	-
Mental Health Research Grants	93.242	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01MH131717-01A1	60,041	-
Mental Health Research Grants	93.242	University of Rochester	5P50MH106435-08	78,884	-
Mental Health Research Grants	93.242	University of Rochester	5P50MH106435-09	496,626	-
Mental Health Research Grants	93.242	University of Rochester	5R01MH045573-33	162,620	-
Mental Health Research Grants	93.242	University of Texas at Austin	R01MH120219	18,672	-
Mental Health Research Grants	93.242	Vanderbilt University	5R01MH130364-03	36,374	-
Mental Health Research Grants	93.242	Worcester Polytechnic Institute	2R01MH130490-02	434,289	-
Mental Health Research Grants	93.242	Yale University	5R01MH123155-05	217,460	-
Mental Health Research Grants	93.242	Yale University	5R01MH127259-03	60,300	-
Mental Health Research Grants	93.242	Yale University	5R61MH135009-02	167,763	-
Minority Health and Health Disparities Research	93.307	Boston University School of Public Health	5R01MD019661-02	40,677	-
Minority Health and Health Disparities Research	93.307	Direct		5,189,410	1,222,763
Minority Health and Health Disparities Research	93.307	Environment and Health Group, Inc.	1R43MD018244-01	(11,647)	-
Minority Health and Health Disparities Research	93.307	Fordham University	5R01MD015715-05	14,362	-
Minority Health and Health Disparities Research	93.307	Harvard Pilgrim Health Care	5R01MD015256-05	60,784	-
Minority Health and Health Disparities Research	93.307	Michigan State University	5R01MD015763-04	31,067	-
Minority Health and Health Disparities Research	93.307	OCHIN, Inc.	1P20MD019799-01	238,123	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD017747-03	20,582	-
Minority Health and Health Disparities Research	93.307	Regents of the University of California, Los Angeles, The	5R01MD013913-05	9,500	-
Minority Health and Health Disparities Research	93.307	Regents of the University of California, Los Angeles, The	5R21MD017499-02	51,136	-
Minority Health and Health Disparities Research	93.307	Trustees of Boston University	5R01MD014312-04	2,275	-
Minority Health and Health Disparities Research	93.307	University of California at Irvine	5R01MD015186-05	96,214	-
Minority Health and Health Disparities Research	93.307	University of Pittsburgh Of the Commonwealth System of Higher Education	1R21MD018106-01A1	36,898	-
Minority Health and Health Disparities Research	93.307	Vanderbilt University Medical Center	4R33MD019323-02	24,064	-
Minority Health and Health Disparities Research	93.307	Yale University	5R01MD017526-03	83,244	-
National Center for Advancing Translational Sciences	93.350	Direct		2,646,980	845,365
National Center for Advancing Translational Sciences	93.350	Phase, Inc.	2R44TR003968-02	99,172	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1UM1TR0044001-01	(29,576)	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1UM1TR004408-01	11,410	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	3UM1TR004408-02S1	165,465	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5K12TR004381-02	96,945	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5UL1TR002541-05	137	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5UM1TR004408-02	2,017,661	-
National Center for Advancing Translational Sciences	93.350	The Broad Institute, Inc.	125846/5400001915	192	-
National Center for Advancing Translational Sciences	93.350	Trustees of Tufts College	5UM1TR004398-03	1,223	-
National Center for Advancing Translational Sciences	93.350	Trustees of Tufts College	UM1TR004398	25,065	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh Of the Commonwealth System of Higher Education	5U24TR004111-03	255,464	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	5P01HL149630-05	426,517	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	5R01HL161012-03	106,809	-
National Center on Sleep Disorders Research	93.233	Cincinnati Children's Hospital Medical Center	4R33HL165366-03	673,795	-
National Center on Sleep Disorders Research	93.233	Direct		9,293,399	1,210,907
National Center on Sleep Disorders Research	93.233	Regents of the University of California, Los Angeles, The	5R01HL160993-03	56,288	-
National Center on Sleep Disorders Research	93.233	Regents of the University of Michigan	5R01HL164755-03	36,404	-
National Center on Sleep Disorders Research	93.233	Stanford University Medical Center	5R01HL148704-04	67,444	-
National Center on Sleep Disorders Research	93.233	University of Miami	3R33HL151253-05S1	(10)	-
National Center on Sleep Disorders Research	93.233	University of Miami	7R33HL151253-05	132,787	-
National Center on Sleep Disorders Research	93.233	University of Washington	5R01HL162311-03	26,622	-
National Institutes of Health Contracts	93.RD1	Altec, Inc.	SA-75N95023C00005	(1,008)	-
National Institutes of Health Contracts	93.RD1	Battelle, Columbus Division	HHSN275201800003I	(10,083)	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children’s Hospital	75N93020C00038	9,613	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children’s Hospital	75N93023C00040	156,083	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children’s Hospital	75N93024C00020	48,497	-
National Institutes of Health Contracts	93.RD1	CRDF Global	OISE-9531011	27,962	-
National Institutes of Health Contracts	93.RD1	Cure Systems, LLC	75N93022C00021	(374)	-
National Institutes of Health Contracts	93.RD1	Cure Systems, LLC	75N93024C00048	33,259	-
National Institutes of Health Contracts	93.RD1	Cure Systems, LLC	75N93024C00084	18,817	-
National Institutes of Health Contracts	93.RD1	Direct		7,493,456	-
National Institutes of Health Contracts	93.RD1	Duke Clinical Research Institute	HHSN275201800003I	3,698	-
National Institutes of Health Contracts	93.RD1	Duke University	75N93019C00050	413,295	-
National Institutes of Health Contracts	93.RD1	Duke University	HHSN275201800003I	(36,775)	-
National Institutes of Health Contracts	93.RD1	Joslin Diabetes Center	Dr.Kahn–20001-2150066	1,773	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	20X013	(733)	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	20X013F	551,954	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	75N91019D00024	733,914	21,600
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	HHSN261200800001E	2,188,788	1,180,681
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	HHSN261201500003I	22,272	-
National Institutes of Health Contracts	93.RD1	Los Alamos National Laboratory		28,577	-
National Institutes of Health Contracts	93.RD1	National Jewish Health	75N92023D00011	4,451,063	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	601140.73009.0000	98,156	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N93019C00071	46,783	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N93019C00071	462,987	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N9301C00071	29,217	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N95023C00008	217,006	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	CFAR-BWH-24-1-Li	100,646	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	HSPH-59/P30CA006516-59	(2,222)	-
National Institutes of Health Contracts	93.RD1	Public Health Institute	HSN261201500003I	(3,283)	-
National Institutes of Health Contracts	93.RD1	Research Foundation for The SUNY on behalf of University of Buffalo	75N92021D00002	181,814	-
National Institutes of Health Contracts	93.RD1	Research Triangle Institute International	1OT2HL67310-01	160,044	-
National Institutes of Health Contracts	93.RD1	Seattle Children's Hospital	75N93021C00029	128,199	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001919	3,232	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001923	28,726	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001981	62,435	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400002018	72,122	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400002061	3,232	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	62931232-207498	29,853	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	HHSN261201500003I	24,723	-
National Institutes of Health Contracts	93.RD1	University of Georgia Research Foundation, Inc. (UGARF)	75N93019C00052	124,428	-
National Institutes of Health Contracts	93.RD1	University of Massachusetts at Lowell	75N95023C00005	28,293	-
National Institutes of Health Contracts	93.RD1	Vanderbilt University Medical Center	75N91019D00024	(12,944)	-
National Institutes of Health Contracts	93.RD1	Wyss Institute at Harvard University	75N95024P00263	8,800	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	President and Fellows of Harvard College	5P42ES030990-05	57,074	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Rhode Island	5P42ES027706-08	29,345	-
Nursing Research	93.361	Brigham and Women's Hospital, Inc.	4R01NR020765-04	112,115	-
Nursing Research	93.361	Direct		3,263,793	420,205
Nursing Research	93.361	Harvard Pilgrim Health Care	5R01NR021137-02	27,641	-
Nursing Research	93.361	Trustees of Columbia University in the City of New York (The)	5R01NR016941-08	21,610	-
Nursing Research	93.361	UMass Memorial Medical Center, Inc.	5R01NR020439-04	46,026	-
Nursing Research	93.361	University of Colorado at Denver	5U2CNR014637-10	969	-
Nursing Research	93.361	University of Massachusetts Medical School	5R01NR020439-04	8,882	-
Nursing Research	93.361	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01NR020031-05	69,581	-
Nursing Research	93.361	Yale University	5R01NR018335-05	3,174	-
Oral Diseases and Disorders Research	93.121	Atrium Health	1UG3DE031250-01	24	-
Oral Diseases and Disorders Research	93.121	Cincinnati Children's Hospital Medical Center	5UH3DE030401-04	14,847	-
Oral Diseases and Disorders Research	93.121	Dana-Farber Cancer Institute, Inc.	1U01DE029188-01	(24,279)	-
Oral Diseases and Disorders Research	93.121	Direct		7,646,820	2,305,975
Oral Diseases and Disorders Research	93.121	Emory University	5R01DE030342-04	203,121	-
Oral Diseases and Disorders Research	93.121	Forsyth Institute, The	3R01DE025020-09S1	52,269	-
Oral Diseases and Disorders Research	93.121	Forsyth Institute, The	5R01DE032834-02	166,178	-
Oral Diseases and Disorders Research	93.121	Hennepin Healthcare Research Institute	UH3DE029973-05	39,030	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	5R01DE030464-04	155,352	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	5UH3DE031920-04	306,233	-
Oral Diseases and Disorders Research	93.121	Ohio State University	5R01DE032334-03	7,820	-
Oral Diseases and Disorders Research	93.121	Ohio State University	7R01DE028565-02	136,027	-
Oral Diseases and Disorders Research	93.121	President and Fellows of Harvard College	5U01DE033239-02	2,414	-
Oral Diseases and Disorders Research	93.121	The Broad Institute, Inc.	U01DE029188	(1,319)	-
Oral Diseases and Disorders Research	93.121	The Broad Institute, Inc.	U01DE029188-01	(5,215)	-
Oral Diseases and Disorders Research	93.121	The University of Texas Health Science Center at Houston	5R01DE030416-03	44,924	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01DE031299-03	104,452	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5U01DE029759-04	107,196	-
Oral Diseases and Disorders Research	93.121	Wake Forest University Health Sciences	5R01DE031285-03	51,344	-
Oral Diseases and Disorders Research	93.121	Wake Forest University Health Sciences	5UH3DE031250-05	23,027	-
Oral Diseases and Disorders Research	93.121	Wake Forest University Health Sciences	6U01DE022939-11	143,111	-
Research and Training in Complementary and Integrative Health	93.213	Altec, Inc.	5R43AT012003-02	1,516	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	1R61AT012284-01	407,147	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5R01AT012072-03	41,869	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5R01AT012166-02	48,145	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5R61AT012284-02	7,386	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	R01AT012072	6,338	-
Research and Training in Complementary and Integrative Health	93.213	Brigham and Women's Hospital, Inc.	3R01AT011729-14S1	17,720	-
Research and Training in Complementary and Integrative Health	93.213	Direct		10,774,392	2,881,797
Research and Training in Complementary and Integrative Health	93.213	Duke University	5U24AT009150-08	(34,608)	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5P01AT009965-05	308,484	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5R01AT011429-05	184,962	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5R33AT009306-05	(2,762)	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts Neuro Technology, Inc.	3R41AT011822-01A1S1	108,879	-
Research and Training in Complementary and Integrative Health	93.213	New York University School of Medicine	4UG3AT009844-05	(852)	-
Research and Training in Complementary and Integrative Health	93.213	RAND Corporation	3R01AT010402-03S1	941	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	3R01AT012144-03S1	117,482	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	5R01AT012144-03	84,991	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	5R21AT011918-02	9,789	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	5U24AT012560-02	325,090	-
Research and Training in Complementary and Integrative Health	93.213	Trustees of Boston University	1UG3AT012530-01	(19,263)	-
Research and Training in Complementary and Integrative Health	93.213	Trustees of Boston University	5UH3AT012530-03	311,595	-
Research and Training in Complementary and Integrative Health	93.213	University of Alabama, Birmingham	5U24AT011969-04	19,553	-
Research and Training in Complementary and Integrative Health	93.213	University of Utah	5R33AT012329-03	123,648	-
Research Infrastructure Programs	93.351	Direct		11,161,978	454,341
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	1R01DC022233-01	121,175	-
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	5R01DC014034-10	189,187	-
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	5U01DC019430-04	285,179	-
Research Related to Deafness and Communication Disorders	93.173	Brigham and Women's Hospital, Inc.	3R01DC020965-02S1	79,802	-
Research Related to Deafness and Communication Disorders	93.173	Brigham and Women's Hospital, Inc.	5R01DC020965-03	224,448	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research Related to Deafness and Communication Disorders	93.173	Brown University	3U01DC017844-05S1	66,084	-
Research Related to Deafness and Communication Disorders	93.173	Brown University	5U01DC017844-05	211,000	-
Research Related to Deafness and Communication Disorders	93.173	Case Western Reserve University	1R01DC021795-01A1	176,712	-
Research Related to Deafness and Communication Disorders	93.173	Children's Hospital Corporation dba Boston Children's Hospital	2R01DC008853-11A1	67,869	-
Research Related to Deafness and Communication Disorders	93.173	Direct		26,283,712	5,661,244
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5R01DC011805-14	121,696	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5U01DC019279-05	225,716	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	5P50DC015446-08	42,037	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	5R01DC019916-03	233,329	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	5R01DC020247-04	208	-
Research Related to Deafness and Communication Disorders	93.173	MGH Institute of Health Professions	1R01DC021446-01A1	159,016	-
Research Related to Deafness and Communication Disorders	93.173	Modality.AI, Inc.	4R42DC019877-02	495,427	-
Research Related to Deafness and Communication Disorders	93.173	President and Fellows of Harvard College	2R01DC017717-04A1	79,233	-
Research Related to Deafness and Communication Disorders	93.173	Ripple Neuro, LLC	1R41DC020869-01A1	65,594	-
Research Related to Deafness and Communication Disorders	93.173	Sunnybrook Research Institute	1R01DC017291-05	214,133	-
Research Related to Deafness and Communication Disorders	93.173	Trustees of Boston University	4500004965	126,644	-
Research Related to Deafness and Communication Disorders	93.173	Trustees of Boston University	5R01DC020867-03	228,659	-
Research Related to Deafness and Communication Disorders	93.173	Tympanogen, Inc.	2SB1DC018255-02	24,822	-
Research Related to Deafness and Communication Disorders	93.173	University of Colorado at Denver	1R61DC021924-01	142,346	-
Research Related to Deafness and Communication Disorders	93.173	University of Miami	5R01DC019404-03	415,445	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Direct		988,345	188,400
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Johns Hopkins University	5UH3HL154280-05	16,578	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	President and Fellows of Harvard College	5R01HL149912-05	122,145	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Wits Reproductive Health and HIV Institute	5UH3HL156388-05	28,300	-
Trans-NIH Research Support	93.310	Baylor College of Medicine	5R01TR004243-04	27,816	-
Trans-NIH Research Support	93.310	Beth Israel Deaconess Medical Center	5U54HL165440-03	24,634	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	1U01HL166060-02	157,402	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	5U01HG007690-08	(38)	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	OT2OD038228-01	10,491	-
Trans-NIH Research Support	93.310	Children's Hospital Corporation dba Boston Children's Hospital	1U01AI191210-01	604	-
Trans-NIH Research Support	93.310	Direct		21,981,392	8,380,937
Trans-NIH Research Support	93.310	Duke University	2U2COD023375-08	39,747	-
Trans-NIH Research Support	93.310	Henry Ford Health + Michigan State University Health Sciences	UG3OD023285	18,286	-
Trans-NIH Research Support	93.310	Henry Ford Health + Michigan State University Health Sciences	UH3OD023285	1,573	-
Trans-NIH Research Support	93.310	Jackson Laboratory, The	5U19NS132304-03	176,395	-
Trans-NIH Research Support	93.310	Massachusetts Eye and Ear Infirmary	1U01TR005352-01	646,533	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	1OT2OD037638-01	499,445	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	3OT2OD026553-01S5	(1,567)	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	5U01DK127587-04	(314)	-
Trans-NIH Research Support	93.310	MGH INTERNAL SUPPORT	1UF1NS131791-01	(52,874)	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	1OT2OD032581-02	108,614	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	3OT2OD033758-01S2	360,020	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5UM1DA058230-02	178,935	-
Trans-NIH Research Support	93.310	Regents of the University of California, San Diego	5UG3CA241687	(3,097)	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	1OT2OD038121-01	73,797	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	1UM1DA058235	23,936	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	OT2OD034190	22,083	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	OT2OD035404	9,506	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	U24HD090743	16,148	-
Trans-NIH Research Support	93.310	Trustees of Tufts College	5UG1HD107691-04	2,018,975	-
Trans-NIH Research Support	93.310	Trustees of Tufts College	UG1HD107691	208,603	-
Trans-NIH Research Support	93.310	University of Connecticut Health Center	5U54AG075941-04	60,097	-
Trans-NIH Research Support	93.310	University of North Texas Health Science Center at Fort Worth, The	3OT2OD032581-01S5	223,538	-
Vision Research	93.867	Brown University	5R01EY030569-03	(328)	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	1U01EY034686-01	41,731	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	2R01EY025794-06A1	172,465	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	5R01EY025794-07	289,344	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	5R01EY034135-02	30,281	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	5U01EY034686-03	84,056	-
Vision Research	93.867	Cincinnati Children's Hospital Medical Center	1R01EY036154-01A1	457	-
Vision Research	93.867	Direct		26,522,515	2,448,804

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number		Total Expenditures	Subrecipient Expenditures
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	1R01EY036460-01		427,371	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY032559-02		216,669	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY032559-04		71,571	-
Vision Research	93.867	Jaeb Center for Health Research	1UG1EY030030-01A1		(527)	-
Vision Research	93.867	Johns Hopkins University	1UG1EY033293-01		113,699	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY020928-12		262,390	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY031708-03		173,149	-
Vision Research	93.867	Massachusetts General Hospital	5R01EY033356-02		22,359	-
Vision Research	93.867	Massachusetts General Hospital	5R01EY034857-02		22,359	-
Vision Research	93.867	Massachusetts General Hospital	7R01EY030877-04		31,459	-
Vision Research	93.867	New York University Grossman School of Medicine	3U10EY026869-05S3		(1)	-
Vision Research	93.867	Oregon Health & Science University (OHSU)	1R21EY035816-01		156,597	-
Vision Research	93.867	Physical Sciences, Inc.	1R44EY034409-01		54,562	-
Vision Research	93.867	Regents of the University of California, San Francisco	1UG1EY033703-01A1		5,250	-
Vision Research	93.867	Schepens Eye Research Institute, Inc.	1R01EY031696-01A1		58,228	-
Vision Research	93.867	Schepens Eye Research Institute, Inc.	1R01EY036222-01		23,839	-
Vision Research	93.867	Scripps Research Institute	2R01EY026202-06A1		33,799	-
Vision Research	93.867	The Broad Institute, Inc.	530795		(8,718)	-
Vision Research	93.867	Trustees of Boston University	1R01EY036399-01		7,340	-
Vision Research	93.867	Trustees of Boston University	5R21EY035437-02		158,508	-
Vision Research	93.867	University of New England	5U01EY034709-03		479,132	-
Vision Research	93.867	University of New Mexico Health Sciences Center	5R01EY013124-24		130,395	-
Vision Research	93.867	University of Pittsburgh Of the Commonwealth System of Higher Education	5UG1EY031651-02		23,532	-
Vision Research	93.867	University of Tennessee Health Science Center	1R01EY033005-01A1		21,736	-
Vision Research	93.867	Vanderbilt University Medical Center	U24EY029893-03		(41,910)	-
				Subtotal	1,352,153,554	275,891,457
NATIONAL SCIENCE FOUNDATION, NATIONAL SCIENCE FOUNDATION						
Biological Sciences	47.074	Direct			1,008,987	361,875
Biological Sciences	47.074	Regents of the University of California, Riverside	2211661		61,112	-
Computer and Information Science and Engineering	47.070	Direct			543,922	-
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 Regents of the University of California, Berkeley	2413624		(12,593)	-
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 University of California at Davis	2116859		(755)	-
Engineering	47.041	Direct			162,468	-
Engineering	47.041	Duke University	HRD-2222336		17,338	-
Engineering	47.041	Regents of the University of Minnesota	2220611		(3)	-
Engineering	47.041	Regents of the University of Minnesota	EEC-194153		1,812,072	-
Engineering	47.041	Vulcan Biologics, Inc.	2126838		(104,203)	-
Engineering	47.041	Direct			(4,776)	-
Integrative Activities	47.083	Direct			(28,938)	-
Mathematical and Physical Sciences	47.049	President and Fellows of Harvard College	2127882		102,021	-
Mathematical and Physical Sciences	47.049	Virginia Polytechnic Institute and State University	DMS-2229819		34,380	-
National Science Foundation Contracts	93.RD18	Regents of the University of California, Los Angeles, The	N00014-23-1-2355		2,375	-
National Science Foundation Contracts	93.RD18	Washington University in St. Louis	2139839		34,264	-
NSF Technology, Innovation, and Partnerships	47.084	Direct			34,116	-
NSF Technology, Innovation, and Partnerships	47.084	INIA Biosciences, Inc.	2312694		85,481	-
NSF Technology, Innovation, and Partnerships	47.084	O2M Technologies, LLC	2028829		92,043	-
NSF Technology, Innovation, and Partnerships	47.084	President and Fellows of Harvard College	ITE-2345107-Amend002		297,074	-
NSF Technology, Innovation, and Partnerships	47.084	Vassar College	GR000467		95,261	-
Social, Behavioral, and Economic Sciences	47.075	Direct			525,957	-
STEM Education (formerly Education and Human Resources)	47.076	Direct			752,000	38,909
				Subtotal	5,509,603	400,784
OFFICE OF JUSTICE PROGRAMS, JUSTICE, DEPARTMENT OF						
Opioid Affected Youth Initiative	16.842	Direct			282,607	-
Services for Trafficking Victims	16.320	Beth Israel Deaconess Medical Center	15POVC-23-GG-04064-HT		121,336	-
				Subtotal	403,943	-
STATE, DEPARTMENT OF, STATE, DEPARTMENT OF						
U.S. Department of State Contracts	93.RD6	Direct			224,418	-
				Subtotal	224,418	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Foundation for Healty Communities	05-95-49-491510-2990	(3,259)	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Foundation for Healty Communities		(3,018)	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	American Academy of Addiction Psychiatry (AAAP)	1H79TI085588-02	(9,678)	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	American Academy of Addiction Psychiatry (AAAP)	1H79TI088037-01	210,734	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	Fenway Community Health Center	1H79TI088037-01	7,128	-
			Subtotal	201,907	-
UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (USUHS), DEPT OF DEFENSE					
COVID-19 Uniformed Services University Medical Research Projects	12.750	COVID-19 The Henry M. Jackson Foundation for the Advancement of Military Medicine	HU00012120089	465,847	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00011920009	88,777	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00011920056	(3,578)	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00012020011	635,985	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00012420044	461,881	-
Uniformed Services University Medical Research Projects	12.750	The Henry M. Jackson Foundation for the Advancement of Military Medicine	HU00011920125	100,419	-
Uniformed Services University Medical Research Projects	12.750	The Henry M. Jackson Foundation for the Advancement of Military Medicine	HU00012320020	175,214	-
Uniformed Services University Medical Research Projects	12.750	The Henry M. Jackson Foundation for the Advancement of Military Medicine	HU00012320021	175,593	-
Uniformed Services University Medical Research Projects	12.750	The Henry M. Jackson Foundation for the Advancement of Military Medicine	HU00012420023	164,030	-
Uniformed Services University Medical Research Projects	12.750	The Henry M. Jackson Foundation for the Advancement of Military Medicine	HU00012520025	319,494	-
			Subtotal	2,583,662	-
VA HEALTH ADMINISTRATION CENTER, VETERANS AFFAIRS, DEPARTMENT OF					
Department of Veterans Affairs Contracts	93.RD2	Direct		2,081,329	-
Department of Veterans Affairs Contracts	93.RD2	President and Fellows of Harvard College	36C24D0023	21,572	-
Department of Veterans Affairs Contracts	93.RD2	President and Fellows of Harvard College	36C24E18D0048	(1,808)	-
Research and Development	64.054	Direct		130,397	-
			Subtotal	2,231,490	-
			Total Research and Development	**$ 1,475,626,222**	**$ 286,339,464**

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research Training					
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Research on Healthcare Costs, Quality and Outcomes	93.226	Direct		$ 154,740	$ 21,384
National Research Service Awards Health Services Research Training	93.225	Children's Hospital Corporation dba Boston Children's Hospital	5T32HS000063-31	136,369	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	1P30HS029762-01	51,030	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	5P30HS029762-02	124,439	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Direct		458,797	-
			Subtotal	925,375	21,384
DEPT OF THE ARMY, DEPT OF DEFENSE					
Military Medical Research and Development	12.420	Direct		193,076	-
			Subtotal	193,076	-
EMPLOYMENT AND TRAINING ADMINISTRATION, LABOR, DEPARTMENT OF					
H-1B Job Training Grants	17.268	Direct		1,250,205	49,500
			Subtotal	1,250,205	49,500
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Geriatric Academic Career Awards Department of Health and Human Services	93.250	President and Fellows of Harvard College	2K01HP49053-02-00	58,448	-
Maternal and Child Health Federal Consolidated Programs	93.110	President and Fellows of Harvard College	5T76MC00001 69	8,059	-
Mental and Behavioral Health Education and Training Grants	93.732	Direct		1,635,554	148,383
Mental and Behavioral Health Education and Training Grants	93.732	Massachusetts General Hospital	5T25HP37602 05 00	107,544	-
Mental and Behavioral Health Education and Training Grants	93.732	MGH Institute of Health Professions	5M01HP41980 02 00	5,264	-
Mental and Behavioral Health Education and Training Grants	93.732	MGH Institute of Health Professions	5M01HP41980 04 00	17,349	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	5T32HP42013 04 00	18,562	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	6T32HP42013-03-01	188,014	-
Nurse Education, Practice Quality and Retention Grants	93.359	Direct		807,292	10,002
Nurse Education, Practice Quality and Retention Grants	93.359	MGH Institute of Health Professions	5UK1HP46057 03 00	8,107	-
			Subtotal	2,854,193	158,385
NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Aging Research	93.866	Direct		7,808,206	121,050
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	T32AG23480-19	30,765	-
Aging Research	93.866	Hebrew Senior Life	5T32AG023480-19	45,602	-
Aging Research	93.866	Hebrew Senior Life	T32AG023480-18	24,743	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AG000222-31	1,467	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AG000222-32	203,342	-
Alcohol Research Programs	93.273	Direct		1,171,458	10,896
Allergy and Infectious Diseases Research	93.855	Direct		5,570,306	46,156
Allergy and Infectious Diseases Research	93.855	FHI 360	UM1AI068619	8,850	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20	(5,975)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5T32AI007245-39	(1,209)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	CFAR-BWH-24-2--Lee	88,125	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	T32AI007245-40	40,170	-
Allergy and Infectious Diseases Research	93.855	Trustees of Boston University	3K01AI151083-04S1	40,439	-
Allergy and Infectious Diseases Research	93.855	Trustees of Boston University	5K01AI151083-03	8,067	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Direct		4,214,538	37,434
Biomedical Research and Research Training	93.859	Direct		1,922,613	-
Blood Diseases and Resources Research	93.839	Beth Israel Deaconess Medical Center	5T32HL007917-25	(9,196)	-
Blood Diseases and Resources Research	93.839	Brigham and Women's Hospital, Inc.	5K12HL141953-05	(9,914)	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	2T32HL066987-22	57,470	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5T32HL066987-22	16,001	-
Blood Diseases and Resources Research	93.839	Direct		1,885,304	2,500
Blood Diseases and Resources Research	93.839	Emory University	5T32HL069769-20	65,254	-
Cancer Cause and Prevention Research	93.393	Direct		237,784	-
Cancer Research Manpower	93.398	Beth Israel Deaconess Medical Center	5K08CA248473-05	16,051	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	2T32CA092203-21A1	43,897	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5R25CA181000-10	(2,269)	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5R25CA246746-05	46,945	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5T32CA092203-20	(13,710)	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	T32CA092203	145,170	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	T32CA236754	25,095	-
Cancer Research Manpower	93.398	Direct		11,436,071	185,915
Cancer Research Manpower	93.398	President and Fellows of Harvard College	1K22CA258960-03	77,671	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-47	(664)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-48	167,441	-
Cancer Research Manpower	93.398	Regents of the University of Michigan	5T32CA009672-32	(1,940)	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5T32HL007734-29	2,275	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5T32HL160522-02	44,437	-
Cardiovascular Diseases Research	93.837	Direct		8,280,293	18,797
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5T32HL098048-15	54,013	-
Cardiovascular Diseases Research	93.837	Westat, Inc.	1OT2HL180049-01	18,084	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	2T32HD098061-06	62,068	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5K08HD100595-04	15,589	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5T32HD040128-20	(5)	-
Child Health and Human Development Extramural Research	93.865	Direct		2,166,023	164,796
Child Health and Human Development Extramural Research	93.865	Duke University	5K12-HD000849-38	81,000	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	T32HD104612	(4,706)	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	5P2CHD101895-05	20,000	-
COVID-19 Allergy and Infectious Diseases Research	93.855	Direct		328,978	59,824
COVID-19 Cancer Research Manpower	93.398	COVID-19 President and Fellows of Harvard College	5T32CA9001-47	(614)	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Brigham and Women's Hospital, Inc.	5K12HD103096-05	86,613	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Direct		9,484,278	127,684
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Direct		1,411,075	-
Drug Abuse and Addiction Research Programs	93.279	American Academy of Child and Adolescent Psychiatry	K12DA000357	118,324	-
Drug Abuse and Addiction Research Programs	93.279	Direct		3,972,753	44,960
Drug Abuse and Addiction Research Programs	93.279	University of Massachusetts Chan Medical School	5R25DA058490-03	63,309	-
Environmental Health	93.113	Direct		462,840	20,904
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Direct		6,548,242	32,905
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute Inc	5K12NS098482-07	3,794	-
Human Genome Research	93.172	Direct		1,328,839	-
International Research and Research Training	93.989	American University of Beirut	2D43TW009118-06	8,776	-
International Research and Research Training	93.989	Mbarara University of Science and Technology	5D43TW011632-05	24,891	-
International Research and Research Training	93.989	NIH-FIC Fogarty International Center		214,536	28,930
International Research and Research Training	93.989	NIH-National Institutes of Health		386,358	262,441
Lung Diseases Research	93.838	Direct		6,503,265	49,618
Lung Diseases Research	93.838	President and Fellows of Harvard College	5T32HL007118-48	56,880	-
Medical Library Assistance	93.879	Direct		179,472	30,967
Medical Library Assistance	93.879	President and Fellows of Harvard College	5T15LM007092-32	44,680	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5T15LM007092 32	7,407	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5T15LM007092-33	49,401	-
Mental Health Research Grants	93.242	American Academy of Child and Adolescent Psychiatry	1R25MH132513	27,345	-
Mental Health Research Grants	93.242	Boston Medical Center	1T32MH135857-01	101,065	-
Mental Health Research Grants	93.242	Direct		7,999,330	223,838
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-43	91,782	-
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-44	267,677	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5T32MH125815-02	57,905	-
Mental Health Research Grants	93.242	Trustees of Columbia University in the City of New York (The)	5R25MH080665-13	20,000	-
Minority Health and Health Disparities Research	93.307	Direct		360,069	-
National Center for Advancing Translational Sciences	93.350	Harvard Catalyst - The Harvard Clinical and Translational Science Center	5K12TR004381-02	103,960	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5K12TR004381-02	299,504	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5KL2TR002542-05	(688)	-
National Center on Sleep Disorders Research	93.233	Direct		1,470,834	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	75N92021F00229	66,368	-
Oral Diseases and Disorders Research	93.121	Direct		324,999	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5T32AT000051-24	(6,539)	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5T32AT000051-25	167,237	-
Research and Training in Complementary and Integrative Health	93.213	Direct		1,764,441	-
Research Related to Deafness and Communication Disorders	93.173	Direct		1,704,394	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Direct		578,779	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	3OT2OD032581-01S5	3,149	-
Vision Research	93.867	Direct		1,992,155	-
				94,770,902	1,469,615
Grand Total			**Total Research Training**	**$ 99,993,751**	**$ 1,698,884**
			Total Research and Development and Research Training	**$ 1,575,619,973**	**$ 288,038,348**

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Student Financial Aid					
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Nurse Faculty Loan Program (NFLP)	93.264	Nurse Faculty Loan Program (NFLP) FY24 Outstanding Loans	Direct	$ 75,139	$ -
Nurse Faculty Loan Program (NFLP)	93.264	Nurse Faculty Loan Program (NFLP) New Loans Issued During FY25	Direct	33,065	-
			Subtotal	108,204	-
OFFICE OF FEDERAL STUDENT AID, EDUCATION, DEPARTMENT OF					
Federal Direct Student Loans	84.268	Department of Education	Direct	42,576,383	-
			Subtotal	42,576,383	-
			Total Student Financial Aid	**$ 42,684,587**	**$ -**

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
SNAP Cluster					
FOOD AND NUTRITION SERVICE, AGRICULTURE, DEPARTMENT OF					
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program	10.561	University of Massachusetts Medical Center	OutreachPartnerAmendment1-4-2016	526	-
			Subtotal	526	-
Special Supplemental Nutrition Program for Women, Infant, and Children					
FOOD AND NUTRITION SERVICE, AGRICULTURE, DEPARTMENT OF					
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	INTF3502M03162726104	990,187	-
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	INTF3502M03162726128	936,026	-
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	WICvoucher	4,804,276	-
			Subtotal	6,730,489	-
Economic Development Cluster					
ECONOMIC DEVELOPMENT ADMINISTRATION, COMMERCE, DEPARTMENT OF					
Economic Adjustment Assistance	11.307	Massachusetts Technology Park Corporation	ED21HDQ3070023	17,815	-
			Subtotal	17,815	-
Highway Safety Cluster					
NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION, TRANSPORTATION, DEPARTMENT OF					
National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants and Cooperative Agreements	20.614	KEA Technologies, Inc.	DTNH22-13-H-00433	121,401	-
			Subtotal	121,401	-
Aging Cluster					
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Alzheimer's Disease Program Initiative (ADPI)	93.470	Alzheimer's Association	90ADP10117-02-00	11,030	-
			Subtotal	11,030	-
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Special Programs for the Aging, Title IV, and Title II, Discretionary Projects	93.048	Oasis Institute	90CCDG0001-04-00	10,809	-
			Subtotal	10,809	-
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Special Programs for the Aging, Title III, Part B, Grants for Supportive Services and Senior Centers	93.044	Mystic Valley Elder Services	Title III-B	(6,042)	-
			Subtotal	(6,042)	-
Other Programs					
AGENCY FOR INTERNATIONAL DEVELOPMENT, AGENCY FOR INTERNATIONAL DEVELOPMENT					
COVID-19 USAID Foreign Assistance for Programs Overseas	98.001	COVID-19 International Medical Corps	720BHA23CA00036	616,355	-
			Subtotal	616,355	-
AGENCY FOR INTERNATIONAL DEVELOPMENT, AGENCY FOR INTERNATIONAL DEVELOPMENT					
USAID Foreign Assistance for Programs Overseas	98.001	Cloudburst Consulting Group, Inc.	7200AA18M0017	2,700	-
USAID Foreign Assistance for Programs Overseas	98.001	Direct	72044024CA00002	13,003	5,306
USAID Foreign Assistance for Programs Overseas	98.001	Direct	AID-440-A-16-00002	1,447,118	1,292,840
USAID Foreign Assistance for Programs Overseas	98.001	Fenway Community Health Center	72038619CA0001	1,834	-
USAID Foreign Assistance for Programs Overseas	98.001	International AIDS Vaccine Initiative (IAVI)	AID-0AA-A-16-00032	59,649	-
USAID Foreign Assistance for Programs Overseas	98.001	Palladium Group, The	7200AA22CA00023	49,952	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	7200AA19APS00002	76,135	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	720BHA23CA00012	15,435	-
			Subtotal	1,665,826	1,298,146
ASSISTANT SECRETARY FOR COMMUNITY PLANNING AND DEVELOPMENT, HOUSING AND URBAN DEVELOPMENT, DEPARTMENT OF					
Continuum of Care Program	14.267	Community Action of Pioneer Valley	MA0401L1T072211	35,385	-
Continuum of Care Program	14.267	Community Action of Pioneer Valley	MA0401L1T072412	27,192	-
Continuum of Care Program	14.267	Massachusetts Department of Public Health	INTF4944MM3181926016	30,050	-
			Subtotal	92,627	-
ASSISTANT SECRETARY FOR COMMUNITY PLANNING AND DEVELOPMENT, HOUSING AND URBAN DEVELOPMENT, DEPARTMENT OF					
Housing Opportunities for Persons with AIDS	14.241	City of Springfield	20210144	(82,910)	-
Housing Opportunities for Persons with AIDS	14.241	City of Springfield	20240090	221,625	-
			Subtotal	138,715	-
CDC NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Drug-Free Communities Support Program Grants	93.276	Direct	5NH28CE002705-08-00	102,738	-
			Subtotal	102,738	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number		Total Expenditures	Subrecipient Expenditures
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
COVID-19 Community Health Workers for Public Health Response and Resilient	93.495	COVID-19 Massachusetts Department of Public Health	INTF4207M03225031014		427	-
				Subtotal	427	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
COVID-19 Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	93.318	COVID-19 Direct	5NU50CK000611-04-00		157,073	-
COVID-19 Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	93.318	COVID-19 Direct	6NU50CK000611-02-01		(2,241)	-
				Subtotal	154,832	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Disabilities Prevention	93.184	University of Alabama, Birmingham	5NU27DD000022-04-00		83,835	-
				Subtotal	83,835	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	Massachusetts Department of Public Health	NU51CK000343		9,434	-
				Subtotal	9,434	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
HIV Prevention Activities Health Department Based	93.940	Massachusetts Department of Public Health	INTF4944MM3181926038		1,078,368	-
				Subtotal	1,078,368	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Injury Prevention and Control Research and State and Community Based Programs	93.136	Massachusetts Department of Public Health	1NU17CE010190-01-00		1,598,364	64,865
				Subtotal	1,598,364	64,865
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Massachusetts Department of Public Health	NU50CK000629		117,723	-
				Subtotal	117,723	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Public Health Preparedness Science	93.316	President and Fellows of Harvard College	6NH78TU000001-01-01		86,077	-
				Subtotal	86,077	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Sexually Transmitted Diseases (STD) Prevention and Control Grants	93.977	Massachusetts Department of Public Health	NH25PS005264		20,404	-
				Subtotal	20,404	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	Massachusetts Department of Public Health	6NU62PS924585		132,920	-
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	Massachusetts Department of Public Health	INTF5290HH4226732026		23,775	-
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	Massachusetts Department of Public Health	INTF5290HH4226732030		609	-
				Subtotal	157,304	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	Direct	5NU50CK000622-03-00		184,258	-
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	Direct	6NU50CK000622-03-00		249,099	70,000
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93.421	Direct	6NU50CK000622-03-05		579,357	82,184
				Subtotal	1,012,714	152,184
HEALTH AND HUMAN SERVICES, DEPARTMENT OF, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Congressional Directives	93.493	Direct	1CE1HS46369-01		(29,805)	-
				Subtotal	(29,805)	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	Dimock Community Health Center	2H12HA24846-06-00		85,732	-
				Subtotal	85,732	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
COVID-19 Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	COVID-19 BOSTON PUBLIC HEALTH COMMISSION	5UT8HA33922-05-00		40,443	-
Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	BOSTON PUBLIC HEALTH COMMISSION	2UT8HA33922-03-00		63,052	-
Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	BOSTON PUBLIC HEALTH COMMISSION	5UT8HA33922-05-00		86,318	-
Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	BOSTON PUBLIC HEALTH COMMISSION	6UT8HA33922-02-03		(310)	-
				Subtotal	189,503	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF						
HIV Care Formula Grants	93.917	Massachusetts Department of Public Health	INTF4944MM3181926016		544,872	-
				Subtotal	544,872	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2025

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	2H89HA00011-35-00	279,055	-
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	2UT8HA33922-03-00	36	-
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	6H89HA00011-32-02	(33,742)	-
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	6H89HA00011-34-03	199,848	-
			Subtotal	445,197	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Maternal and Child Health Federal Consolidated Programs	93.110	COMMONWEALTH OF MASSACHUSETTS	INTF3000H78W23011288	141,168	-
Maternal and Child Health Federal Consolidated Programs	93.110	Icahn School of Medicine at Mount Sinai	5H30MC24048-14	18,523	-
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts Department of Public Health	4513-9131	120,682	-
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts Department of Public Health	INTF3121MM3W23005040	2,270	-
Maternal and Child Health Federal Consolidated Programs	93.110	University of Colorado at Denver	5UA6MC31101 08 00	29,390	-
			Subtotal	312,033	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Maternal, Infant and Early Childhood Home Visiting Grant	93.870	Massachusetts Department of Public Health	INTF3617MM3220226202	408,321	-
Maternal, Infant and Early Childhood Home Visiting Grant	93.870	Massachusetts Department of Public Health	INTF3617MM3220226207	364,021	-
			Subtotal	772,342	-
IMMED OFFICE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	COVID-19 Direct	5U3REP220683-02-00	593,679	340,000
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	COVID-19 Direct	5U3REP220683-03-00	936,832	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct	6U3REP220683-04-01	4,983	-
			Subtotal	1,535,494	340,000
OFFICE OF JUSTICE PROGRAMS, JUSTICE, DEPARTMENT OF					
Crime Victim Assistance	16.575	COMMONWEALTH OF MASSACHUSETTS	15POVC-22-GG-00755ASSI	184,354	-
Crime Victim Assistance	16.575	COMMONWEALTH OF MASSACHUSETTS	24VOCAVWA	15,647	-
Crime Victim Assistance	16.575	COMMONWEALTH OF MASSACHUSETTS	VSS-2026-Brigham	41,069	-
			Subtotal	241,070	-
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Block Grants for Prevention and Treatment of Substance Abuse	93.959	**City of Chelsea**	2025-193	176,012	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Foundation for Healthy Communities	NUMBER NOT AVAILABLE	46,626	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	ADDICTIONTREATOBAT00725	662,018	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626051	(1,427,279)	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626053	(963,285)	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626061	(1,518,671)	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2400H78241733574	288,530	99,222
			Subtotal	(2,736,049)	99,222
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Opioid STR	93.788	New Hampshire Department of Health and Human Services	05-95-92-7040-500731	(1,011)	-
Opioid STR	93.788	New Hampshire Department of Health and Human Services	SS-2019-BDAS-05-ACCES-08	61,120	-
			Subtotal	60,109	-
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.343	New Hampshire Department of Health and Human Services	BD-24-1022-DMH08-8210C-96774	49,423	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.343	New Hampshire Department of Health and Human Services	SCDMH8220024MCLEANHO	97,342	-
			Subtotal	146,765	-
FEDERAL EMERGENCY MANAGEMENT AGENCY, HOMELAND SECURITY, DEPARTMENT OF					
Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97.036	Direct	679853	(111,416)	-
Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97.036	Direct	698983	(2,072,796)	-
			Subtotal	(2,184,212)	
			Total Other Programs	**$ 13,204,822**	**$ 1,954,417**
			Total Federal Expenditures	**$ 1,631,509,382**	**$ 289,992,765**

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Notes to Schedule of Expenditures of Federal Awards
September 30, 2025

1. Organization

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in the consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Insurance Company) (collectively referred to as the Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), Medicare Advantage program, ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the Schedule) includes the Federal award activity of Mass General Brigham and is recorded on the accrual basis of accounting.

The information in the Schedule is presented in accordance with Title 2 U.S. Code of Federal Regulations (CFR) 200 Uniform Administrative Requirements Cost Principles and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic consolidated financial statements. Negative amounts represent adjustments to amounts reported as expenditures in prior years in the normal course of business. Assistance Listing Number (ALN) and pass-through award numbers are provided where available. The Schedule combines expenditures of The Brigham and Women's Hospital, Inc., The General Hospital Corporation d/b/a The Massachusetts General Hospital, Massachusetts Eye and Ear Infirmary, including The Schepens Eye Research Institute, Inc., The McLean Hospital Corporation, The MGH Institute of Health Professions, Inc., The Spaulding Rehabilitation Hospital Corporation, Cooley Dickinson Hospital, Inc., Newton-Wellesley Hospital, Brigham and Women's Faulkner Hospital, Inc., Martha's Vineyard Hospital, Inc., Wentworth-Douglass Hospital, and Mass General Brigham Incorporated. These entities are all affiliates of Mass General Brigham.

2. Facilities and Administrative and Fringe Benefit Costs

Federal expenditures for Research and Development and Research and Development Training for Brigham and Women's Hospital, Massachusetts General Hospital, McLean, Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital and the MGH Institute of Health Professions include facilities and administrative cost recoveries and fringe benefit cost recoveries in the amounts reported in the Schedule based on rates negotiated and awarded with the DHHS Division of Cost Allocation. These rates are based on financial information submitted utilizing the methods prescribed in Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts with Hospitals, contained in the Code of Federal Regulation, Title 45, Part 74, Appendix E (OASC-3). The predetermined facilities and administrative cost rates for IHP are based on financial information submitted utilizing the simplified method for small institutions prescribed in Indirect (F&A) Costs Identification and Assignment, and Rate Determination for Institutions of Higher Education (IHEs), contained in the Code of Federal Regulation, Title 2, Part 200, Appendix III. Expenditures reported in Training and Other include the maximum facilities and administrative recoveries approved by the sponsor. The de-minimis rate is not utilized on Research and Development or Research and Development Training by Mass General Brigham because they have approved negotiated rate agreements. The de-minimis rate is used for Other awards where allowed.

3. Federal Student Loan Programs

The amounts reported in the Student Financial Aid Cluster of the Schedule represent the beginning balances and newly issued loans in fiscal year 2025. As of September 30, 2025, the MGH Institute of Health Professions (IHP) had loans outstanding of $30,769 for loans issued as part of the Nurse Faculty Loan Program (ALN 93.264). IHP had Direct Loans issued by the Department of Education of $42,576,383 as of September 30, 2025 for ALN 84.268.

Part II
Reports on Compliance and Internal Control

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

To the Board of Directors of Mass General Brigham Incorporated

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Mass General Brigham Incorporated (the "Company") and its affiliates, which comprise the consolidated balance sheet as of September 30, 2025, and the related consolidated statements of operations, changes in net assets and cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated December 19, 2025.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Company and its affiliates' internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control. Accordingly, we do not express an opinion on the effectiveness of the Company and its affiliates' internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the Company and its affiliates financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company and its affiliates' financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company and its affiliates' internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company and its affiliates' internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 19, 2025

Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Directors of Mass General Brigham Incorporated

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Mass General Brigham Incorporated (the "Company") and its affiliates' compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company and its affiliates' major federal programs for the year ended September 30, 2025. The Company and its affiliates' major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company and its affiliates complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2025.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company and its affiliates' compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company and its affiliates' federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company and its affiliates' compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company and its affiliates' compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company and its affiliates' compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company and its affiliates' internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 19, 2025

Part III
Federal Award Findings and Questioned Cost

Mass General Brigham Incorporated and Affiliates
Schedule of Findings and Questioned Costs
Fiscal Year Ended September 30, 2025

1. Summary of Auditor's Results

Financial Statements	
Type of auditor's report issued	
Internal control over financial reporting	Unmodified
Material weakness(es) identified?	___yes__ X__no
Significant deficiency(ies) identified that are not considered to be material weaknesses?	___yes __X __none reported
Noncompliance material to financial statements noted?	___yes__ X__no
Federal Awards	
Internal control over major programs Material weakness(es) identified?	___yes__ X__no
Significant deficiency(ies) identified that are not considered to be material weaknesses?	___yes __X __none reported
Type of auditor's report issued on compliance for major programs	Unmodified
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200, 516(a)	____yes__X__no

Identification of Major Programs	**Name of Federal Program or Cluster**
Various Assistance Listing Numbers	Research and Development, Research Training Cluster
98.001	USAID

Dollar threshold used to distinguish between Type A and Type B programs Auditee qualified as low-risk auditee?	$4,894,528
Auditee qualified as low-risk auditee?	___X___yes_____no

2. Financial Statement Findings

No findings to report.

3. Federal Findings and Questioned Costs

No findings to report.

Mass General Brigham Incorporated and Affiliates
Summary Schedule of Prior Audit Findings and Status
Fiscal Year Ended September 30, 2025

Summary of Status of Prior Year Findings

Current Status of the Prior Year Findings

2024-001 - Non-Compliance with Monthly Direct Loan Reconciliations

Prior Year Finding: The Company could not evidence that a monthly reconciliation was being performed between Direct Loan funds received from the Department of Education and Direct Loan disbursement records submitted to the Department of Education.

A formal Direct Loan Reconciliation was implemented in January 2025 to summarize weekly draws and monthly results in a single schedule including preparers and approvers.

2024-002 - Equipment Management

Prior Year Finding: In testing the Company's conformity with the compliance requirements for equipment management, PwC selected 25 pieces of equipment from the detailed listings provided to physically inspect. Additionally, in order to test the completeness of the detailed listings, PwC selected 25 pieces of equipment from the "floor" and traced these to the detailed listings provided. Two pieces of equipment out of the 25 selections made from the detailed listings for physical inspection were incorrectly included in the listings.

Mass General Brigham developed supplemental training materials highlighting the importance of correct and complete equipment inventory listings including accuracy of the disposal process. The supplemental training materials were incorporated into the annual Asset Certification process and reviewed with Lab Managers who initiate the disposal process. The multi-step corrective action commenced in April with the start of Asset Certification and was completed in June 2025 with required in person training conducted by the Director of Research Space Management during the monthly Lab Manger meeting.

2024-003 - Cash Management

Prior Year Finding: In testing the period of performance compliance requirement in accordance with the OMB Compliance Supplement, PwC requested support for the expenditures on the FY2024 Schedule of Federal Awards, as they were outside of the period of performance of the subaward, which ended September 30, 2023. The Company issued an invoice to Advanced Regenerative Manufacturing Institute, the Prime awardee, for $215,192 on September 14, 2023, but did not incur those expenses until after the period of performance of the subaward. Therefore, the Company requested and received the funds in advance of incurring the expenses.

Further, the Company did not liquidate its obligations under the subaward within the required 90 calendar days after the conclusion of the performance of the subaward, as expenditures were recorded through August 2024. There were no terms in the award that allowed retention of unused funds.

The process to refund Advanced Regenerative Manufacturing Institute, Inc identified an immaterial difference in the amount to be refunded and clarified the correct Program Name and Award Listing Number omitted from award documents. After issuing the original refund based on the 2024-003 Cash Management finding, Mass General Brigham reissued a refund to Advanced Regenerative Manufacturing Institute, Inc in the amount of $215,169 for the Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development with Award Listing Number 93.360. The replacement check was issued August 2025 and cashed September 2025 including updated notification of the finding to correct the original program references and amount.